{
    "paper_id": "6851512e393a3ec79c9b158a0b138fccdaaab913",
    "metadata": {
        "title": "Center for Disease Control and Prevention Interim Guidance for Healthcare Facilities: Preparing for Community Transmission of COVID-19 in the United States 8",
        "authors": [
            {
                "first": "J",
                "middle": [],
                "last": "Covid-Net ; Willan",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "A",
                "middle": [
                    "J"
                ],
                "last": "King",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "K",
                "middle": [],
                "last": "Jeffery",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "N",
                "middle": [],
                "last": "Bienz",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "W",
                "middle": [
                    "A"
                ],
                "last": "Orenstein",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "D",
                "middle": [
                    "L"
                ],
                "last": "Heymann",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "R",
                "middle": [
                    "J"
                ],
                "last": "Ellis",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "R",
                "middle": [
                    "L"
                ],
                "last": "Rosenberg",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "J",
                "middle": [],
                "last": "Nakano",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "N",
                "middle": [
                    "A"
                ],
                "last": "Halsey",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "J",
                "middle": [
                    "J"
                ],
                "last": "Witte",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020 9 cerebrovascular isqu\u00e9mica o hemorr\u00e1gica, 40%). f. Enfermedad renal cr\u00f3nica (definida como reducci\u00f3n del FG por debajo de 60 ml/min/1,73 m 2 ).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "hace menos de 48 horas: (A)Temperatura axilar 37,5\u00b0C o equivalente febril (definido por sensaci\u00f3n de fr\u00edo y/o escalofr\u00edos y/o sudoraci\u00f3n inexplicada), combinado con (a) tos seca y/o (b) dificultad respiratoria y/o (c) odinofagia y/o (d) anosmia/disgeusia y/o (e) alguno de los siguientes s\u00edntomas: fatiga, anorexia, mialgias o rinorrea.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "3. Diagn\u00f3stico de SARS-CoV2 confirmado por RT-PCR 4. Ser capaz, seg\u00fan juicio m\u00e9dico, de comprender y cumplir con los procedimientos del estudio y de consentir o no su participaci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "5. Proveer consentimiento informado por s\u00ed mismo.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Un sujeto que cumple cualquiera de los siguientes criterios ser\u00e1 excluido del estudio:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "16 Un EA tambi\u00e9n incluye cualquier empeoramiento (es decir, cualquier cambio cl\u00ednicamente significativo en la frecuencia y / o intensidad) de una afecci\u00f3n preexistente que se asocia temporalmente con el uso del producto en investigaci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "La progresi\u00f3n de COVID-19 no se considerar\u00e1 un EA si es claramente coherente con el patr\u00f3n de progresi\u00f3n t\u00edpico de la enfermedad",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Si existe alguna incertidumbre acerca de que un EA se deba solo a la progresi\u00f3n de COVID-19, se informar\u00e1 como un EA o EAS como se describe en la secci\u00f3n respectiva.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Un EAS, por definici\u00f3n, es cualquier evento m\u00e9dico desfavorable que a cualquier dosis:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Resulte en la muerte: incluye todas las muertes, incluso aquellas que parecen no tener relaci\u00f3n alguna con el f\u00e1rmaco del estudio (por ejemplo, un accidente automovil\u00edstico en el que un paciente es pasajero).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Es potencialmente mortal: en opini\u00f3n del investigador, el paciente corre un riesgo inmediato de muerte en el momento del evento. Esto no incluye un AE que si hubiera ocurrido en una forma m\u00e1s severa, podr\u00eda haber causado la muerte.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "edad avanzada, quienes representan entre el 73 y 90% de los casos fatales en distintas regiones del mundo [28, 30, 40] . La mortalidad, la necesidad de cuidados intensivos, la ventilaci\u00f3n mec\u00e1nica, el requerimiento de ox\u00edgeno, y las hospitalizaciones por enfermedad respiratoria aumentan marcadamente con el avance de la edad en los pacientes [2, 3, 29, 32, 46] . De hecho, la frecuencia de muerte por enfermedad por SARS-CoV2 (COVID-19) es del 8% en los pacientes entre 70 y 80 a\u00f1os, y aumenta a 14,8% en los mayores de 80 [23] . Espec\u00edficamente en pacientes hospitalizados mayores de 75 a\u00f1os, la mortalidad es de 29,4% [24] , y en la terapia intensiva asciende a un alarmante 43,5% [25] . Varias comorbilidades asociadas con enfermedad vascular y/o pulmonar agravan el pron\u00f3stico de los infectados aun en pacientes menores de 70, incluyendo hipertensi\u00f3n arterial, diabetes, obesidad y enfermedad pulmonar obstructiva cr\u00f3nica (EPOC) [3, 23, 30, 31] . A la fecha, el virus ha causado m\u00e1s de 290.000 muertes en el mundo, m\u00e1s de 300 de ellas en Argentina donde se encuentra contenido a trav\u00e9s de una estrategia transitoria de cuarentena cuasi-universal [4] . No existe a\u00fan ning\u00fan tratamiento espec\u00edfico disponible. Los resultados de los ensayos de eficacia para vacunas contra SARS-CoV2 se conocer\u00e1n dentro de m\u00ednimamente 10-14 meses.",
            "cite_spans": [
                {
                    "start": 106,
                    "end": 110,
                    "text": "[28,",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 111,
                    "end": 114,
                    "text": "30,",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 115,
                    "end": 118,
                    "text": "40]",
                    "ref_id": null
                },
                {
                    "start": 343,
                    "end": 346,
                    "text": "[2,",
                    "ref_id": null
                },
                {
                    "start": 347,
                    "end": 349,
                    "text": "3,",
                    "ref_id": null
                },
                {
                    "start": 350,
                    "end": 353,
                    "text": "29,",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 354,
                    "end": 357,
                    "text": "32,",
                    "ref_id": null
                },
                {
                    "start": 358,
                    "end": 361,
                    "text": "46]",
                    "ref_id": null
                },
                {
                    "start": 524,
                    "end": 528,
                    "text": "[23]",
                    "ref_id": null
                },
                {
                    "start": 621,
                    "end": 625,
                    "text": "[24]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 684,
                    "end": 688,
                    "text": "[25]",
                    "ref_id": null
                },
                {
                    "start": 934,
                    "end": 937,
                    "text": "[3,",
                    "ref_id": null
                },
                {
                    "start": 938,
                    "end": 941,
                    "text": "23,",
                    "ref_id": null
                },
                {
                    "start": 942,
                    "end": 945,
                    "text": "30,",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 946,
                    "end": 949,
                    "text": "31]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 1151,
                    "end": 1154,
                    "text": "[4]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "El SARS-CoV2 es un virus envuelto que contiene ARN monocatenario en sentido positivo unido a una nucleoprote\u00edna (prote\u00edna N), dentro de una c\u00e1pside compuesta por prote\u00ednas de la matriz (prote\u00edna M). La envoltura posee glicoprote\u00ednas en forma de espinas (prote\u00edna S) que se unen al receptor celular ACE2 en humanos y generan anticuerpos neutralizantes [13] . La primo infecci\u00f3n por SARS-CoV2, como otras enfermedades respiratorias, genera una respuesta de anticuerpos con producci\u00f3n temprana de IgM seguida de IgG espec\u00edfica contra las prote\u00ednas virales [14] . La detecci\u00f3n de anticuerpos neutralizantes del virus es frecuente, y alcanza niveles altos de hasta 1:21,500 PRNT50, mayormente excediendo t\u00edtulos de 1:500 despu\u00e9s de 28 d\u00edas del inicio de s\u00edntomas en pacientes leves [41] . Aproximadamente 5% de los pacientes presentan niveles de anticuerpos neutralizantes <1:40, especialmente los m\u00e1s j\u00f3venes [41] . Un estudio de infecci\u00f3n primaria v\u00eda respiratoria en macacos Rhesus, utilizando 10 6 pfu de SARS-CoV2 seguido de un segundo desaf\u00edo intratraqueal usando el mismo virus y dosis 28 d\u00edas m\u00e1s tarde, demostr\u00f3 ausencia de reinfecci\u00f3n tras una extensa evaluaci\u00f3n por RT-PCR de tejidos post-necropsia [42] . Los t\u00edtulos neutralizantes antes del segundo in\u00f3culo variaban entre 1:8-1:16 PRNT50 [42] . Estos hallazgos -limitados por Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020 3 cierto, dada la novedad del problema-sugieren que a\u00fan bajos t\u00edtulos de anticuerpos neutralizantes podr\u00edan prevenir la enfermedad severa por el virus.",
            "cite_spans": [
                {
                    "start": 351,
                    "end": 355,
                    "text": "[13]",
                    "ref_id": null
                },
                {
                    "start": 553,
                    "end": 557,
                    "text": "[14]",
                    "ref_id": null
                },
                {
                    "start": 777,
                    "end": 781,
                    "text": "[41]",
                    "ref_id": null
                },
                {
                    "start": 905,
                    "end": 909,
                    "text": "[41]",
                    "ref_id": null
                },
                {
                    "start": 1205,
                    "end": 1209,
                    "text": "[42]",
                    "ref_id": null
                },
                {
                    "start": 1296,
                    "end": 1300,
                    "text": "[42]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Proteger a las poblaciones m\u00e1s vulnerables al SARS-CoV2 es imperioso, en el contexto de un germen altamente infeccioso (R 0 estimado entre 2 y 3,28) [27, 33, 34] . Su contagiosidad desborda r\u00e1pidamente la capacidad sanitaria de pa\u00edses desarrollados en distintas regiones del mundo [5] y amenaza los recursos sanitarios de pa\u00edses en v\u00edas de desarrollo [6] . Regiones de Italia, Espa\u00f1a y Estados Unidos se han visto desbordadas por la pandemia, que representa una seria amenaza para Argentina, en coincidencia con el inicio de la circulaci\u00f3n anual de otros pat\u00f3genos pulmonares, como la gripe com\u00fan y el virus sincicial respiratorio [26] . Evidentemente, resultar\u00eda imposible dar respuesta a una avalancha de pacientes graves [7] , y toda estrategia tendiente a disminuir las infecciones y el desarrollo de enfermedad severa se alinea directamente con el objetivo m\u00e9dico de salvar vidas y con las necesidades sanitarias del pa\u00eds para poder brindar la mejor atenci\u00f3n posible a aquellos pacientes que lo necesiten.",
            "cite_spans": [
                {
                    "start": 149,
                    "end": 153,
                    "text": "[27,",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 154,
                    "end": 157,
                    "text": "33,",
                    "ref_id": null
                },
                {
                    "start": 158,
                    "end": 161,
                    "text": "34]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 281,
                    "end": 284,
                    "text": "[5]",
                    "ref_id": null
                },
                {
                    "start": 351,
                    "end": 354,
                    "text": "[6]",
                    "ref_id": null
                },
                {
                    "start": 631,
                    "end": 635,
                    "text": "[26]",
                    "ref_id": null
                },
                {
                    "start": 724,
                    "end": 727,
                    "text": "[7]",
                    "ref_id": "BIBREF128"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "La profilaxis post-exposici\u00f3n a virus y el tratamiento en fases tempranas de enfermedad, a trav\u00e9s de defensas obtenidas en plasma de convalecientes, es una pr\u00e1ctica extendida con antecedentes exitosos en la historia de la medicina a nivel nacional y global. Ya en 1960, Brunell y col. lograron prevenir la varicela cl\u00ednica en hermanos con padres enfermos, usando inmunoglobulinas anti-varicela zoster obtenidas del plasma de pacientes previamente infectados [8] . Hoy mismo, por ejemplo, la inmunoglobulina enriquecida para sarampi\u00f3n se utiliza en personas no vacunadas que estuvieron en contacto con un enfermo durante los 6 d\u00edas previos con una eficacia cercana al 100% [9, 52] ; un producto similar enriquecido para el virus de varicela zoster se administra en embarazadas, reci\u00e9n nacidos, e inmunosuprimidos no vacunados en contacto con infectados dentro de las 96 horas disminuyendo un 90% la incidencia de enfermedad grave [10, 53, 54] ; la inmunoglobulina antitet\u00e1nica suplementa la vacunaci\u00f3n en v\u00edctimas de heridas sucias con inmunizaci\u00f3n primaria incompleta [43] ; la gammaglobulina contra hepatitis B se utiliza como prevenci\u00f3n para reci\u00e9n nacidos de madres infectadas con una eficacia del 75% [44, 55] ; y la gammaglobulina antirr\u00e1bica es ~100% efectiva en la profilaxis posterior a la agresi\u00f3n de un animal sospechoso [11, 56] . Las intervenciones utilizando inmunidad humana derivada del plasma de convalecientes han demostrado ser seguras, han prevenido innumerables casos de enfermedad severa, y han preservado vidas en todo el mundo.",
            "cite_spans": [
                {
                    "start": 458,
                    "end": 461,
                    "text": "[8]",
                    "ref_id": null
                },
                {
                    "start": 672,
                    "end": 675,
                    "text": "[9,",
                    "ref_id": null
                },
                {
                    "start": 676,
                    "end": 679,
                    "text": "52]",
                    "ref_id": "BIBREF171"
                },
                {
                    "start": 929,
                    "end": 933,
                    "text": "[10,",
                    "ref_id": null
                },
                {
                    "start": 934,
                    "end": 937,
                    "text": "53,",
                    "ref_id": "BIBREF172"
                },
                {
                    "start": 938,
                    "end": 941,
                    "text": "54]",
                    "ref_id": "BIBREF173"
                },
                {
                    "start": 1068,
                    "end": 1072,
                    "text": "[43]",
                    "ref_id": null
                },
                {
                    "start": 1205,
                    "end": 1209,
                    "text": "[44,",
                    "ref_id": null
                },
                {
                    "start": 1210,
                    "end": 1213,
                    "text": "55]",
                    "ref_id": null
                },
                {
                    "start": 1331,
                    "end": 1335,
                    "text": "[11,",
                    "ref_id": null
                },
                {
                    "start": 1336,
                    "end": 1339,
                    "text": "56]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020 4 El objetivo principal de nuestro estudio es evaluar la eficacia del plasma de convaleciente en reducir la progresi\u00f3n a enfermedad severa en personas entre 65-74 a\u00f1os con al menos una comorbilidad y en todos los 75 a\u00f1os que se presenten con sintomatolog\u00eda leve de menos de 48 hs de evoluci\u00f3n al momento del inicio de la pesquisa y reciban diagn\u00f3stico temprano de COVID-19. Nuestra hip\u00f3tesis central es que una dosis \u00fanica de plasma de convaleciente comparada contra placebo (soluci\u00f3n salina al 0,9%), y administrada hasta 72 horas despu\u00e9s del inicio de los s\u00edntomas por SARS-CoV2 (o sea, hasta 24 horas despu\u00e9s del l\u00edmite de tiempo para presentarse a pesquisa y testeo), prevendr\u00e1 la progresi\u00f3n a una enfermedad respiratoria severa en sujetos entre 65-74 a\u00f1os con al menos una comorbilidad y en independientemente de presencia de comorbilidad basal.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Evaluar la eficacia del plasma de convaleciente, a partir de 12 horas de la administraci\u00f3n, en reducir la progresi\u00f3n a enfermedad respiratoria severa en personas entre 65-74 a\u00f1os con al menos una comorbilidad y en todos los de 75 a\u00f1os con sintomatolog\u00eda leve y diagn\u00f3stico temprano de COVID-19 hasta los 15 d\u00edas de administraci\u00f3n del tratamiento (16-18 d\u00edas de enfermedad considerando el periodo sintom\u00e1tico pre-enrolamiento),",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivo Primario"
        },
        {
            "text": "Los Objetivos Secundarios incluyen determinar si la administraci\u00f3n de plasma de convaleciente hasta los 15 d\u00edas o a partir de entonces hasta un m\u00e1ximo de 25 d\u00edas de la administraci\u00f3n de tratamiento si continuase internado consigue:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Secundarios"
        },
        {
            "text": "Disminuir la necesidad de soporte de ox\u00edgeno con oxigenoterapia m\u00e1xima (mascara de reservorio de O2) y/o utilizaci\u00f3n de soporte respiratorio no invasivo (soporte de VNI incluyendo CPAP) y/o admisi\u00f3n a UTI y/o requerimiento de ventilaci\u00f3n mec\u00e1nica invasiva por SARS-CoV2 en pacientes entre 65-Disminuir la enfermedad cr\u00edtica definida como (a) presencia de falla resp 200 mm Hg.) y/o (b) shock (definido por necesidades de soporte con drogas vasoactivas para mantener P.A.M. igual o mayor a 65 mm. Hg), y/o (c) s\u00edndrome de disfunci\u00f3n multiorg\u00e1nica (SDMO): injuria renal aguda (definida por aumento de creatinina por dos o m\u00e1s veces con respecto al basal o aumento de creatinina 0.3 mg/dl), elevaci\u00f3n de Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020 5 enzimas hep\u00e1ticas (transaminasas) mayor a tres veces el valor superior normal, miocardiopat\u00eda aguda (definida por elevaci\u00f3n de troponina por encima del nivel normal y/o nuevas alteraciones electrocardiogr\u00e1ficas o ecocardiogr\u00e1ficas para da\u00f1o mioc\u00e1rdico) por SARS-CoV2 en pacientes entre Disminuir la mortalidad por SARS-CoV2 en pacientes entre 65-74 a\u00f1os con al COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Secundarios"
        },
        {
            "text": "Disminuir la duraci\u00f3n de soporte de oxigeno debido a COVID-19 en pacientes hipox\u00e9micos.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Secundarios"
        },
        {
            "text": "Describir la seguridad de la administraci\u00f3n de plasma de convaleciente en pacientes entre 65-75 a\u00f1os con COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Secundarios"
        },
        {
            "text": "Explorar la concentraci\u00f3n de IgG anti-S de SARS CoV2 en plasma de los participantes asociada con ausencia de enfermedad respiratoria severa obtenidas a las 24 horas de la infusi\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Secundarios"
        },
        {
            "text": "Explorar si, en lugar de proteger contra la enfermedad respiratoria severa, la administraci\u00f3n de plasma de convaleciente retarda la aparici\u00f3n de dicha enfermedad.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Exploratorios"
        },
        {
            "text": "Explorar los efectos del plasma de convaleciente sobre la respuesta inmune humoral primaria contra la infecci\u00f3n por SARS CoV2. a los 90 d\u00edas de enrolamiento Explorar si los efectos en enfermedad respiratoria, cardiovascular y mortalidad a largo plazo fueron afectados por la intervenci\u00f3n a los 12 meses de enrolamiento.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Exploratorios"
        },
        {
            "text": "Explorar la correlaci\u00f3n entre carga viral determinada por RT-PCR al diagn\u00f3stico y la respuesta a tratamiento con plasma. Enfermedad respiratoria severa por SARS-CoV2, confirmada por detecci\u00f3n de ARN viral por RT-PCR, y definida por la presencia de cualquiera de las dos siguientes saturaci\u00f3n de ox\u00edgeno en aire ambiental <93% [20, 21] . El endpoint primario se determinar\u00e1 a partir de 12 horas del inicio de la infusi\u00f3n hasta 15 d\u00edas desde la administraci\u00f3n del tratamiento. Mortalidad por COVID-19.",
            "cite_spans": [
                {
                    "start": 326,
                    "end": 330,
                    "text": "[20,",
                    "ref_id": null
                },
                {
                    "start": 331,
                    "end": 334,
                    "text": "21]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Objetivos Exploratorios"
        },
        {
            "text": "HIP\u00d3TESIS Y JUSTIFICACI\u00d3N",
            "cite_spans": [],
            "ref_spans": [],
            "section": "4."
        },
        {
            "text": "Nuestra hip\u00f3tesis central es que una dosis de plasma de convaleciente comparada contra placebo, y administrada hasta 72 horas desde el inicio de los s\u00edntomas leves, prevendr\u00e1 la progresi\u00f3n a enfermedad respiratoria severa por COVID-19 en pacientes entre 65presenten con menos de 48 horas de evoluci\u00f3n al proceso de pesquisa y con sintomatolog\u00eda leve.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hip\u00f3tesis"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020 7",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hip\u00f3tesis"
        },
        {
            "text": "La eficacia de una preparaci\u00f3n terap\u00e9utica contra el SARS-CoV2 econ\u00f3micamente accesible analizada mediante un estudio aleatorizado, doble ciego, en pacientes vulnerables permitir\u00eda escalar de inmediato su aplicabilidad a nivel nacional e internacional mediante campa\u00f1as masivas de donaci\u00f3n de plasma de convalecientes a la espera de soluciones definitivas tales como medicamentos exitosos, anticuerpos monoclonales, o vacunas [17] . Inclusive, de existir protecci\u00f3n parcial concentrada en el tracto respiratorio inferior [18] , esta misma estrategia podr\u00eda hipot\u00e9ticamente permitir la inmunizaci\u00f3n de los sujetos mediante la replicaci\u00f3n controlada del germen en el tracto respiratorio alto (como en el caso de la administraci\u00f3n pasiva de anticuerpos contra el virus sincicial respiratorio en lactantes [19] ).",
            "cite_spans": [
                {
                    "start": 426,
                    "end": 430,
                    "text": "[17]",
                    "ref_id": null
                },
                {
                    "start": 521,
                    "end": 525,
                    "text": "[18]",
                    "ref_id": null
                },
                {
                    "start": 802,
                    "end": 806,
                    "text": "[19]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Justificaci\u00f3n"
        },
        {
            "text": "Un estudio aleatorizado, doble-ciego, controlado con placebo para testear la eficacia del plasma de convaleciente, administrado hasta 72 horas despu\u00e9s del inicio de s\u00edntomas, con el fin de evitar la progresi\u00f3n hacia una enfermedad respiratoria severa. El estudio se llevar\u00e1 a cabo en sujetos entre 65-74 a\u00f1os con al menos una de menos de 48 horas de evoluci\u00f3n al momento de la pesquisa (definida en secci\u00f3n 5.1) y diagn\u00f3stico precoz de COVID-19. El estudio se realizar\u00e1 durante un per\u00edodo de observaci\u00f3n m\u00ednimo de 15 d\u00edas en el que los participantes permanecer\u00e1n bajo control m\u00e9dico diario por protocolo para determinar el criterio de valoraci\u00f3n primario. El per\u00edodo de monitoreo se extender\u00e1 a partir de entonces, hasta un m\u00e1ximo de 25 d\u00edas de la administraci\u00f3n de tratamiento, si continuase internado, para analizar los criterios de valoraci\u00f3n de eficacia secundarios.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "DISE\u00d1O DEL ESTUDIO"
        },
        {
            "text": "Se proyecta que el estudio incorpore un m\u00e1ximo estimado de 210 pacientes (ver 9.0 Tama\u00f1o muestral). Los participantes ser\u00e1n aleatorizados en una proporci\u00f3n de 1:1. T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020 8 Todos los participantes recibir\u00e1n una dosis \u00fanica endovenosa (EV) -acorde a las NORMAS ADMINISTRATIVAS Y T\u00c9CNICAS RM 797/13 139/14 1507/15 Direcci\u00f3n de Sangre y Hemoderivados Ministerio de Salud de la Naci\u00f3n (por http://www.msal.gob.ar/disahe/images/stories/pdf/normas-hemoterapia.pdf) el D\u00eda 0 con el art\u00edculo de prueba asignado, plasma de convaleciente o placebo (ver Tabla 1). Para cada sujeto, la participaci\u00f3n en el estudio se extender\u00e1 un m\u00ednimo de 15 d\u00edas o hasta la resoluci\u00f3n de s\u00edntomas desde la administraci\u00f3n del art\u00edculo de prueba con un m\u00e1ximo de 25 d\u00edas. Los sujetos participantes ser\u00e1n monitoreados durante y despu\u00e9s de la administraci\u00f3n del art\u00edculo de prueba para evaluar eventos de seguridad esperables y no esperables luego de la administraci\u00f3n de plasma. Un Comit\u00e9 de Monitoreo de Datos y Seguridad supervisar\u00e1 el enrolamiento, la eficacia y la seguridad de los participantes a lo largo del estudio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "DISE\u00d1O DEL ESTUDIO"
        },
        {
            "text": "El estudio se llevar\u00e1 a cabo en el Hospital San Juan de Dios, el Hospital Simplemente Evita, el Hospital Dr. Carlos Bocalandro, el Hospital Evita Pueblo, en estrecha coordinaci\u00f3n con los efectores sanitarios del Ministerio de Salud provincial y en el Hospital Militar Central, el Sanatorio de Los Arcos, CEMIC, el Centro de Investigaci\u00f3n OSECAC, garantizando que no se interferir\u00e1 con los cuidados y las normas de atenci\u00f3n de pacientes dispuestas para la notificaci\u00f3n y manejo de esta enfermedad.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Tabla 1. Asignaciones de Tratamiento"
        },
        {
            "text": "Criterios de elegibilidad 5.1.1 Criterios de Inclusi\u00f3n:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.1."
        },
        {
            "text": "Un sujeto debe cumplir los siguientes criterios para ser incluido en el estudio:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.1."
        },
        {
            "text": "1. a\u00f1os o edad entre 65-74 a\u00f1os con al menos una de las comorbilidades siguientes: a. Diagn\u00f3stico de hipertensi\u00f3n arterial bajo tratamiento farmacol\u00f3gico. b. Diagn\u00f3stico conocido de diabetes en tratamiento con algunas de las drogas disponibles (Ap\u00e9ndice I). c. Obesidad (IMC -\u00cdndice de masa corporald. Diagn\u00f3stico de enfermedad pulmonar obstructiva cr\u00f3nica (EPOC) en tratamiento con algunas de las drogas disponibles (Ap\u00e9ndice I). e. Enfermedad cardiovascular establecida definida como a) diagn\u00f3stico conocido de enfermedad coronaria, b) historia de enfermedad Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. (clasificaci\u00f3n OMS: linfomas perif\u00e9ricos de linfocitos B, linfomas de linfocitos T y c\u00e9lulas NK, Linfoma de Hodgkin). 9. HIPERSENSIBILIDAD CONOCIDA a la administraci\u00f3n de inmunoglobulinas, plasma, anticuerpos monoclonales y/o vacunas. 10 . C\u00e1ncer activo, definido por estar recibiendo o haber recibido o estar recibiendo quimioterapia, radioterapia o tratamientos con drogas nuevas de dise\u00f1o o monoclonales en los \u00faltimos seis meses. 11. Infecci\u00f3n conocida por HIV, HBV o HCV. 12. Administraci\u00f3n cr\u00f3nica (definida como m\u00e1s de 14 d\u00edas corridos) de inmunosupresores u otras drogas que modifican el sistema inmune al momento del enrolamiento o dentro de los 6 meses previos a la administraci\u00f3n de la medicaci\u00f3n del estudio. Una dosis inmunosupresora de glucocorticoides se definir\u00e1 como una dosis equivalente. 13. Antecedente de transplante de \u00f3rgano s\u00f3lido. 14. Enfermedad hep\u00e1tica cr\u00f3nica conocida con diagn\u00f3stico de cirrosis estadio II-III-IV. 15 . Enfermedad pulmonar cr\u00f3nica con requerimiento de ox\u00edgeno. 16 . Cualquier otra condici\u00f3n f\u00edsica, psiqui\u00e1trica o social que pueda, a criterio del investigador, aumentar los riesgos por la participaci\u00f3n en el estudio a los participantes o que puedan conducir a la recolecci\u00f3n de datos de seguridad incompletos o inexactos.",
            "cite_spans": [
                {
                    "start": 1067,
                    "end": 1069,
                    "text": "10",
                    "ref_id": null
                },
                {
                    "start": 1776,
                    "end": 1778,
                    "text": "15",
                    "ref_id": null
                },
                {
                    "start": 1839,
                    "end": 1841,
                    "text": "16",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "5.1."
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Dichos candidatos ser\u00e1n invitados a contactarse de inmediato con el fin de evaluar su participaci\u00f3n a trav\u00e9s de los n\u00fameros designados por las organizaciones intervinientes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.1."
        },
        {
            "text": "Aquellos pacientes que cumplan con los criterios de inclusi\u00f3n y no cumplan ninguno de los criterios de exclusi\u00f3n arriba mencionados ser\u00e1n invitados a participar en la fase de pesquisa del estudio en el cual, en caso de aceptar (plasmando su conformidad a trav\u00e9s de la firma del consentimiento informado de pesquisa -ANEXO), se obtendr\u00e1 una muestra de secreci\u00f3n respiratoria por medio de hisopados nasofar\u00edngeo y orofar\u00edngeo (de acuerdo al procedimiento y normativa implementada por el Ministerio de Salud) para detectar ARN de SARS-CoV2 por la prueba de cadena de la polimerasa (RT-PCR).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.1."
        },
        {
            "text": "Dicha muestra ser\u00e1 procesada y analizada por los laboratorios intervinientes designados para las instituciones participantes, y que actualmente proveen este mismo servicio diagnostico diariamente, utilizando el mismo test de RT-PCR para evaluar la presencia de ARN de SARS-CoV2. Esta determinaci\u00f3n se realizar\u00e1 lo antes posible (en un m\u00e1ximo de 24 horas) y, tal como hasta hoy, bajo todas las normas de bioseguridad indicadas por las autoridades sanitarias. Las muestras se conservar\u00e1n para posterior testeo por RT-PCR de co-infecciones con influenza A y B, virus sincicial respiratorio y otros pat\u00f3genos virales de invierno en la Fundaci\u00f3n INFANT.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.1."
        },
        {
            "text": "En caso de detectarse en la muestra respiratoria ARN de SARS-CoV2, se informar\u00e1 al candidato sobre los detalles del estudio y se verificar\u00e1 su elegibilidad nuevamente. El candidato podr\u00e1 decidir no participar de la investigaci\u00f3n seg\u00fan su libre albedr\u00edo y sin consecuencia alguna de ning\u00fan tipo. En caso de que el sujeto est\u00e9 interesado en participar en el estudio, y tras su consentimiento atestado con la firma del consentimiento informado de participaci\u00f3n (ANEXO), se proceder\u00e1 a asignarle un n\u00famero de identificaci\u00f3n \u00fanico. Una vez asignado su c\u00f3digo alfanum\u00e9rico, se proceder\u00e1 a obtener los signos vitales y realizar un examen f\u00edsico completo para obtener la siguiente informaci\u00f3n demogr\u00e1fica y cl\u00ednica [1-3, 25, 47-51]:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.b. Enrolamiento para la participaci\u00f3n en el estudio"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020 12 -Sexo -Edad -Medicaciones habituales y de los \u00faltimos 15 d\u00edas.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.b. Enrolamiento para la participaci\u00f3n en el estudio"
        },
        {
            "text": "-Antecedentes de tabaquismo -Comorbilidades de inter\u00e9s primario: hipertensi\u00f3n arterial, diabetes, enfermedad coronaria, insuficiencia card\u00edaca, antecedentes de ACV e IAM, EPOC, nefropat\u00eda cr\u00f3nica, y obesidad. -Comorbilidades secundarias: asma, antecedentes de c\u00e1ncer, enfermedades hep\u00e1ticas, y enfermedades neurol\u00f3gicas.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.b. Enrolamiento para la participaci\u00f3n en el estudio"
        },
        {
            "text": "Todos los participantes con elegibilidad confirmada ser\u00e1n asignados aleatoriamente a un grupo de tratamiento. La asignaci\u00f3n aleatoria de sujetos participantes se realizar\u00e1 utilizando un sistema electr\u00f3nico por el encargado de aleatorizaci\u00f3n del estudio. Una vez aleatorizado el paciente, el encargado de la asignaci\u00f3n se comunicar\u00e1 con un miembro del equipo de Medicina Transfusional Central del estudio quien proceder\u00e1 a extraer la bolsa opaca de tratamiento indicada del freezer del Laboratorio Central. El equipo de Medicina Transfusional proceder\u00e1 a llevar dicha bolsa en fr\u00edo al hospital asignado. All\u00ed completar\u00e1 la preparaci\u00f3n del producto enmascarado y administrar\u00e1 el tratamiento indicado al paciente participante utilizando para su infusi\u00f3n un acceso venoso previamente obtenido por un miembro del equipo del hospital. Solo este equipo (el encargado de aleatorizaci\u00f3n y el encargado de Medicina Transfusional Central de administrar el tratamiento) conocer\u00e1n el producto a administrar a cada paciente (equipo no ciego). Ni el paciente ni los investigadores tendr\u00e1n conocimiento del tratamiento administrado, realizando un estudio de doble ciego. El equipo no ciego llevar\u00e1 un registro de las asignaciones de producto y sus administraciones que ser\u00e1 guardado de manera confidencial. En la eventual necesidad de una ruptura de ciego se podr\u00e1 recurrir a dichos registros.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.c. Asignaci\u00f3n aleatoria"
        },
        {
            "text": "La preparaci\u00f3n y administraci\u00f3n del plasma de convaleciente o placebo (soluci\u00f3n fisiol\u00f3gica) se realizar\u00e1 acorde a las NORMAS ADMINISTRATIVAS Y T\u00c9CNICAS RM 797/13 139/14 1507/15 Direcci\u00f3n de Sangre y Hemoderivados Ministerio de Salud de la Naci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.d. Preparaci\u00f3n y administraci\u00f3n del art\u00edculo de prueba"
        },
        {
            "text": "(http://www.msal.gob.ar/disahe/images/stories/pdf/normashemoterapia.pdf).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.d. Preparaci\u00f3n y administraci\u00f3n del art\u00edculo de prueba"
        },
        {
            "text": "Una vez enmascarado el producto, el equipo de Medicina Transfusional lo administrar\u00e1 en forma endovenosa lenta al paciente durante un m\u00ednimo de 3 horas y hasta 4 horas Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020 13 de acuerdo a las normas. Luego de la administraci\u00f3n se monitorear\u00e1 la ocurrencia de reacciones locales en el sitio de inyecci\u00f3n y sist\u00e9micas por 12 horas. Este es un estudio de m\u00ednimo riesgo, ya que la administraci\u00f3n de plasma y de soluci\u00f3n salina (placebo en este estudio) son de h\u00e1bito diario en la pr\u00e1ctica m\u00e9dica. En el caso de una emergencia m\u00e9dica, cuando se tenga conocimiento de que la asignaci\u00f3n de tratamiento puede influir en la atenci\u00f3n m\u00e9dica del paciente, el investigador o la persona designada pueden solicitar que se rompa el ciego para el sujeto que est\u00e1 experimentando la emergencia. Sin embargo, antes del quiebre de ciego el investigador debe realizar todos los esfuerzos razonables de ponerse en contacto con la persona designada para discutir la decisi\u00f3n de quebrar el ciego. Se espera que el investigador proporcione una raz\u00f3n para la necesidad de romper el ciego, en base a un cambio significativo en la atenci\u00f3n m\u00e9dica inmediata o de corto plazo del participante que resultar\u00e1 del conocimiento de la asignaci\u00f3n del tratamiento.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.d. Preparaci\u00f3n y administraci\u00f3n del art\u00edculo de prueba"
        },
        {
            "text": "2.e. Toma de muestra de sangre para titulaci\u00f3n de IgG anti-S SARS CoV2 en suero.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5."
        },
        {
            "text": "A las 24 horas de completada la infusi\u00f3n del tratamiento, se obtendr\u00e1 una muestra de 5 ml de sangre venosa de todos los participantes para la titulaci\u00f3n en suero de IgG anti-S SARS-CoV2, a realizarse en la Fundaci\u00f3n INFANT por m\u00e9todo ELISA (COVIDAR IgG, Leloir/CONICET). El suero se preservar\u00e1 a -20 C hasta su traslado en fr\u00edo por un sistema de transporte autorizado para manejo de muestras biol\u00f3gicas a la Fundaci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5."
        },
        {
            "text": "Se realizar\u00e1 un control diario a partir del Dia 0, y por lo menos durante 15 d\u00edas desde la infusi\u00f3n y hasta 25 d\u00edas para aquellos sujetos que contin\u00faan hospitalizados a partir del d\u00eda 15. Aquellos pacientes que sean dados de alta previo al d\u00eda 15, ser\u00e1n monitoreados por un equipo de m\u00e9dicos domiciliarios entrenados para tal fin que trabajar\u00e1n en colaboraci\u00f3n con los centros de investigaci\u00f3n. La siguiente informaci\u00f3n cl\u00ednica se recolectar\u00e1 diariamente (utilizando un cuestionario dise\u00f1ado para tal fin) por personal del estudio y sin interferir con la atenci\u00f3n m\u00e9dica del paciente ni alterar las normas recomendadas por las autoridades sanitarias para el manejo de los pacientes con COVID-19: (a) frecuencia respiratoria (mirando como excursiona el t\u00f3rax durante 30 segundos), (b) saturaci\u00f3n de ox\u00edgeno, (c) temperatura, (d) frecuencia cardiaca central, (e) tos y duraci\u00f3n, (f) dolor de garganta y duraci\u00f3n, (g) sensaci\u00f3n de fiebre/escalofr\u00edos, (h) necesidad de provisi\u00f3n de ox\u00edgeno suplementario y duraci\u00f3n, (i) necesidad de cuidados intensivos y duraci\u00f3n, (j) necesidad de asistencia respiratoria no invasiva o invasiva y duraci\u00f3n, (k) evidencia de SDMO: seg\u00fan criterios de injuria renal Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020 14 aguda, criterios de elevaci\u00f3n de enzimas hep\u00e1ticas y criterios de miocardiopat\u00eda aguda (detallados en secci\u00f3n 2.2), (l) sobrevida. Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020 15",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.f. Seguimiento cl\u00ednico diario"
        },
        {
            "text": "Un Comit\u00e9 Independiente de Monitoreo de Datos supervisar\u00e1 la seguridad de los sujetos durante todo el estudio. El CIMD incluir\u00e1, como m\u00ednimo, miembros con experiencia en el manejo de medicina interna, enfermedades infecciosas, y un bioestad\u00edstico con experiencia espec\u00edfica en el dise\u00f1o, an\u00e1lisis y monitoreo de seguridad de estudios cl\u00ednicos. El CIMD operar\u00e1 bajo un plan aprobado y tendr\u00e1 la responsabilidad de monitorear las medidas de resultado / puntos finales, eventos adversos (EA) y eventos adversos serios (EAS), y recomendar la finalizaci\u00f3n del estudio si aparece en alg\u00fan momento durante el estudio que los participantes (o un subgrupo de participantes) se encuentran en riesgo indebido como resultado de su participaci\u00f3n. El CIMD se reunir\u00e1 (por teleconferencia) semanalmente para revisar el acumulado de datos sobre seguridad y eficacia y realizar\u00e1 un an\u00e1lisis interino de los datos. El CIMD emitir\u00e1 recomendaciones escritas en base a sus reuniones acerca de la continuidad del estudio. Las actas de cada reuni\u00f3n se registrar\u00e1n en minutas documentadas en base a una agenda de trabajo preestablecida. Cualquier informaci\u00f3n de salud protegida espec\u00edfica del participante revisado por el CIMD se mantendr\u00e1 completamente confidencial. Las sesiones ser\u00e1n cerradas sin acceso a terceros.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comit\u00e9 Independiente de Monitoreo de Datos"
        },
        {
            "text": "El investigador en cada instituci\u00f3n y a nivel general supervisar\u00e1 la seguridad del paciente del estudio en su(s) sitio(s) seg\u00fan los requisitos de este protocolo y de acuerdo con las Buenas Pr\u00e1cticas Cl\u00ednicas (GCP) actuales. El investigador monitorear\u00e1 los datos de seguridad en todos los sitios de estudio. El monitoreo de seguridad se realizar\u00e1 de manera continua (por ejemplo, revisi\u00f3n individual de EAS, EAs y puntos finales) y de forma acumulada peri\u00f3dica.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoreo de Seguridad"
        },
        {
            "text": "Un EA es cualquier acontecimiento m\u00e9dico desfavorable en un paciente al que se le administr\u00f3 un f\u00e1rmaco del estudio que puede tener o no una relaci\u00f3n causal con el f\u00e1rmaco del estudio. Por lo tanto, una EA es cualquier signo desfavorable e involuntario (incluido el hallazgo anormal de laboratorio), s\u00edntoma o enfermedad que se asocia temporalmente con el uso de un medicamento del estudio, independientemente de si se considera relacionado con el medicamento del estudio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso (EA)"
        },
        {
            "text": "Requiere hospitalizaci\u00f3n o prolongaci\u00f3n de la hospitalizaci\u00f3n existente. La hospitalizaci\u00f3n se define como el ingreso a un hospital o sala de emergencias por m\u00e1s de 24 horas. La prolongaci\u00f3n de la hospitalizaci\u00f3n existente se define como una estad\u00eda en el hospital que es m\u00e1s larga de lo previsto originalmente para el evento, o se prolonga debido al desarrollo de un nuevo EA seg\u00fan lo determinado por el investigador o el m\u00e9dico tratante.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso (EA)"
        },
        {
            "text": "Resulta en discapacidad/incapacidad persistente o significativa (interrupci\u00f3n sustancial de la capacidad de uno para llevar a cabo funciones normales de la vida).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso (EA)"
        },
        {
            "text": "Es un evento m\u00e9dico importante: los eventos m\u00e9dicos importantes pueden no poner en peligro la vida de inmediato o provocar la muerte u hospitalizaci\u00f3n, pero pueden poner en peligro al paciente o pueden requerir intervenci\u00f3n para prevenir uno de los otros resultados graves enumerados anteriormente (por ejemplo, tratamiento intensivo en una emergencia o en casa para broncoespasmo al\u00e9rgico; discrasias sangu\u00edneas que no resultan en hospitalizaci\u00f3n).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso (EA)"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso (EA)"
        },
        {
            "text": "En el caso espec\u00edfico de este estudio se considerar\u00e1n como EA o EAS, seg\u00fan la descripci\u00f3n detallada en la secci\u00f3n 11.2, aquellos que se inicien dentro de las 12 horas posteriores a la administraci\u00f3n del tratamiento y los agravamientos cl\u00ednicos y muertes asociadas con estos eventos. No se considerar\u00e1n EA o EAS aquellos eventos cl\u00ednicos que se inicien luego de las 12 horas de iniciaci\u00f3n del tratamiento, que constituir\u00e1n parte de la evoluci\u00f3n cl\u00ednica de los pacientes enrolados infectados con SARS CoV2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "17"
        },
        {
            "text": "El per\u00edodo de informe EA / EAS comienza cuando el participante se incluye inicialmente en el estudio (fecha de firma del consentimiento informado de participaci\u00f3n) y recibe la infusi\u00f3n y continuar\u00e1 para los eventos que se inicien en las siguientes 12 horas desde su inicio (ver secci\u00f3n 11.2). Durante el seguimiento posterior a las 12 horas iniciales de la administraci\u00f3n del producto de investigaci\u00f3n, se monitorear\u00e1 la evoluci\u00f3n cl\u00ednica asociada a los criterios de valoraci\u00f3n primario y secundarios.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Periodo de Recolecci\u00f3n de Eventos Adversos"
        },
        {
            "text": "Los sujetos podr\u00e1n abandonar el estudio en cualquier momento si as\u00ed lo deseasen, pero ser\u00e1n igualmente monitoreados durante el periodo estipulado para garantizar su seguridad.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abandono Prematuro del Estudio"
        },
        {
            "text": "Aquellos pacientes que decidan abandonar el estudio antes de la administraci\u00f3n de la droga ser\u00e1n reemplazados, de ser necesario, para asegurar un n\u00famero adecuado de pacientes evaluables.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Reemplazo de Pacientes"
        },
        {
            "text": "Existe una incertidumbre significativa en el tama\u00f1o del efecto esperado de la intervenci\u00f3n, y considerando que se espera que el ensayo se complete en un per\u00edodo de tiempo relativamente corto, el estudio est\u00e1 dise\u00f1ado para tener un an\u00e1lisis intermedio cuando los resultados del 50% de los sujetos hayan sido adquiridos.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Justificaci\u00f3n del tama\u00f1o muestral y an\u00e1lisis estad\u00edstico"
        },
        {
            "text": "Dada la relativa complejidad de implementar esta intervenci\u00f3n, la diferencia m\u00ednimamente importante cl\u00ednicamente se establece en una reducci\u00f3n relativa del 40%, para una tasa de resultado esperada del 50% en el grupo control que se reduce al 30% en el grupo de intervenci\u00f3n. Un tama\u00f1o de muestra total de 210 sujetos (105 por brazo Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Justificaci\u00f3n del tama\u00f1o muestral y an\u00e1lisis estad\u00edstico"
        },
        {
            "text": "18 de prueba) tendr\u00e1 una potencia del 80%, a un nivel de significancia (alfa) de 0.05 utilizando una prueba z de dos lados con correcci\u00f3n de continuidad. Estos resultados suponen que se realizan 2 pruebas secuenciales utilizando la funci\u00f3n de gasto O'Brien-Fleming para determinar los l\u00edmites de la prueba, como se describe en la tabla a continuaci\u00f3n. T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Justificaci\u00f3n del tama\u00f1o muestral y an\u00e1lisis estad\u00edstico"
        },
        {
            "text": "Para poder donar plasma, el paciente debe cumplir con las condiciones determinadas a la fecha (https://www.boletinoficial.gob.ar/detalleAviso/primera/227976/20200418) o seguir la actualizaci\u00f3n de ellas que realice el Ministerio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "19"
        },
        {
            "text": "Tras el proceso de la donaci\u00f3n de plasma por af\u00e9resis o hemodonaci\u00f3n, adicionalmente a las muestras que se toman para controles de rutina del banco de sangre, se obtendr\u00e1 un tubo seco de 5 mL de sangre entera rotulados con la identificaci\u00f3n dada al donante, identificaci\u00f3n del Banco de Sangre y etiqueta que Estos se realizar\u00e1n mediante el ensayo de ELISA anti-prote\u00edna S de SARS CoV2, que a luz de los datos existentes sobre protecci\u00f3n contra el virus permiten una extrapolaci\u00f3n indirecta de la capacidad de neutralizaci\u00f3n del suero, optimizado por el Instituto Leloir a cargo de la Dra. Gamarnik, y actualmente utilizado por los equipos de salud nacionales para estudiar prevalencia de inmunidad. Asimismo, de ser posible, se correlacionar\u00e1 este dato con el t\u00edtulo de anticuerpos neutralizantes contra un pseudovirus codificando la prote\u00edna S optimizado por el mismo laboratorio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Titulaci\u00f3n de anticuerpos anti-SARS CoV2"
        },
        {
            "text": "El tubo ser\u00e1 almacenado en un lugar designado dentro del Banco y enviado en un transporte autorizado de muestras biol\u00f3gicas al laboratorio de la Fundaci\u00f3n INFANT (con m\u00e1s de 18 a\u00f1os de experiencia en realizaci\u00f3n de ensayos de estas caracter\u00edsticas) donde se realizar\u00e1 la t\u00e9cnica de ELISA y la titulaci\u00f3n de anticuerpos neutralizantes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Titulaci\u00f3n de anticuerpos anti-SARS CoV2"
        },
        {
            "text": "Los t\u00edtulos obtenidos por ELISA de S ser\u00e1n luego clasificados y aquellos que est\u00e9n por encima de 1:1.000 seleccionados para proveer plasma de convaleciente para este estudio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Titulaci\u00f3n de anticuerpos anti-SARS CoV2"
        },
        {
            "text": "Los plasmas de alto t\u00edtulo adicionales ser\u00e1n almacenados asimismo para enviar al Centro de Hemoderivados de C\u00f3rdoba (UNC) que producir\u00e1 gammaglobulina enriquecida con anticuerpos anti-SARS-CoV2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Titulaci\u00f3n de anticuerpos anti-SARS CoV2"
        },
        {
            "text": "Plasmaf\u00e9resis (Instituto de Hemoterapia de la Provincia de La Plata, Hospital Militar Central, Fundaci\u00f3n Hemocentro Buenos Aires, y Fundaci\u00f3n Hematol\u00f3gica Sarmiento) La donaci\u00f3n de plasma se efectuar\u00e1 a trav\u00e9s de un procedimiento de af\u00e9resis con equipos e insumos descartables aprobados para tal fin, durante el cual se recomienda extraer un volumen no mayor al 15% de la volemia del donante. El anticoagulante a Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020 20 utilizar ser\u00e1 ACD-A o similar. En los casos en que no se realizare la reposici\u00f3n del volumen, la extracci\u00f3n de plasma no deber\u00e1 superar los 600 ml por procedimiento. Se deber\u00e1 respetar el intervalo de 48 hs. entre cada procedimiento, y no superar las 2 donaciones en una semana o 24 donaciones en un periodo de 12 meses. Las unidades de PCC19 se podr\u00e1n separar en al\u00edcuotas de 300ml respetando el circuito cerrado y siguiendo las indicaciones del procedimiento operativo est\u00e1ndar vigente.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Titulaci\u00f3n de anticuerpos anti-SARS CoV2"
        },
        {
            "text": "1-La obtenci\u00f3n de plasma se realizar\u00e1 con un equipo Cobe Spectra. Se extraer\u00e1n 1,5 a 2 L de plasma de acuerdo al peso y tolerancia al procedimiento del donante. En caso de inaccesibilidad venosa u oposici\u00f3n del donante, se extraer\u00e1 entre 400 y 500 ml de sangre entera (hemodonaci\u00f3n cl\u00e1sica) 2-El reemplazo de volumen se efectuar\u00e1 con soluci\u00f3n fisiol\u00f3gica y de alb\u00famina. 3-Durante el procedimiento el plasma ser\u00e1 derivado a bolsas de transferencia de similar volumen cada una (aproximadamente 500ml). Se denominar\u00e1 Bolsa 1 a la inicialmente obtenida, Bolsa 2 la media y Bolsa 3 la final. 4-Las bolsas recolectadas ser\u00e1n rotuladas como detallado abajo 5-Se congelar\u00e1n en el ultrafreezer vertical Righi de -56\u00b0C (rotulado como Freezer # I, identificado con r\u00f3tulo de plasma de convaleciente COVID-19, en el Banco de Sangre) separadas en estantes por tipo de bolsa (1, 2 o 3). 6-El plasma de convaleciente permanecer\u00e1 almacenado hasta su uso o caducidad (1 a\u00f1o), con criterios de seguridad apropiados. 7-El descarte se efectuar\u00e1 bajo normas de seguridad que se estipulen. 8-Se guardar\u00e1n al\u00edcuotas de suero/plasma para futuras determinaciones congelado a -80 o C, en tubos de Eppendorf del PC de las diferentes etapas, y congelados y almacenados a -80\u00b0C: Previo al procedimiento de af\u00e9resis de las bolsas 1, 2 y 3 (previo al congelamiento) luego del descongelamiento de las bolsas 1, 2 y 3.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hemodonaci\u00f3n (CEMIC)"
        },
        {
            "text": "Todas las unidades de PC COVID-19 deben cumplir con el etiquetado requerido para el plasma fresco congelado de cada Banco de Sangre y adem\u00e1s deber\u00e1n tener una clara identificaci\u00f3n, en la que deber\u00e1 constar: COVID-19 anticuerpos para SARS-Cov-",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Etiquetado"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Fundaci\u00f3n INFANT Suero enriquecido con anticuerpos anti SARS-CoV2"
        },
        {
            "text": "Cadena de Fr\u00edo de PCCOVID-19",
            "cite_spans": [],
            "ref_spans": [],
            "section": "21"
        },
        {
            "text": "1. Las unidades se almacenar\u00e1n debidamente separadas del resto de las unidades de plasma habilitadas para uso transfusional, en un lugar claramente identificado para tal fin.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "21"
        },
        {
            "text": "2. Las unidades de PCC19 se almacenar\u00e1n a temperatura inferior a -25C, la cual permite un almacenamiento de 36 meses y entre -18C y -25C para 3 meses de almacenamiento.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "21"
        },
        {
            "text": "3. El transporte de las unidades se realizar\u00e1 de forma tal que se garantice fehacientemente el mantenimiento de la cadena de fr\u00edo.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "21"
        },
        {
            "text": "4. La conservaci\u00f3n de las unidades de plasma una vez descongeladas deber\u00e1 realizarse entre 2 y 6\u00baC hasta las 24 horas de finalizado el descongelamiento. Pasado ese tiempo, se deber\u00e1n descartar.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "21"
        },
        {
            "text": "El Banco de Sangre y el Servicio de Transfusi\u00f3n de la Instituci\u00f3n solicitante implementar\u00e1n un sistema de registros que garantice la trazabilidad entre donantes y receptores. En esta situaci\u00f3n especial, adem\u00e1s, deber\u00e1n disponer de un registro espec\u00edfico por tratarse de una terapia transfusional administrada en un contexto experimental.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Trazabilidad"
        },
        {
            "text": "Una vez evaluados los signos vitales y verificada la elegibilidad, el equipo no ciego de Medicina Transfusional Central ser\u00e1 notificado del resultado del proceso de asignaci\u00f3n aleatoria y se trasladar\u00e1 al hospital asignado con el producto de tratamiento enmascarado y en fr\u00edo. Al arribar proceder\u00e1 nuevamente verificar el c\u00f3digo de tratamiento asignado con el miembro de laboratorio de Medicina Transfusional del hospital correspondiente (ver 5.2.c).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administraci\u00f3n de la intervenci\u00f3n"
        },
        {
            "text": "Como placebo, se utilizar\u00e1n 250 ml de soluci\u00f3n salina al 0,9% est\u00e9ril enmascarada y administrada de la misma forma y velocidad que el plasma. Para evitar sesgos y mantener el ciego del estudio, el plasma y la soluci\u00f3n salina al 0,9% ser\u00e1n enmascarados, utilizando una bolsa opaca y cinta que no permitir\u00e1n diferenciar de qu\u00e9 producto se trata. El miembro de Medicina Transfusional Central ser\u00e1 quien entregue al Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administraci\u00f3n de la intervenci\u00f3n"
        },
        {
            "text": "22 miembro del equipo local para que administre la intervenci\u00f3n en conjunto con el equipo central. De esta manera tanto los miembros de Medicina Transfusional Central como los miembros de Medicina Transfusional de los hospitales ser\u00e1n no ciegos, mientras que todo el resto del equipo delegado en funciones en el estudio en cada Centro de Investigaci\u00f3n como los pacientes ser\u00e1n ciegos a la intervenci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administraci\u00f3n de la intervenci\u00f3n"
        },
        {
            "text": "Para preparar el plasma, se descongelar\u00e1 la bolsa de 250 ml a 37\u00b0C, seg\u00fan procedimientos operativos del Departamento de Medicina Transfusional del Hospital. Se infundir\u00e1 al receptor en forma lenta (en no menos de 3 horas y hasta 4 horas) de acuerdo a las condiciones hemodin\u00e1micas del paciente y se monitorear\u00e1n por 12 horas y registrar\u00e1n los efectos adversos tempranos y tard\u00edos atribuibles a la transfusi\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administraci\u00f3n de la intervenci\u00f3n"
        },
        {
            "text": "Sobrecarga circulatoria asociada a transfusi\u00f3n (TACO) La sobrecarga circulatoria asociada a transfusi\u00f3n (transfusion-associated circulatory overload, TACO) es la complicaci\u00f3n pulmonar m\u00e1s frecuente y es un factor de riesgo independiente para morbimortalidad hospitalaria, con mayor incidencia en pacientes cr\u00edticos [58] . La frecuencia estimada de TACO var\u00eda del 1% a 5% seg\u00fan el sistema de hemovigilancia sea [59] , hasta los 8% en pacientes post quir\u00fargicos de avanzada, y 11% en pacientes cr\u00edticos [60 61 62] . Los factores de riesgo incluyen enfermedad transfusional [63 64 ]. La mayor\u00eda de los casos de TACO se previenen disminuyendo la velocidad de transfusi\u00f3n y la instauraci\u00f3n de las medidas habituales para sobrecarga h\u00eddrica en poblaciones susceptibles. La sobrecarga constituye un EA solicitado, pero de no mejorar en el curso de 120 minutos despu\u00e9s de la infusi\u00f3n o de requerir -a juicio de los profesionales responsables-el paso del paciente a cuidados intensivos por mala progresi\u00f3n cl\u00ednica a causa de dicha sobrecarga, deber\u00e1 informarse de inmediato como un EAS.",
            "cite_spans": [
                {
                    "start": 315,
                    "end": 319,
                    "text": "[58]",
                    "ref_id": "BIBREF175"
                },
                {
                    "start": 410,
                    "end": 414,
                    "text": "[59]",
                    "ref_id": "BIBREF176"
                },
                {
                    "start": 505,
                    "end": 511,
                    "text": "61 62]",
                    "ref_id": null
                },
                {
                    "start": 571,
                    "end": 577,
                    "text": "[63 64",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Monitoreo de eventos adversos asociados a la transfusi\u00f3n de plasma"
        },
        {
            "text": "Criterios diagn\u00f3sticos de TACO [19] Durante o hasta 12 horas posteriores a la transfusi\u00f3n, TACO se caracteriza por la presencia de un total de 3 o m\u00e1s de los criterios listados: A. Compromiso respiratorio agudo o que empeora B. Evidencia de edema pulmonar agudo o que empeora basado en la cl\u00ednica y / o im\u00e1genes radiogr\u00e1ficas del t\u00f3rax y / u otra evaluaci\u00f3n no invasiva de la funci\u00f3n card\u00edaca (ecocardiograma) C. Evidencia de cambios cardiovasculares no explicados por la condici\u00f3n m\u00e9dica subyacente del paciente, incluido: taquicardia, hipertensi\u00f3n, presi\u00f3n de pulso Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020 23 ensanchada, distensi\u00f3n venosa yugular, silueta card\u00edaca agrandada y / o edema perif\u00e9rico D. Evidencia de sobrecarga de l\u00edquidos, incluyendo cualquiera de los siguientes: un balance positivo de l\u00edquidos; respuesta a la terapia diur\u00e9tica, o di\u00e1lisis combinada con mejor\u00eda cl\u00ednica; y variaci\u00f3n del peso del paciente E. Aumento del nivel de p\u00e9ptido natriur\u00e9tico de tipo B (por ejemplo, BNP o NT-pro BNP) por encima del rango de referencia espec\u00edfico del grupo de edad y mayor de 1,5 veces el valor de pre transfusi\u00f3n.",
            "cite_spans": [
                {
                    "start": 31,
                    "end": 35,
                    "text": "[19]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Monitoreo de eventos adversos asociados a la transfusi\u00f3n de plasma"
        },
        {
            "text": "Injuria Pulmonar Aguda Asociada a Transfusi\u00f3n (TRALI) Es un s\u00edndrome de dificultad respiratoria aguda, ser\u00e1 considerado un EAS y ocurre durante o dentro de las seis horas posteriores a la administraci\u00f3n de la transfusi\u00f3n. Estudios prospectivos de TRALI en diversas encontraron tasas de incidencia muy bajas (0,0008% a 0,001% de pacientes transfundidos) [19] despu\u00e9s de la implementaci\u00f3n de estrategias para prevenir la transfusi\u00f3n de componentes de la sangre obtenido de donantes femeninas mult\u00edparas. En nuestro estudio no se transfundir\u00e1 plasma convaleciente de mujeres mult\u00edparas. El tratamiento del paciente con TRALI incluye la interrupci\u00f3n inmediata de la transfusi\u00f3n.",
            "cite_spans": [
                {
                    "start": 353,
                    "end": 357,
                    "text": "[19]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Monitoreo de eventos adversos asociados a la transfusi\u00f3n de plasma"
        },
        {
            "text": "Criterios diagn\u00f3sticos de TRALI: [28] TRALI Tipo I: pacientes que no tienen factores de riesgo de SDRA y cumplen con los siguientes criterios: A. i. Inicio agudo ii. Hipoxemia (PaO 2 / FiO 2 2 <90% en aire ambiente). iii. Evidencia clara de edema pulmonar bilateral en im\u00e1genes (radiograf\u00eda de t\u00f3rax, tac o ecograf\u00eda) iv. No hay evidencia de hipertrofia ventricular izquierda o, si est\u00e1 presente, no es la principal contribuyente de la hipoxemia B. Inicio durante o dentro de las 6 horas de la transfusi\u00f3n C. Sin relaci\u00f3n temporal con un factor de riesgo alternativo para SDRA TRALI Tipo II: pacientes que tienen factores de riesgo de SDRA (pero que no han sido diagnosticados con SDRA) o que tienen SDRA leve existente (Pa / Fi de 200-300), pero cuyo estado respiratorio se deteriora y se considera que se debe a una transfusi\u00f3n basado en: a. Los resultados descritos en las categor\u00edas a y b de TRALI Tipo I, y b. Estado respiratorio estable en las 12 horas previas a la transfusi\u00f3n",
            "cite_spans": [
                {
                    "start": 33,
                    "end": 37,
                    "text": "[28]",
                    "ref_id": "BIBREF17"
                }
            ],
            "ref_spans": [],
            "section": "Monitoreo de eventos adversos asociados a la transfusi\u00f3n de plasma"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Reacciones Al\u00e9rgicas Anafil\u00e1cticas"
        },
        {
            "text": "Las reacciones al\u00e9rgicas ocurren en general durante o dentro de las 4 horas posteriores a la transfusi\u00f3n y est\u00e1n m\u00e1s frecuentemente asociadas a la transfusi\u00f3n de plaquetas (302 cada 100 000 unidades de plaquetas) [29] . Los s\u00edntomas son causados por mediadores como la histamina, liberados en la activaci\u00f3n de mastocitos y bas\u00f3filos [30] . En general la presentaci\u00f3n cl\u00ednica es leve (erupci\u00f3n cut\u00e1nea, prurito, urticaria, y angioedema localizado) y constituye un EA solicitado. Las reacciones transfusionales al\u00e9rgicas leves en general resuelven con la administraci\u00f3n del tratamiento habitual para reacciones al\u00e9rgicas, pudiendo reiniciar la infusi\u00f3n de la unidad. La transfusi\u00f3n debe suspenderse si los s\u00edntomas reaparecen. La incidencia de reacciones anafil\u00e1cticas es de 8/100,000 unidades de plaquetas transfundidas. Las reacciones m\u00e1s severas generalmente se presentan con broncoespasmo, dificultad respiratoria e hipotensi\u00f3n y constituyen un EAS y debe ser reportado como tal inmediatamente [31] [32] [33] [34] [35] .",
            "cite_spans": [
                {
                    "start": 213,
                    "end": 217,
                    "text": "[29]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 333,
                    "end": 337,
                    "text": "[30]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 996,
                    "end": 1000,
                    "text": "[31]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 1001,
                    "end": 1005,
                    "text": "[32]",
                    "ref_id": null
                },
                {
                    "start": 1006,
                    "end": 1010,
                    "text": "[33]",
                    "ref_id": null
                },
                {
                    "start": 1011,
                    "end": 1015,
                    "text": "[34]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 1016,
                    "end": 1020,
                    "text": "[35]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "24"
        },
        {
            "text": "Las reacciones de transfusionales hemol\u00edticas agudas (RTHA) pueden ocurrir cuando se transfunden gl\u00f3bulos rojos incompatibles o en menor frecuencia, grandes cantidades de plasma incompatible con el ABO del paciente. El mecanismo fisiopatol\u00f3gico central es la hem\u00f3lisis intravascular y se considerar\u00e1 un EAS. Se presenta con fiebre repentina y escalofr\u00edos, dolor retroperitoneal y disnea, hemoglobinuria y hasta coagulaci\u00f3n intravascular diseminada, insuficiencia renal aguda y shock. Dado que la fiebre y los escalofr\u00edos pueden ser los \u00fanicos signos tempranos, es importante controlar al paciente durante la transfusi\u00f3n y detenerla transfusi\u00f3n inmediatamente si hay alg\u00fan cambio en los signos vitales o ante la aparici\u00f3n de s\u00edntomas inesperados. El tratamiento se basa en medidas de sost\u00e9n para mitigar los s\u00edntomas. La identificaci\u00f3n adecuada del paciente y el cumplimiento de todos los procesos relacionados con el manejo de muestras pre-transfusionales y con la administraci\u00f3n de la transfusi\u00f3n, son esenciales para prevenir la RTHA [36] .",
            "cite_spans": [
                {
                    "start": 1036,
                    "end": 1040,
                    "text": "[36]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Reacciones transfusionales hemol\u00edticas agudas"
        },
        {
            "text": "Infecciones Transmisibles por Transfusi\u00f3n [39] El riesgo de transmisi\u00f3n de enfermedades infecciosas por transfusiones se ha reducido dram\u00e1ticamente, secundario a los grandes avances en el testeo de las unidades, inactivaci\u00f3n de pat\u00f3genos para unidades de plasma y sus componentes [51] y a la implementaci\u00f3n de rigurosos m\u00e9todos de selecci\u00f3n de donantes. En nuestro medio, las muestras son testeadas para HBV, HCV, HIV, HTLV y Trypanosoma cruzi [52] . En Estados Unidos, el riesgo de adquirir HBV y HIV por transfusi\u00f3n es de 1:280.000 y 1:1.467.000, respectivamente [53 54] . Gracias al congelamiento de las muestras de plasma, la contaminaci\u00f3n de las mismas por pat\u00f3genos bacterianos y CMV es extremadamente rara. Hay solo una decena de casos entre los millones de transfusiones realizadas, reportados en Alemania y Canad\u00e1 de transmisi\u00f3n bacteriana. Se estima que la fuente potencial de esta contaminaci\u00f3n habr\u00edan sido los ba\u00f1os de Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020 25 agua utilizados para el descongelamiento de las unidades. Esto es f\u00e1cilmente evitable con la limpieza y esterilizaci\u00f3n correctas de los descongeladores [39] .",
            "cite_spans": [
                {
                    "start": 42,
                    "end": 46,
                    "text": "[39]",
                    "ref_id": null
                },
                {
                    "start": 280,
                    "end": 284,
                    "text": "[51]",
                    "ref_id": null
                },
                {
                    "start": 444,
                    "end": 448,
                    "text": "[52]",
                    "ref_id": "BIBREF171"
                },
                {
                    "start": 565,
                    "end": 572,
                    "text": "[53 54]",
                    "ref_id": null
                },
                {
                    "start": 1383,
                    "end": 1387,
                    "text": "[39]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Reacciones transfusionales hemol\u00edticas agudas"
        },
        {
            "text": "Este estudio se llevar\u00e1 a cabo de conformidad con el protocolo y con las siguientes consideraciones:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Declaraci\u00f3n de Buena Pr\u00e1ctica Cl\u00ednica"
        },
        {
            "text": "los principios \u00e9ticos que tienen su origen en la Declaraci\u00f3n de Helsinki, las pautas vigentes de las buenas pr\u00e1cticas cl\u00ednicas (Good Clinical Practice, GCP) del Consejo Internacional de Armonizaci\u00f3n (International Council of Harmonisation, ICH), las leyes y regulaciones vigentes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Declaraci\u00f3n de Buena Pr\u00e1ctica Cl\u00ednica"
        },
        {
            "text": "El protocolo, los formularios de Consentimiento Informado (FCI) y otros documentos relevantes han sido revisados y aprobados por Fundaci\u00f3n INFANT, las autoridades participantes y enviados al Comit\u00e9 de \u00c9tica (CE) para su evaluaci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Declaraci\u00f3n de Buena Pr\u00e1ctica Cl\u00ednica"
        },
        {
            "text": "Un CE debidamente constituido, como se describe en las pautas de ICH para GCP, debe revisar y aprobar:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comit\u00e9 de \u00e9tica (CE):"
        },
        {
            "text": "El protocolo, FCI y cualquier otro material que se proporcione a los participantes antes de que cualquier sujeto pueda ingresar en el estudio Cualquier enmienda o modificaci\u00f3n al protocolo de estudio o al FCI antes de la implementaci\u00f3n, a menos que el cambio sea necesario para eliminar un peligro inmediato para los pacientes, en cuyo caso el CE debe ser informado lo antes posible Adem\u00e1s, debe ser informado de cualquier evento que pueda afectar la seguridad de los pacientes o la realizaci\u00f3n continua del estudio cl\u00ednico.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comit\u00e9 de \u00e9tica (CE):"
        },
        {
            "text": "INFANT debe recibir una copia de la carta de aprobaci\u00f3n del CE antes de enviar los suministros de medicamentos al investigador de cada hospital. La carta de aprobaci\u00f3n debe incluir el t\u00edtulo del estudio, los documentos revisados y la fecha de la revisi\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comit\u00e9 de \u00e9tica (CE):"
        },
        {
            "text": "El investigador debe mantener en el archivo los registros de la revisi\u00f3n del CE y la aprobaci\u00f3n de todos los documentos del estudio",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comit\u00e9 de \u00e9tica (CE):"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Proceso de Consentimiento Informado"
        },
        {
            "text": "El FCI utilizado por el investigador ser\u00e1 el aprobado por el CE correspondiente.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "26"
        },
        {
            "text": "Es responsabilidad del investigador o profesional delegado obtener el consentimiento informado por escrito de cada sujeto antes de su participaci\u00f3n en el estudio y despu\u00e9s de que los objetivos, procedimientos y riesgos potenciales del estudio se han explicado completamente en un lenguaje que el sujeto pueda entender. El FCI debe estar firmado y fechado por el investigador o personal delegado que realiz\u00f3 el proceso de toma de consentimiento.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "26"
        },
        {
            "text": "El investigador o personal delegado le explicar\u00e1 al participante la naturaleza del estudio y responder\u00e1 todas las preguntas sobre el estudio. Les informar\u00e1 que su participaci\u00f3n es voluntaria. El participante deber\u00e1 firmar el formulario de consentimiento informado (FCI) antes de que se realice cualquier actividad espec\u00edfica del estudio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "26"
        },
        {
            "text": "A los participantes que pueden entender pero que no pueden escribir y/o leer se les leer\u00e1 el CI en presencia de un testigo imparcial, que firmar\u00e1 y fechar\u00e1 el FCI para confirmar que se obtuvo el consentimiento informado.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "26"
        },
        {
            "text": "Se firmar\u00e1n dos ejemplares. El investigador debe conservar un ejemplar como parte del registro del estudio del paciente, y se debe entregar el otro ejemplar firmado al participante.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "26"
        },
        {
            "text": "El investigador tomar\u00e1 todas las medidas apropiadas para garantizar que se mantenga el anonimato de cada sujeto del estudio en los registros para investigaci\u00f3n transmitidos fuera del centro de salud. Los documentos originales y esenciales del estudio deben mantenerse en estricta confidencialidad en cada centro de investigaci\u00f3n por el equipo del estudio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Confidencialidad y Protecci\u00f3n de Datos Personales"
        },
        {
            "text": "Los datos personales de los participantes se almacenar\u00e1n en el centro del estudio en un formato impreso y/o electr\u00f3nico protegidos por contrase\u00f1a o en un cuarto bajo llave, para garantizar el acceso exclusivo del personal autorizado del estudio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Confidencialidad y Protecci\u00f3n de Datos Personales"
        },
        {
            "text": "Para proteger los derechos y las libertades de las personas f\u00edsicas en relaci\u00f3n con el tratamiento de datos personales, se asignar\u00e1 a los participantes un c\u00f3digo alfanum\u00e9rico \u00fanico y espec\u00edfico. Los registros o conjuntos de datos de los participantes que se transfieran contendr\u00e1n el c\u00f3digo alfanum\u00e9rico; los nombres de los participantes no se transferir\u00e1n. Todos los dem\u00e1s datos identificables transferidos entre los investigadores se identificar\u00e1n mediante este c\u00f3digo \u00fanico y espec\u00edfico del participante. El centro del estudio mantendr\u00e1 una lista confidencial de los participantes que participaron en el Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Confidencialidad y Protecci\u00f3n de Datos Personales"
        },
        {
            "text": "27 estudio bajo estricta seguridad (protegidos por contrase\u00f1a o en un cuarto bajo llave), vinculando el c\u00f3digo alfanum\u00e9rico de cada participante con su identidad real.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Confidencialidad y Protecci\u00f3n de Datos Personales"
        },
        {
            "text": "Los registros y los documentos, incluidos los FCI firmados, respecto a la realizaci\u00f3n de este estudio, ser\u00e1n conservados por el investigador durante 15 a\u00f1os despu\u00e9s de la finalizaci\u00f3n del estudio, a menos que las regulaciones locales o las pol\u00edticas institucionales requieran un per\u00edodo de conservaci\u00f3n m\u00e1s prolongado. El investigador de cada instituci\u00f3n participante deber\u00e1 consultar con INFANT antes de descartar o destruir cualquier documento esencial del estudio despu\u00e9s de la finalizaci\u00f3n o interrupci\u00f3n del estudio. En caso de ser aprobado, los registros deben destruirse de manera que se garantice la confidencialidad.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Documentaci\u00f3n del Estudio"
        },
        {
            "text": "El monitor del estudio visitar\u00e1 cada sitio antes de inscribir al primer paciente y peri\u00f3dicamente durante el estudio de acuerdo con el Plan de Monitoreo del Estudio Aprobado.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoreo de sitios de estudio"
        },
        {
            "text": "El monitor recibir\u00e1 semanalmente de cada uno de los centros un informe con el n\u00famero de pacientes en periodo de pesquisa y enrolados y verificar\u00e1 que el envi\u00f3 de datos se encuentre al d\u00eda y completo, realizando de ser necesario seguimiento a cada uno de los centros.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoreo de sitios de estudio"
        },
        {
            "text": "Cada centro contar\u00e1 con una persona designada por el Investigador a verificar procesos realizados bajo protocolo y datos originales y se documentar\u00e1 dicha verificaci\u00f3n por escrito.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoreo de sitios de estudio"
        },
        {
            "text": "Las visitas de monitoreo y las actividades de monitoreo centralizado se realizar\u00e1n de acuerdo con todos los requisitos reglamentarios aplicables y normas vigentes en Argentina. Se entiende que el monitor contactar\u00e1 a cada investigador y a su equipo responsable regularmente y se le permitir\u00e1 verificar la generaci\u00f3n de los distintos registros del estudio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoreo de sitios de estudio"
        },
        {
            "text": "Ser\u00e1 responsabilidad del monitor inspeccionar los sistemas de captura de datos a intervalos regulares durante todo el estudio para verificar el cumplimiento del protocolo y la integridad, precisi\u00f3n y consistencia de los datos; y adhesi\u00f3n al ICH GCP y normativa local sobre la realizaci\u00f3n de investigaciones cl\u00ednicas. El monitor debe tener Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoreo de sitios de estudio"
        },
        {
            "text": "28 acceso a informes de laboratorio, medicaci\u00f3n de estudio, registros asociados con \u00e9l, y otros registros m\u00e9dicos necesario para verificar las entradas en el EDC.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoreo de sitios de estudio"
        },
        {
            "text": "Se asignar\u00e1 un monitor no ciego cuyo rol estar\u00e1 limitado a auditar los datos de log\u00edstica manejo y registro del tratamiento de estudio de acuerdo con el protocolo aprobado y las instrucciones de tratamiento: recepci\u00f3n y condiciones de almacenaje randomizaci\u00f3n y administraci\u00f3n retorno o destrucci\u00f3n/ reconciliaci\u00f3n final",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoreo de sitios de estudio"
        },
        {
            "text": "Se requiere que los investigadores preparen y mantengan registros de pacientes adecuados y precisos (documentos fuente).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Requisitos del documento fuente"
        },
        {
            "text": "El investigador debe mantener todos los documentos fuente en el archivo de los datos volcados al formulario del estudio (CRF). Algunos datos generados del estudio podr\u00e1n volcarse directamente en el sistema de EDC (captura directa de datos), previa aprobaci\u00f3n de dicho proceso por los Comit\u00e9s de \u00c9tica intervinientes. Los formularios de informes de casos y los documentos fuente deben estar disponibles en todo momento.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Requisitos del documento fuente"
        },
        {
            "text": "Los datos del estudio obtenidos en el curso del estudio ser\u00e1n registrados en formularios de informes de casos (CRF) y enviados a INFANT en formato scan. Una vez recibidos ser\u00e1n archivados y procesados mediante el ingresados al del sistema EDC por personal capacitado de INFANT. Todos los CRF requeridos deben completarse para cada paciente inscrito en el estudio. El investigador debe conservar una copia del libro de casos de CRF de cada paciente como parte del registro del estudio y debe estar disponible en todo momento para su inspecci\u00f3n por parte de representantes autorizados del patrocinador y las autoridades reguladoras.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Requisitos del formulario de informe de caso"
        },
        {
            "text": "Este estudio puede estar sujeto a una auditor\u00eda o inspecci\u00f3n de garant\u00eda de calidad. Si esto ocurre, el investigador es responsable de:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "16.. Auditorias e inspecciones"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 2.0 12-mayo-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "16.. Auditorias e inspecciones"
        },
        {
            "text": "-Brindar acceso a todas las instalaciones, datos de estudio y documentos necesarios para la inspecci\u00f3n o auditor\u00eda. -Comunicar cualquier informaci\u00f3n que surja de la inspecci\u00f3n de las autoridades reguladoras a INFANT de inmediato. -Tomar todas las medidas apropiadas solicitadas por INFANT para resolver los problemas encontrados durante la auditor\u00eda o inspecci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "29"
        },
        {
            "text": "Los documentos sujetos a auditor\u00eda o inspecci\u00f3n incluyen, entre otros, todos los documentos fuente, CRF, registros m\u00e9dicos, correspondencia, FCI, archivos del CE, documentaci\u00f3n de certificaci\u00f3n y control de calidad de laboratorios de apoyo, y registros relevantes para el estudio que se mantienen Instalaciones de farmacia. Las condiciones de almacenamiento del material de estudio tambi\u00e9n est\u00e1n sujetas a inspecci\u00f3n. Adem\u00e1s, los representantes del patrocinador pueden observar la conducta de cualquier aspecto del estudio cl\u00ednico o sus actividades de apoyo tanto dentro como fuera de la instituci\u00f3n del investigador.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "29"
        },
        {
            "text": "En todos los casos, se debe respetar la confidencialidad de los datos. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "29"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020 2",
            "cite_spans": [],
            "ref_spans": [],
            "section": "CLASIFICACI\u00d3N FUNCIONAL"
        },
        {
            "text": "SARS-CoV2 es un virus nuevo y particularmente agresivo para individuos de edad avanzada, quienes representan entre el 73 y 90% de los casos fatales en distintas regiones del mundo [28, 30, 40] . La mortalidad, la necesidad de cuidados intensivos, la ventilaci\u00f3n mec\u00e1nica, el requerimiento de ox\u00edgeno, y las hospitalizaciones por enfermedad respiratoria aumentan marcadamente con el avance de la edad en los pacientes [2, 3, 29, 32, 46] . De hecho, la frecuencia de muerte por enfermedad por SARS-CoV2 (covid-19) es del 8% en los pacientes entre 70 y 80 a\u00f1os, y aumenta a 14,8% en los mayores de 80 [23] . Espec\u00edficamente en pacientes hospitalizados mayores de 75 a\u00f1os, la mortalidad es de 29,4% [24] , y en la terapia intensiva asciende a un alarmante 43,5% [25] . Varias comorbilidades asociadas con enfermedad vascular y/o pulmonar agravan el pron\u00f3stico de los infectados aun en pacientes menores de 70, incluyendo hipertensi\u00f3n arterial, diabetes, obesidad y enfermedad pulmonar obstructiva cr\u00f3nica (EPOC) [3, 23, 30, 31] . A la fecha, el virus ha causado m\u00e1s de 290.000 muertes en el mundo, m\u00e1s de 300 de ellas en Argentina donde se encuentra contenido a trav\u00e9s de una estrategia transitoria de cuarentena cuasi-universal [4] . No existe a\u00fan ning\u00fan tratamiento espec\u00edfico disponible. Los resultados de los ensayos de eficacia para vacunas contra SARS-CoV2 se conocer\u00e1n dentro de m\u00ednimamente 10-14 meses.",
            "cite_spans": [
                {
                    "start": 180,
                    "end": 184,
                    "text": "[28,",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 185,
                    "end": 188,
                    "text": "30,",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 189,
                    "end": 192,
                    "text": "40]",
                    "ref_id": null
                },
                {
                    "start": 417,
                    "end": 420,
                    "text": "[2,",
                    "ref_id": null
                },
                {
                    "start": 421,
                    "end": 423,
                    "text": "3,",
                    "ref_id": null
                },
                {
                    "start": 424,
                    "end": 427,
                    "text": "29,",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 428,
                    "end": 431,
                    "text": "32,",
                    "ref_id": null
                },
                {
                    "start": 432,
                    "end": 435,
                    "text": "46]",
                    "ref_id": null
                },
                {
                    "start": 598,
                    "end": 602,
                    "text": "[23]",
                    "ref_id": null
                },
                {
                    "start": 695,
                    "end": 699,
                    "text": "[24]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 758,
                    "end": 762,
                    "text": "[25]",
                    "ref_id": null
                },
                {
                    "start": 1008,
                    "end": 1011,
                    "text": "[3,",
                    "ref_id": null
                },
                {
                    "start": 1012,
                    "end": 1015,
                    "text": "23,",
                    "ref_id": null
                },
                {
                    "start": 1016,
                    "end": 1019,
                    "text": "30,",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 1020,
                    "end": 1023,
                    "text": "31]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 1225,
                    "end": 1228,
                    "text": "[4]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "INTRODUCCI\u00d3N"
        },
        {
            "text": "El SARS-CoV2 es un virus envuelto que contiene ARN monocatenario en sentido positivo unido a una nucleoprote\u00edna (prote\u00edna N), dentro de una c\u00e1pside compuesta por prote\u00ednas de la matriz (prote\u00edna M). La envoltura posee glicoprote\u00ednas en forma de espinas (prote\u00edna S) que se unen al receptor celular ACE2 en humanos y generan anticuerpos neutralizantes [13] . La primo infecci\u00f3n por SARS-CoV2, como otras enfermedades respiratorias, genera una respuesta de anticuerpos con producci\u00f3n temprana de IgM seguida de IgG espec\u00edfica contra las prote\u00ednas virales [14] . La detecci\u00f3n de anticuerpos neutralizantes del virus es frecuente, y alcanza niveles altos de hasta 1:21,500 PRNT50, mayormente excediendo t\u00edtulos de 1:500 despu\u00e9s de 28 d\u00edas del inicio de s\u00edntomas en pacientes leves [41] . Aproximadamente 5% de los pacientes presentan niveles de anticuerpos neutralizantes <1:40, especialmente los m\u00e1s j\u00f3venes [41] . Un estudio de infecci\u00f3n primaria v\u00eda respiratoria en macacos Rhesus, utilizando 10 6 pfu de SARS-CoV2 seguido de un segundo desaf\u00edo intratraqueal usando el mismo virus y dosis 28 d\u00edas m\u00e1s tarde, demostr\u00f3 ausencia de reinfecci\u00f3n tras una extensa evaluaci\u00f3n por RT-PCR de tejidos post-necropsia [42] . Los t\u00edtulos neutralizantes antes del segundo in\u00f3culo variaban entre 1:8-1:16 PRNT50 [42] . Estos hallazgos -limitados por Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020 3 cierto, dada la novedad del problema-sugieren que a\u00fan bajos t\u00edtulos de anticuerpos neutralizantes podr\u00edan prevenir la enfermedad severa por el virus.",
            "cite_spans": [
                {
                    "start": 351,
                    "end": 355,
                    "text": "[13]",
                    "ref_id": null
                },
                {
                    "start": 553,
                    "end": 557,
                    "text": "[14]",
                    "ref_id": null
                },
                {
                    "start": 777,
                    "end": 781,
                    "text": "[41]",
                    "ref_id": null
                },
                {
                    "start": 905,
                    "end": 909,
                    "text": "[41]",
                    "ref_id": null
                },
                {
                    "start": 1205,
                    "end": 1209,
                    "text": "[42]",
                    "ref_id": null
                },
                {
                    "start": 1296,
                    "end": 1300,
                    "text": "[42]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "INTRODUCCI\u00d3N"
        },
        {
            "text": "Proteger a las poblaciones m\u00e1s vulnerables al SARS-CoV2 es imperioso, en el contexto de un germen altamente infeccioso (R 0 estimado entre 2 y 3,28) [27, 33, 34] . Su contagiosidad desborda r\u00e1pidamente la capacidad sanitaria de pa\u00edses desarrollados en distintas regiones del mundo [5] y amenaza los recursos sanitarios de pa\u00edses en v\u00edas de desarrollo [6] . Regiones de Italia, Espa\u00f1a y Estados Unidos se han visto desbordadas por la pandemia, que representa una seria amenaza para Argentina, en coincidencia con el inicio de la circulaci\u00f3n anual de otros pat\u00f3genos pulmonares, como la gripe com\u00fan y el virus sincicial respiratorio [26] . Evidentemente, resultar\u00eda imposible dar respuesta a una avalancha de pacientes graves [7] , y toda estrategia tendiente a disminuir las infecciones y el desarrollo de enfermedad severa se alinea directamente con el objetivo m\u00e9dico de salvar vidas y con las necesidades sanitarias del pa\u00eds para poder brindar la mejor atenci\u00f3n posible a aquellos pacientes que lo necesiten.",
            "cite_spans": [
                {
                    "start": 149,
                    "end": 153,
                    "text": "[27,",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 154,
                    "end": 157,
                    "text": "33,",
                    "ref_id": null
                },
                {
                    "start": 158,
                    "end": 161,
                    "text": "34]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 281,
                    "end": 284,
                    "text": "[5]",
                    "ref_id": null
                },
                {
                    "start": 351,
                    "end": 354,
                    "text": "[6]",
                    "ref_id": null
                },
                {
                    "start": 631,
                    "end": 635,
                    "text": "[26]",
                    "ref_id": null
                },
                {
                    "start": 724,
                    "end": 727,
                    "text": "[7]",
                    "ref_id": "BIBREF128"
                }
            ],
            "ref_spans": [],
            "section": "INTRODUCCI\u00d3N"
        },
        {
            "text": "La profilaxis post-exposici\u00f3n a virus y el tratamiento en fases tempranas de enfermedad, a trav\u00e9s de defensas obtenidas en plasma de convalecientes, es una pr\u00e1ctica extendida con antecedentes exitosos en la historia de la medicina a nivel nacional y global. Ya en 1960, Brunell y col. lograron prevenir la varicela cl\u00ednica en hermanos con padres enfermos, usando inmunoglobulinas anti-varicela zoster obtenidas del plasma de pacientes previamente infectados [8] . Hoy mismo, por ejemplo, la inmunoglobulina enriquecida para sarampi\u00f3n se utiliza en personas no vacunadas que estuvieron en contacto con un enfermo durante los 6 d\u00edas previos con una eficacia cercana al 100% [9, 52]; un producto similar enriquecido para el virus de varicela zoster se administra en embarazadas, reci\u00e9n nacidos, e inmunosuprimidos no vacunados en contacto con infectados dentro de las 96 horas disminuyendo un 90% la incidencia de enfermedad grave [10, 53, 54] ; la inmunoglobulina antitet\u00e1nica suplementa la vacunaci\u00f3n en v\u00edctimas de heridas sucias con inmunizaci\u00f3n primaria incompleta [43] ; la gammaglobulina contra hepatitis B se utiliza como prevenci\u00f3n para reci\u00e9n nacidos de madres infectadas con una eficacia del 75% [44, 55] ; y la gammaglobulina antirr\u00e1bica es ~100% efectiva en la profilaxis posterior a la agresi\u00f3n de un animal sospechoso [11, 56] . Las intervenciones utilizando inmunidad humana derivada del plasma de convalecientes han demostrado ser seguras, han prevenido innumerables casos de enfermedad severa, y han preservado vidas en todo el mundo.",
            "cite_spans": [
                {
                    "start": 458,
                    "end": 461,
                    "text": "[8]",
                    "ref_id": null
                },
                {
                    "start": 928,
                    "end": 932,
                    "text": "[10,",
                    "ref_id": null
                },
                {
                    "start": 933,
                    "end": 936,
                    "text": "53,",
                    "ref_id": "BIBREF172"
                },
                {
                    "start": 937,
                    "end": 940,
                    "text": "54]",
                    "ref_id": "BIBREF173"
                },
                {
                    "start": 1067,
                    "end": 1071,
                    "text": "[43]",
                    "ref_id": null
                },
                {
                    "start": 1204,
                    "end": 1208,
                    "text": "[44,",
                    "ref_id": null
                },
                {
                    "start": 1209,
                    "end": 1212,
                    "text": "55]",
                    "ref_id": null
                },
                {
                    "start": 1330,
                    "end": 1334,
                    "text": "[11,",
                    "ref_id": null
                },
                {
                    "start": 1335,
                    "end": 1338,
                    "text": "56]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "INTRODUCCI\u00d3N"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020 4 El objetivo principal de nuestro estudio es evaluar la eficacia del plasma de convaleciente en reducir la progresi\u00f3n a enfermedad severa en personas entre 65-74 a\u00f1os con al menos una comorbilidad y en todos los 75 a\u00f1os que se presenten con sintomatolog\u00eda leve de menos de 48 hs de evoluci\u00f3n al momento del inicio de la pesquisa y reciban diagn\u00f3stico temprano de COVID-19. Nuestra hip\u00f3tesis central es que una dosis \u00fanica de plasma de convaleciente comparada contra placebo (soluci\u00f3n salina al 0,9%), y administrada hasta 72 horas despu\u00e9s del inicio de los s\u00edntomas por SARS-Cov2 (o sea, hasta 24 horas despu\u00e9s del l\u00edmite de tiempo para presentarse a pesquisa y testeo), prevendr\u00e1 la progresi\u00f3n a una enfermedad respiratoria severa en sujetos entre 65-74 a\u00f1os con al menos una comorbilidad y en independientemente de presencia de comorbilidad basal.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "INTRODUCCI\u00d3N"
        },
        {
            "text": "Evaluar la eficacia del plasma de convaleciente, a partir de 12 horas de la administraci\u00f3n, en reducir la progresi\u00f3n a enfermedad respiratoria severa en personas entre 65-74 a\u00f1os con al menos una comorbilidad y en todos los de 75 a\u00f1os con sintomatolog\u00eda leve y diagn\u00f3stico temprano de COVID-19 hasta los 15 d\u00edas de administraci\u00f3n del tratamiento (16-18 d\u00edas de enfermedad considerando el periodo sintom\u00e1tico pre-enrolamiento),",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivo Primario"
        },
        {
            "text": "Los Objetivos Secundarios incluyen determinar si la administraci\u00f3n de plasma de convaleciente hasta los 15 d\u00edas o a partir de entonces hasta un m\u00e1ximo de 25 d\u00edas de la administraci\u00f3n de tratamiento si continuase internado consigue:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Secundarios"
        },
        {
            "text": "Disminuir la necesidad de soporte de ox\u00edgeno con oxigenoterapia m\u00e1xima T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020 5 enzimas hep\u00e1ticas (transaminasas) mayor a tres veces el valor superior normal, miocardiopat\u00eda aguda (definida por elevaci\u00f3n de troponina por encima del nivel normal y/o nuevas alteraciones electrocardiogr\u00e1ficas o ecocardiogr\u00e1ficas para da\u00f1o mioc\u00e1rdico) por SARS-Cov2 en pacientes entre 65-74 a\u00f1os con al menos una comorbilidad y en de COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Secundarios"
        },
        {
            "text": "Disminuir la mortalidad por SARS-CoV2 en pacientes entre 65-74 a\u00f1os con al -19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Secundarios"
        },
        {
            "text": "Disminuir la duraci\u00f3n de soporte de oxigeno debido a covid-19 en pacientes hipox\u00e9micos.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Secundarios"
        },
        {
            "text": "Describir la seguridad de la administraci\u00f3n de plasma de convaleciente en pacientes entre 65-75 a\u00f1os con COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Secundarios"
        },
        {
            "text": "Explorar la concentraci\u00f3n de IgG anti-S de SARS CoV2 en plasma de los participantes asociada con ausencia de enfermedad respiratoria severa obtenidas a las 24 horas de la infusi\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Secundarios"
        },
        {
            "text": "Explorar si, en lugar de proteger contra la enfermedad respiratoria severa, la administraci\u00f3n de plasma de convaleciente retarda la aparici\u00f3n de dicha enfermedad.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Exploratorios"
        },
        {
            "text": "Explorar los efectos del plasma de convaleciente sobre la respuesta inmune humoral primaria contra la infecci\u00f3n por SARS CoV2. a los 90 d\u00edas de enrolamiento Explorar si los efectos en enfermedad respiratoria, cardiovascular y mortalidad a largo plazo fueron afectados por la intervenci\u00f3n a los 12 meses de enrolamiento.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Exploratorios"
        },
        {
            "text": "Explorar la correlaci\u00f3n entre carga viral determinada por RT-PCR al diagn\u00f3stico y la respuesta a tratamiento con plasma.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Exploratorios"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020 6",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Objetivos Exploratorios"
        },
        {
            "text": "Enfermedad respiratoria severa por SARS-CoV2, confirmada por detecci\u00f3n de ARN viral por RT-PCR, y definida por la presencia de cualquiera de las dos siguientes saturaci\u00f3n de ox\u00edgeno en aire ambiental <93% [20, 21] . El endpoint primario se determinar\u00e1 a partir de 12 horas del inicio de la infusi\u00f3n hasta 15 d\u00edas desde la administraci\u00f3n del tratamiento. Duraci\u00f3n del requerimiento de soporte de oxigeno en pacientes con covid-19 debido a saturaci\u00f3n en aire ambiental <93%.",
            "cite_spans": [
                {
                    "start": 205,
                    "end": 209,
                    "text": "[20,",
                    "ref_id": null
                },
                {
                    "start": 210,
                    "end": 213,
                    "text": "21]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Criterio Primario de Valoraci\u00f3n de Eficacia"
        },
        {
            "text": "HIP\u00d3TESIS Y JUSTIFICACI\u00d3N",
            "cite_spans": [],
            "ref_spans": [],
            "section": "4."
        },
        {
            "text": "Nuestra hip\u00f3tesis central es que una dosis de plasma de convaleciente comparada contra placebo, y administrada hasta 72 horas desde el inicio de los s\u00edntomas leves, prevendr\u00e1 la progresi\u00f3n a enfermedad respiratoria severa por covid-19 en pacientes Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020 7 entre 65presenten con menos de 48 horas de evoluci\u00f3n al proceso de pesquisa y con sintomatolog\u00eda leve.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hip\u00f3tesis"
        },
        {
            "text": "La eficacia de una preparaci\u00f3n terap\u00e9utica contra el SARS-CoV2 econ\u00f3micamente accesible analizada mediante un estudio aleatorizado, doble ciego, en pacientes vulnerables permitir\u00eda escalar de inmediato su aplicabilidad a nivel nacional e internacional mediante campa\u00f1as masivas de donaci\u00f3n de plasma de convalecientes a la espera de soluciones definitivas tales como medicamentos exitosos, anticuerpos monoclonales, o vacunas [17] . Inclusive, de existir protecci\u00f3n parcial concentrada en el tracto respiratorio inferior [18] , esta misma estrategia podr\u00eda hipot\u00e9ticamente permitir la inmunizaci\u00f3n de los sujetos mediante la replicaci\u00f3n controlada del germen en el tracto respiratorio alto (como en el caso de la administraci\u00f3n pasiva de anticuerpos contra el virus sincicial respiratorio en lactantes [19] ).",
            "cite_spans": [
                {
                    "start": 426,
                    "end": 430,
                    "text": "[17]",
                    "ref_id": null
                },
                {
                    "start": 521,
                    "end": 525,
                    "text": "[18]",
                    "ref_id": null
                },
                {
                    "start": 802,
                    "end": 806,
                    "text": "[19]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Justificaci\u00f3n"
        },
        {
            "text": "Un estudio aleatorizado, doble-ciego, controlado con placebo para testear la eficacia del plasma de convaleciente, administrado hasta 72 horas despu\u00e9s del inicio de s\u00edntomas, con el fin de evitar la progresi\u00f3n hacia una enfermedad respiratoria severa. El estudio se llevar\u00e1 a cabo en sujetos entre 65-74 a\u00f1os con al menos una 75 a\u00f1os que se presenten con sintomatolog\u00eda leve de menos de 48 horas de evoluci\u00f3n al momento de la pesquisa (definida en secci\u00f3n 5.1) y diagn\u00f3stico precoz de covid-19. El estudio se realizar\u00e1 durante un per\u00edodo de observaci\u00f3n m\u00ednimo de 15 d\u00edas en el que los participantes permanecer\u00e1n bajo control m\u00e9dico diario por protocolo para determinar el criterio de valoraci\u00f3n primario. El per\u00edodo de monitoreo se extender\u00e1 a partir de entonces, hasta un m\u00e1ximo de 25 d\u00edas de la administraci\u00f3n de tratamiento, si continuase internado, para analizar los criterios de valoraci\u00f3n de eficacia secundarios.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "DISE\u00d1O DEL ESTUDIO"
        },
        {
            "text": "Se proyecta que el estudio incorpore un m\u00e1ximo estimado de 210 pacientes (ver 9.0 Tama\u00f1o muestral). Los participantes ser\u00e1n aleatorizados en una proporci\u00f3n de 1:1. Todos los participantes recibir\u00e1n una dosis \u00fanica endovenosa (EV) -acorde a las NORMAS ADMINISTRATIVAS Y T\u00c9CNICAS RM 797/13 139/14 1507/15 Direcci\u00f3n de Sangre y Hemoderivados Ministerio de Salud de la Naci\u00f3n (por http://www.msal.gob.ar/disahe/images/stories/pdf/normas-hemoterapia.pdf) el D\u00eda 0 con el art\u00edculo de prueba asignado, plasma de convaleciente o placebo (ver Tabla 1). Para cada sujeto, la participaci\u00f3n en el estudio se extender\u00e1 un m\u00ednimo de 15 d\u00edas o hasta la resoluci\u00f3n de s\u00edntomas desde la administraci\u00f3n del art\u00edculo de prueba con un m\u00e1ximo de 25 d\u00edas. Los sujetos participantes ser\u00e1n monitoreados durante y despu\u00e9s de la administraci\u00f3n del art\u00edculo de prueba para evaluar eventos de seguridad esperables y no esperables luego de la administraci\u00f3n de plasma. Un Comit\u00e9 de Monitoreo de Datos y Seguridad supervisar\u00e1 el enrolamiento, la eficacia y la seguridad de los participantes a lo largo del estudio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "DISE\u00d1O DEL ESTUDIO"
        },
        {
            "text": "El estudio se llevar\u00e1 a cabo en el Hospital San Juan de Dios, el Hospital Simplemente Evita, el Hospital Dr. Carlos Bocalandro, el Hospital Evita Pueblo, el Hospital Central de San Isidro y el Sanatorio Ant\u00e1rtida de la Provincia de Buenos Aires en estrecha coordinaci\u00f3n con los efectores sanitarios del Ministerio de Salud provincial y en el Hospital Militar Central, el Sanatorio de Los Arcos, CEMIC, el Centro de Investigaci\u00f3n OSECAC, el Sanatorio Finochietto, el Centro Gallego de Buenos Aires, el Sanatorio Anchorena y la Cl\u00ednica Olivos garantizando que no se interferir\u00e1 con los cuidados y las normas de atenci\u00f3n de pacientes dispuestas para la notificaci\u00f3n y manejo de esta enfermedad.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Tabla 1. Asignaciones de Tratamiento"
        },
        {
            "text": "EQUIPO MOVIL-COVID. Dado el contexto de la situaci\u00f3n covid-19 en el AMBA con la reducci\u00f3n de disponibilidad de camas y la sobrecarga del personal hospitalario sumado al aumento exponencial de los casos graves, los pacientes levemente sintom\u00e1ticos pero sin requerimientos de ox\u00edgeno y provenientes de geri\u00e1tricos encuentran extraordinariamente dif\u00edcil (casi imposible) su internaci\u00f3n en los hospitales. Por tanto, para facilitar la incorporaci\u00f3n de los principales beneficiarios potenciales de esta intervenci\u00f3n al estudio (es decir, los ancianos mas vulnerables) y dada la enorme necesidad de salud publica existente para proveer alternativas terap\u00e9uticas contra este flagelo, se agregara una unidad COVID-M\u00f3vil que monitorear\u00e1 participantes voluntarios en Centros COVID-PAMI donde la administraci\u00f3n del producto de investigaci\u00f3n (hoy Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020 9 demostrado claramente como seguro en publicaciones de m\u00e1s de 20.000 pacientes) se realizar\u00e1 bajo las mismas normas y por el mismo equipo que en todos los otros sitios de investigaci\u00f3n y el equipo COVID-M\u00f3vil registrara la evoluci\u00f3n de dichos participantes que se encuentran bajo el cuidado de m\u00e9dicos y personal de salud del PAMI in situ. Todo traslado de estos pacientes a centros de mayor complejidad por la evoluci\u00f3n natural de su enfermedad ser\u00e1 decisi\u00f3n de los m\u00e9dicos tratantes del PAMI, y el equipo de investigaci\u00f3n m\u00f3vil se limitar\u00e1 a continuar recabando datos de su progreso cl\u00ednico de la misma forma que lo hace hoy cuando un paciente es trasladado o recibe un alta temprana en otra instituci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Tabla 1. Asignaciones de Tratamiento"
        },
        {
            "text": "Criterios de elegibilidad",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.1."
        },
        {
            "text": "Un sujeto debe cumplir los siguientes criterios para ser incluido en el estudio:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Criterios de Inclusi\u00f3n:"
        },
        {
            "text": "1. a\u00f1os o edad entre 65-74 a\u00f1os con al menos una de las comorbilidades siguientes: a. Diagn\u00f3stico de hipertensi\u00f3n arterial bajo tratamiento farmacol\u00f3gico. b. Diagn\u00f3stico conocido de diabetes en tratamiento con algunas de las drogas disponibles (Ap\u00e9ndice I). c. Obesidad (IMC -\u00cdndice de masa corporald. Diagn\u00f3stico de enfermedad pulmonar obstructiva cr\u00f3nica (EPOC) en tratamiento con algunas de las drogas disponibles (Ap\u00e9ndice I). e. Enfermedad cardiovascular establecida definida como a) diagn\u00f3stico conocido de enfermedad coronaria, b) historia de enfermedad cerebrovascular isqu\u00e9mica o hemorr\u00e1gica, 40%). f. Enfermedad renal cr\u00f3nica (definida como reducci\u00f3n del FG por debajo de 60 ml/min/1,73 m 2 ). ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Criterios de Inclusi\u00f3n:"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020 10 4. Ser capaz, seg\u00fan juicio m\u00e9dico, de comprender y cumplir con los procedimientos del estudio y de consentir o no su participaci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Diagn\u00f3stico de SARS-Cov2 confirmado por RT-PCR"
        },
        {
            "text": "5. Proveer consentimiento informado por s\u00ed mismo.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Diagn\u00f3stico de SARS-Cov2 confirmado por RT-PCR"
        },
        {
            "text": "6. Pacientes con vulnerabilidad cognitiva con apoyo en la toma de decisi\u00f3n por su representante seg\u00fan corresponda. (ver secci\u00f3n 12)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Diagn\u00f3stico de SARS-Cov2 confirmado por RT-PCR"
        },
        {
            "text": "Un sujeto que cumple cualquiera de los siguientes criterios ser\u00e1 excluido del estudio: inmunosupresores u otras drogas que modifican el sistema inmune al momento del enrolamiento o dentro de los 6 meses previos a la administraci\u00f3n de la medicaci\u00f3n del estudio. Una dosis inmunosupresora de glucocorticoides se Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020 11 definir\u00e1 como una dosis equivalente. 13. Antecedente de transplante de \u00f3rgano s\u00f3lido. 14. Enfermedad hep\u00e1tica cr\u00f3nica conocida con diagn\u00f3stico de cirrosis estadio II-III-IV. 15. Enfermedad pulmonar cr\u00f3nica con requerimiento de ox\u00edgeno. 16 . Cualquier otra condici\u00f3n f\u00edsica, psiqui\u00e1trica o social que pueda, a criterio del investigador, aumentar los riesgos por la participaci\u00f3n en el estudio a los participantes o que puedan conducir a la recolecci\u00f3n de datos de seguridad incompletos o inexactos. 17. Pacientes que est\u00e9n recibiendo cualquier tipo de terapia anticoagulante sea por v\u00eda oral; familia de los dicumar\u00ednicos (Warfarina como Acenocumarol) o anticoagulantes de acci\u00f3n directa (ACOD) (Rivaroxaban, Dabigatran, Apixaban) as\u00ed como tampoco aquellos que est\u00e9n recibiendo heparina en cualquiera de sus tipos con fines de terapia anticoagulante.",
            "cite_spans": [
                {
                    "start": 850,
                    "end": 852,
                    "text": "16",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Criterios de Exclusi\u00f3n"
        },
        {
            "text": "5.2.a. Poblaci\u00f3n participante y proceso de identificaci\u00f3n de potenciales sujetos. Dichos candidatos ser\u00e1n invitados a contactarse de inmediato con el fin de evaluar su participaci\u00f3n a trav\u00e9s de los n\u00fameros designados por las organizaciones intervinientes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Procedimientos del estudio (Tabla 2)"
        },
        {
            "text": "Aquellos pacientes que cumplan con los criterios de inclusi\u00f3n y no cumplan ninguno de los criterios de exclusi\u00f3n arriba mencionados ser\u00e1n invitados a participar en la fase de pesquisa del estudio en el cual, en caso de aceptar (plasmando su conformidad a trav\u00e9s de la firma del consentimiento informado de pesquisa -ANEXO), se obtendr\u00e1 una muestra de secreci\u00f3n respiratoria por medio de hisopados nasofar\u00edngeo y orofar\u00edngeo (de acuerdo al procedimiento y normativa implementada por el Ministerio de Salud) para detectar ARN de SARS-CoV2 por la prueba de cadena de la polimerasa (RT-PCR).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Procedimientos del estudio (Tabla 2)"
        },
        {
            "text": "Dicha muestra ser\u00e1 procesada y analizada por los laboratorios intervinientes designados para las instituciones participantes, y que actualmente proveen este mismo servicio diagnostico diariamente, utilizando el mismo test de RT-PCR para evaluar la presencia de ARN de SARS-CoV2. Esta determinaci\u00f3n se realizar\u00e1 lo antes posible (en Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020 12 un m\u00e1ximo de 24 horas) y, tal como hasta hoy, bajo todas las normas de bioseguridad indicadas por las autoridades sanitarias. Las muestras se conservar\u00e1n para posterior testeo por RT-PCR de co-infecciones con influenza A y B, virus sincicial respiratorio y otros pat\u00f3genos virales de invierno en la Fundaci\u00f3n INFANT.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Procedimientos del estudio (Tabla 2)"
        },
        {
            "text": "Aquellos pacientes que ya cuenten con un resultado positivo (+) y considerado v\u00e1lido podr\u00e1n ser invitados a participar de la fase de pesquisa del estudio y no ser\u00e1n hisopados nuevamente.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Procedimientos del estudio (Tabla 2)"
        },
        {
            "text": "En caso de detectarse en la muestra respiratoria ARN de SARS-CoV2, se informar\u00e1 al candidato sobre los detalles del estudio y se verificar\u00e1 su elegibilidad nuevamente. El candidato podr\u00e1 decidir no participar de la investigaci\u00f3n seg\u00fan su libre albedr\u00edo y sin consecuencia alguna de ning\u00fan tipo. En caso de que el sujeto est\u00e9 interesado en participar en el estudio, y tras su consentimiento atestado con la firma del consentimiento informado de participaci\u00f3n (ANEXO), se proceder\u00e1 a asignarle un n\u00famero de identificaci\u00f3n \u00fanico. Una vez asignado su c\u00f3digo alfanum\u00e9rico, se proceder\u00e1 a obtener los signos vitales y realizar un examen f\u00edsico completo para obtener la siguiente informaci\u00f3n demogr\u00e1fica y cl\u00ednica [1-3, 25, 47-51]:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.b. Enrolamiento para la participaci\u00f3n en el estudio"
        },
        {
            "text": "-Sexo -Edad -Medicaciones habituales y de los \u00faltimos 15 d\u00edas. -Antecedentes de tabaquismo -Comorbilidades de inter\u00e9s primario: hipertensi\u00f3n arterial, diabetes, enfermedad coronaria, insuficiencia card\u00edaca, antecedentes de ACV e IAM, EPOC, nefropat\u00eda cr\u00f3nica, y obesidad. -Comorbilidades secundarias: asma, antecedentes de c\u00e1ncer, enfermedades hep\u00e1ticas, y enfermedades neurol\u00f3gicas.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.b. Enrolamiento para la participaci\u00f3n en el estudio"
        },
        {
            "text": "Todos los participantes con elegibilidad confirmada ser\u00e1n asignados aleatoriamente a un grupo de tratamiento. La asignaci\u00f3n aleatoria de sujetos participantes se realizar\u00e1 utilizando un sistema electr\u00f3nico por el encargado de aleatorizaci\u00f3n del estudio. Una vez aleatorizado el paciente, el encargado de la asignaci\u00f3n se comunicar\u00e1 con un miembro del equipo de Medicina Transfusional Central del estudio quien proceder\u00e1 a extraer la bolsa opaca de tratamiento indicada del freezer del Laboratorio Central. El",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.c. Asignaci\u00f3n aleatoria"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.c. Asignaci\u00f3n aleatoria"
        },
        {
            "text": "13 equipo de Medicina Transfusional proceder\u00e1 a llevar dicha bolsa en fr\u00edo al hospital asignado. All\u00ed completar\u00e1 la preparaci\u00f3n del producto enmascarado y administrar\u00e1 el tratamiento indicado al paciente participante utilizando para su infusi\u00f3n un acceso venoso previamente obtenido por un miembro del equipo del hospital. Solo este equipo (el encargado de aleatorizaci\u00f3n y el encargado de Medicina Transfusional Central de administrar el tratamiento) conocer\u00e1n el producto a administrar a cada paciente (equipo no ciego). Ni el paciente ni los investigadores tendr\u00e1n conocimiento del tratamiento administrado, realizando un estudio de doble ciego. El equipo no ciego llevar\u00e1 un registro de las asignaciones de producto y sus administraciones que ser\u00e1 guardado de manera confidencial. En la eventual necesidad de una ruptura de ciego se podr\u00e1 recurrir a dichos registros.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.c. Asignaci\u00f3n aleatoria"
        },
        {
            "text": "La preparaci\u00f3n y administraci\u00f3n del plasma de convaleciente o placebo (soluci\u00f3n fisiol\u00f3gica) se realizar\u00e1 acorde a las NORMAS ADMINISTRATIVAS Y T\u00c9CNICAS RM 797/13 139/14 1507/15 Direcci\u00f3n de Sangre y Hemoderivados Ministerio de Salud de la Naci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.d. Preparaci\u00f3n y administraci\u00f3n del art\u00edculo de prueba"
        },
        {
            "text": "(http://www.msal.gob.ar/disahe/images/stories/pdf/normashemoterapia.pdf). T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020 14 5.2.e. Toma de muestra de sangre para titulaci\u00f3n de IgG anti-S SARS CoV2 en suero.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.d. Preparaci\u00f3n y administraci\u00f3n del art\u00edculo de prueba"
        },
        {
            "text": "A las 24 horas de completada la infusi\u00f3n del tratamiento, se obtendr\u00e1 una muestra de 5 ml de sangre venosa de todos los participantes para la titulaci\u00f3n en suero de IgG anti-S SARS-CoV2, a realizarse en la Fundaci\u00f3n INFANT por m\u00e9todo ELISA (COVIDAR IgG, Leloir/CONICET). El suero se preservar\u00e1 a -20 C hasta su traslado en fr\u00edo por un sistema de transporte autorizado para manejo de muestras biol\u00f3gicas a la Fundaci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.d. Preparaci\u00f3n y administraci\u00f3n del art\u00edculo de prueba"
        },
        {
            "text": "Ventana de toma de muestra: +/-4 horas. La muestra podr\u00e1 tomarse en un plazo m\u00ednimo de 20 hs y uno m\u00e1ximo de 28 horas post-finalizaci\u00f3n de la administraci\u00f3n del Producto de Investigaci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.d. Preparaci\u00f3n y administraci\u00f3n del art\u00edculo de prueba"
        },
        {
            "text": "Se realizar\u00e1 un control diario a partir del Dia 0, y por lo menos durante 15 d\u00edas desde la infusi\u00f3n y hasta 25 d\u00edas para aquellos sujetos que contin\u00faan hospitalizados a partir del d\u00eda 15. Aquellos pacientes que sean dados de alta previo al d\u00eda 15, ser\u00e1n monitoreados por un equipo de m\u00e9dicos domiciliarios entrenados para tal fin que trabajar\u00e1n en colaboraci\u00f3n con los centros de investigaci\u00f3n. La siguiente informaci\u00f3n cl\u00ednica se recolectar\u00e1 diariamente (utilizando un cuestionario dise\u00f1ado para tal fin) por personal del estudio y sin interferir con la atenci\u00f3n m\u00e9dica del paciente ni alterar las normas recomendadas por las autoridades sanitarias para el manejo de los pacientes con COVID-19: (a) frecuencia respiratoria (mirando como excursiona el t\u00f3rax durante 30 segundos), (b) saturaci\u00f3n de ox\u00edgeno, (c) temperatura, (d) frecuencia cardiaca central, (e) tos y duraci\u00f3n, (f) dolor de garganta y duraci\u00f3n, (g) sensaci\u00f3n de fiebre/escalofr\u00edos, (h) necesidad de provisi\u00f3n de ox\u00edgeno suplementario y duraci\u00f3n, (i) necesidad de cuidados intensivos y duraci\u00f3n, (j) necesidad de asistencia respiratoria no invasiva o invasiva y duraci\u00f3n, (k) evidencia de SDMO: seg\u00fan criterios de injuria renal aguda, criterios de elevaci\u00f3n de enzimas hep\u00e1ticas y criterios de miocardiopat\u00eda aguda (detallados en secci\u00f3n 2.2), (l) sobrevida. T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.f. Seguimiento cl\u00ednico diario"
        },
        {
            "text": "15 ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.f. Seguimiento cl\u00ednico diario"
        },
        {
            "text": "Un Comit\u00e9 Independiente de Monitoreo de Datos supervisar\u00e1 la seguridad de los sujetos durante todo el estudio. El CIMD incluir\u00e1, como m\u00ednimo, miembros con experiencia en el manejo de medicina interna, enfermedades infecciosas, y un bioestad\u00edstico con experiencia espec\u00edfica en el dise\u00f1o, an\u00e1lisis y monitoreo de seguridad de estudios cl\u00ednicos. El CIMD operar\u00e1 bajo un plan aprobado y tendr\u00e1 la responsabilidad de monitorear las medidas de resultado / puntos finales, eventos adversos (EA) y eventos adversos serios (EAS), y recomendar la finalizaci\u00f3n del estudio si aparece en alg\u00fan momento durante el estudio que los participantes (o un subgrupo de participantes) se encuentran en riesgo indebido como resultado de su Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comit\u00e9 Independiente de Monitoreo de Datos"
        },
        {
            "text": "16 participaci\u00f3n. El CIMD se reunir\u00e1 (por teleconferencia) semanalmente para revisar el acumulado de datos sobre seguridad y eficacia y realizar\u00e1 un an\u00e1lisis interino de los datos. El CIMD emitir\u00e1 recomendaciones escritas en base a sus reuniones acerca de la continuidad del estudio. Las actas de cada reuni\u00f3n se registrar\u00e1n en minutas documentadas en base a una agenda de trabajo preestablecida. Cualquier informaci\u00f3n de salud protegida espec\u00edfica del participante revisado por el CIMD se mantendr\u00e1 completamente confidencial. Las sesiones ser\u00e1n cerradas sin acceso a terceros.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comit\u00e9 Independiente de Monitoreo de Datos"
        },
        {
            "text": "El investigador en cada instituci\u00f3n y a nivel general supervisar\u00e1 la seguridad del paciente del estudio en su(s) sitio(s) seg\u00fan los requisitos de este protocolo y de acuerdo con las Buenas Pr\u00e1cticas Cl\u00ednicas (GCP) actuales. El investigador monitorear\u00e1 los datos de seguridad en todos los sitios de estudio. El monitoreo de seguridad se realizar\u00e1 de manera continua (por ejemplo, revisi\u00f3n individual de EAS, EAs y puntos finales) y de forma acumulada peri\u00f3dica.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoreo de Seguridad"
        },
        {
            "text": "Un EA es cualquier acontecimiento m\u00e9dico desfavorable en un paciente al que se le administr\u00f3 un f\u00e1rmaco del estudio que puede tener o no una relaci\u00f3n causal con el f\u00e1rmaco del estudio. Por lo tanto, una EA es cualquier signo desfavorable e involuntario (incluido el hallazgo anormal de laboratorio), s\u00edntoma o enfermedad que se asocia temporalmente con el uso de un medicamento del estudio, independientemente de si se considera relacionado con el medicamento del estudio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso (EA)"
        },
        {
            "text": "Un EA tambi\u00e9n incluye cualquier empeoramiento (es decir, cualquier cambio cl\u00ednicamente significativo en la frecuencia y / o intensidad) de una afecci\u00f3n preexistente que se asocia temporalmente con el uso del producto en investigaci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso (EA)"
        },
        {
            "text": "La progresi\u00f3n de covid-19 no se considerar\u00e1 un EA si es claramente coherente con el patr\u00f3n de progresi\u00f3n t\u00edpico de la enfermedad",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso (EA)"
        },
        {
            "text": "Si existe alguna incertidumbre acerca de que un EA se deba solo a la progresi\u00f3n de covid-19, se informar\u00e1 como un EA o EAS como se describe en la secci\u00f3n respectiva.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso (EA)"
        },
        {
            "text": "Un EAS, por definici\u00f3n, es cualquier evento m\u00e9dico desfavorable que a cualquier dosis:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso serio (EAS)"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso serio (EAS)"
        },
        {
            "text": "17",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso serio (EAS)"
        },
        {
            "text": "Resulte en la muerte: incluye todas las muertes, incluso aquellas que parecen no tener relaci\u00f3n alguna con el f\u00e1rmaco del estudio (por ejemplo, un accidente automovil\u00edstico en el que un paciente es pasajero).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso serio (EAS)"
        },
        {
            "text": "Es potencialmente mortal: en opini\u00f3n del investigador, el paciente corre un riesgo inmediato de muerte en el momento del evento. Esto no incluye un AE que si hubiera ocurrido en una forma m\u00e1s severa, podr\u00eda haber causado la muerte.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso serio (EAS)"
        },
        {
            "text": "Requiere hospitalizaci\u00f3n o prolongaci\u00f3n de la hospitalizaci\u00f3n existente. La hospitalizaci\u00f3n se define como el ingreso a un hospital o sala de emergencias por m\u00e1s de 24 horas. La prolongaci\u00f3n de la hospitalizaci\u00f3n existente se define como una estad\u00eda en el hospital que es m\u00e1s larga de lo previsto originalmente para el evento, o se prolonga debido al desarrollo de un nuevo EA seg\u00fan lo determinado por el investigador o el m\u00e9dico tratante.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso serio (EAS)"
        },
        {
            "text": "Resulta en discapacidad/incapacidad persistente o significativa (interrupci\u00f3n sustancial de la capacidad de uno para llevar a cabo funciones normales de la vida).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso serio (EAS)"
        },
        {
            "text": "Es un evento m\u00e9dico importante: los eventos m\u00e9dicos importantes pueden no poner en peligro la vida de inmediato o provocar la muerte u hospitalizaci\u00f3n, pero pueden poner en peligro al paciente o pueden requerir intervenci\u00f3n para prevenir uno de los otros resultados graves enumerados anteriormente (por ejemplo, tratamiento intensivo en una emergencia o en casa para broncoespasmo al\u00e9rgico; discrasias sangu\u00edneas que no resultan en hospitalizaci\u00f3n).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso serio (EAS)"
        },
        {
            "text": "En el caso espec\u00edfico de este estudio se considerar\u00e1n como EA o EAS, seg\u00fan la descripci\u00f3n detallada en la secci\u00f3n 11.2, aquellos que se inicien dentro de las 12 horas posteriores a la administraci\u00f3n del tratamiento y los agravamientos cl\u00ednicos y muertes asociadas con estos eventos. No se considerar\u00e1n EA o EAS aquellos eventos cl\u00ednicos que se inicien luego de las 12 horas de iniciaci\u00f3n del tratamiento, que constituir\u00e1n parte de la evoluci\u00f3n cl\u00ednica de los pacientes enrolados infectados con SARS CoV2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Evento adverso serio (EAS)"
        },
        {
            "text": "El per\u00edodo de informe EA / EAS comienza cuando el participante se incluye inicialmente en el estudio (fecha de firma del consentimiento informado de participaci\u00f3n) y recibe la infusi\u00f3n y continuar\u00e1 para los eventos que se inicien en las siguientes 12 horas desde su inicio (ver secci\u00f3n 11.2). Durante el seguimiento posterior a las 12 horas iniciales de Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Periodo de Recolecci\u00f3n de Eventos Adversos"
        },
        {
            "text": "18 la administraci\u00f3n del producto de investigaci\u00f3n, se monitorear\u00e1 la evoluci\u00f3n cl\u00ednica asociada a los criterios de valoraci\u00f3n primario y secundarios.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Periodo de Recolecci\u00f3n de Eventos Adversos"
        },
        {
            "text": "Los sujetos podr\u00e1n abandonar el estudio en cualquier momento si as\u00ed lo deseasen, pero ser\u00e1n igualmente monitoreados durante el periodo estipulado para garantizar su seguridad.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abandono Prematuro del Estudio"
        },
        {
            "text": "Aquellos pacientes que decidan abandonar el estudio antes de la administraci\u00f3n de la droga ser\u00e1n reemplazados, de ser necesario, para asegurar un n\u00famero adecuado de pacientes evaluables.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Reemplazo de Pacientes"
        },
        {
            "text": "Existe una incertidumbre significativa en el tama\u00f1o del efecto esperado de la intervenci\u00f3n, y considerando que se espera que el ensayo se complete en un per\u00edodo de tiempo relativamente corto, el estudio est\u00e1 dise\u00f1ado para tener un an\u00e1lisis intermedio cuando los resultados del 50% de los sujetos hayan sido adquiridos.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Justificaci\u00f3n del tama\u00f1o muestral y an\u00e1lisis estad\u00edstico"
        },
        {
            "text": "Dada la relativa complejidad de implementar esta intervenci\u00f3n, la diferencia m\u00ednimamente importante cl\u00ednicamente se establece en una reducci\u00f3n relativa del 40%, para una tasa de resultado esperada del 50% en el grupo control que se reduce al 30% en el grupo de intervenci\u00f3n. Un tama\u00f1o de muestra total de 210 sujetos (105 por brazo de prueba) tendr\u00e1 una potencia del 80%, a un nivel de significancia (alfa) de 0.05 utilizando una prueba z de dos lados con correcci\u00f3n de continuidad. Estos resultados suponen que se realizan 2 pruebas secuenciales utilizando la funci\u00f3n de gasto O'Brien-Fleming para determinar los l\u00edmites de la prueba, como se describe en la tabla a continuaci\u00f3n. T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Justificaci\u00f3n del tama\u00f1o muestral y an\u00e1lisis estad\u00edstico"
        },
        {
            "text": "19 Bajo la estrategia de an\u00e1lisis primario, usaremos la distribuci\u00f3n de l\u00edmite de producto de Kaplan-Meier para comparar los grupos de tratamiento durante el tiempo necesario para alcanzar el resultado primario. Tambi\u00e9n se informar\u00e1 una estimaci\u00f3n del riesgo relativo y el intervalo de confianza del 95%.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Lower"
        },
        {
            "text": "Por recomendaci\u00f3n del Comit\u00e9 Independiente de Monitoreo de Seguridad, se realizar\u00e1 adem\u00e1s un an\u00e1lisis estratificado por edad (65-74 a\u00f1os y 75 a\u00f1os) y se ajustar\u00e1 el an\u00e1lisis estad\u00edstico por aquellos factores de riesgo cuya distribuci\u00f3n entre grupos pueda afectar el resultado. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Lower"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Titulaci\u00f3n de anticuerpos anti-SARS Cov2"
        },
        {
            "text": "20 Tras el proceso de la donaci\u00f3n de plasma por af\u00e9resis o hemodonaci\u00f3n, adicionalmente a las muestras que se toman para controles de rutina del banco de sangre, se obtendr\u00e1 un tubo seco de 5 mL de sangre entera rotulados con la identificaci\u00f3n dada al donante, identificaci\u00f3n del Banco de Sangre y etiqueta que identifica la finalidad de Estos se realizar\u00e1n mediante el ensayo de ELISA anti-prote\u00edna S de SARS CoV2, que a luz de los datos existentes sobre protecci\u00f3n contra el virus permiten una extrapolaci\u00f3n indirecta de la capacidad de neutralizaci\u00f3n del suero, optimizado por el Instituto Leloir a cargo de la Dra. Gamarnik, y actualmente utilizado por los equipos de salud nacionales para estudiar prevalencia de inmunidad. Asimismo, de ser posible, se correlacionar\u00e1 este dato con el t\u00edtulo de anticuerpos neutralizantes contra un pseudovirus codificando la prote\u00edna S optimizado por el mismo laboratorio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Titulaci\u00f3n de anticuerpos anti-SARS Cov2"
        },
        {
            "text": "El tubo ser\u00e1 almacenado en un lugar designado dentro del Banco y enviado en un transporte autorizado de muestras biol\u00f3gicas al laboratorio de la Fundaci\u00f3n INFANT (con m\u00e1s de 18 a\u00f1os de experiencia en realizaci\u00f3n de ensayos de estas caracter\u00edsticas) donde se realizar\u00e1 la t\u00e9cnica de ELISA y la titulaci\u00f3n de anticuerpos neutralizantes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Titulaci\u00f3n de anticuerpos anti-SARS Cov2"
        },
        {
            "text": "Los t\u00edtulos obtenidos por ELISA de S ser\u00e1n luego clasificados y aquellos que est\u00e9n por encima de 1:1.000 seleccionados para proveer plasma de convaleciente para este estudio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Titulaci\u00f3n de anticuerpos anti-SARS Cov2"
        },
        {
            "text": "Los plasmas de alto t\u00edtulo adicionales ser\u00e1n almacenados asimismo para enviar al Centro de Hemoderivados de C\u00f3rdoba (UNC) que producir\u00e1 gammaglobulina enriquecida con anticuerpos anti-SARS-CoV2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Titulaci\u00f3n de anticuerpos anti-SARS Cov2"
        },
        {
            "text": "Plasmaf\u00e9resis (Instituto de Hemoterapia de la Provincia de La Plata, Hospital Militar Central, Fundaci\u00f3n Hemocentro Buenos Aires, y Fundaci\u00f3n Hematol\u00f3gica Sarmiento) La donaci\u00f3n de plasma se efectuar\u00e1 a trav\u00e9s de un procedimiento de af\u00e9resis con equipos e insumos descartables aprobados para tal fin, durante el cual se recomienda extraer un volumen no mayor al 15% de la volemia del donante. El anticoagulante a utilizar ser\u00e1 ACD-A o similar. En los casos en que no se realizare la reposici\u00f3n del volumen, la extracci\u00f3n de plasma no deber\u00e1 superar los 600 ml por procedimiento. Se deber\u00e1 respetar el intervalo de 48 hs. entre cada procedimiento, y no superar las 2 donaciones en una semana o 24 donaciones en un periodo de 12 meses. Las unidades de PCC19 se podr\u00e1n separar en al\u00edcuotas de 300ml respetando el circuito cerrado y siguiendo las indicaciones del procedimiento operativo est\u00e1ndar vigente.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Titulaci\u00f3n de anticuerpos anti-SARS Cov2"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Titulaci\u00f3n de anticuerpos anti-SARS Cov2"
        },
        {
            "text": "21",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Titulaci\u00f3n de anticuerpos anti-SARS Cov2"
        },
        {
            "text": "1-La obtenci\u00f3n de plasma se realizar\u00e1 con un equipo Cobe Spectra. Se extraer\u00e1n 1,5 a 2 L de plasma de acuerdo al peso y tolerancia al procedimiento del donante. En caso de inaccesibilidad venosa u oposici\u00f3n del donante, se extraer\u00e1 entre 400 y 500 ml de sangre entera (hemodonaci\u00f3n cl\u00e1sica) 2-El reemplazo de volumen se efectuar\u00e1 con soluci\u00f3n fisiol\u00f3gica y de alb\u00famina. 3-Durante el procedimiento el plasma ser\u00e1 derivado a bolsas de transferencia de similar volumen cada una (aproximadamente 500ml). Se denominar\u00e1 Bolsa 1 a la inicialmente obtenida, Bolsa 2 la media y Bolsa 3 la final. 4-Las bolsas recolectadas ser\u00e1n rotuladas como detallado abajo 5-Se congelar\u00e1n en el ultrafreezer vertical Righi de -56\u00b0C (rotulado como Freezer # I, identificado con r\u00f3tulo de plasma de convaleciente COVID-19, en el Banco de Sangre) separadas en estantes por tipo de bolsa (1, 2 o 3). 6-El plasma de convaleciente permanecer\u00e1 almacenado hasta su uso o caducidad (1 a\u00f1o), con criterios de seguridad apropiados. 7-El descarte se efectuar\u00e1 bajo normas de seguridad que se estipulen. 8-Se guardar\u00e1n al\u00edcuotas de suero/plasma para futuras determinaciones congelado a -80 o C, en tubos de Eppendorf del PC de las diferentes etapas, y congelados y almacenados a -80\u00b0C: Previo al procedimiento de af\u00e9resis de las bolsas 1, 2 y 3 (previo al congelamiento) luego del descongelamiento de las bolsas 1, 2 y 3.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hemodonaci\u00f3n (CEMIC)"
        },
        {
            "text": "Todas las unidades de PC COVID-19 deben cumplir con el etiquetado requerido para el plasma fresco congelado de cada Banco de Sangre y adem\u00e1s deber\u00e1n tener una clara identificaci\u00f3n, en la que deber\u00e1 constar: --Cov-Fundaci\u00f3n INFANT Suero enriquecido con anticuerpos anti SARS-",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Etiquetado"
        },
        {
            "text": "1. Las unidades se almacenar\u00e1n debidamente separadas del resto de las unidades de plasma habilitadas para uso transfusional, en un lugar claramente identificado para tal fin.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cadena de Fr\u00edo de PCCOVID-19"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020 22 2. Las unidades de PCC19 se almacenar\u00e1n a temperatura inferior a -25 C, la cual permite un almacenamiento de 36 meses y entre -18C y -25 para 3 meses de almacenamiento.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cadena de Fr\u00edo de PCCOVID-19"
        },
        {
            "text": "3. El transporte de las unidades se realizar\u00e1 de forma tal que se garantice fehacientemente el mantenimiento de la cadena de fr\u00edo.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cadena de Fr\u00edo de PCCOVID-19"
        },
        {
            "text": "4. La conservaci\u00f3n de las unidades de plasma una vez descongeladas deber\u00e1 realizarse entre 2 y 6\u00baC hasta las 24 horas de finalizado el descongelamiento. Pasado ese tiempo, se deber\u00e1n descartar.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Cadena de Fr\u00edo de PCCOVID-19"
        },
        {
            "text": "El Banco de Sangre y el Servicio de Transfusi\u00f3n de la Instituci\u00f3n solicitante implementar\u00e1n un sistema de registros que garantice la trazabilidad entre donantes y receptores. En esta situaci\u00f3n especial, adem\u00e1s, deber\u00e1n disponer de un registro espec\u00edfico por tratarse de una terapia transfusional administrada en un contexto experimental.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Trazabilidad"
        },
        {
            "text": "Una vez evaluados los signos vitales y verificada la elegibilidad, el equipo no ciego de Medicina Transfusional Central ser\u00e1 notificado del resultado del proceso de asignaci\u00f3n aleatoria y se trasladar\u00e1 al hospital asignado con el producto de tratamiento enmascarado y en fr\u00edo. Al arribar proceder\u00e1 nuevamente verificar el c\u00f3digo de tratamiento asignado con el miembro de laboratorio de Medicina Transfusional del hospital correspondiente (ver 5.2.c).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administraci\u00f3n de la intervenci\u00f3n"
        },
        {
            "text": "Como placebo, se utilizar\u00e1n 250 ml de soluci\u00f3n salina al 0,9% est\u00e9ril enmascarada y administrada de la misma forma y velocidad que el plasma. Para evitar sesgos y mantener el ciego del estudio, el plasma y la soluci\u00f3n salina al 0,9% ser\u00e1n enmascarados, utilizando una bolsa opaca y cinta que no permitir\u00e1n diferenciar de qu\u00e9 producto se trata. El miembro de Medicina Transfusional Central ser\u00e1 quien entregue al miembro del equipo local para que administre la intervenci\u00f3n en conjunto con el equipo central. De esta manera tanto los miembros de Medicina Transfusional Central como los miembros de Medicina Transfusional de los hospitales ser\u00e1n no ciegos, mientras que todo el resto del equipo delegado en funciones en el estudios en cada Centro de Investigaci\u00f3n como los pacientes ser\u00e1n ciegos a la intervenci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administraci\u00f3n de la intervenci\u00f3n"
        },
        {
            "text": "Para preparar el plasma, se descongelar\u00e1 la bolsa de 250 ml a 37\u00b0C, seg\u00fan procedimientos operativos del Departamento de Medicina Transfusional del Hospital.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administraci\u00f3n de la intervenci\u00f3n"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administraci\u00f3n de la intervenci\u00f3n"
        },
        {
            "text": "23 Se infundir\u00e1 al receptor en forma lenta (en no menos de 1.5 horas y hasta 2 horas) de acuerdo a las condiciones hemodin\u00e1micas del paciente y se monitorear\u00e1n por 12 horas y registrar\u00e1n los efectos adversos tempranos y tard\u00edos atribuibles a la transfusi\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administraci\u00f3n de la intervenci\u00f3n"
        },
        {
            "text": "Ventana nocturna para pasaje del producto de investigaci\u00f3n: entre las 20.00 hs y las 8.00 hs, se tolerar\u00e1 una ventana de +8 horas para el pasaje del Producto de investigaci\u00f3n. Siendo posible un m\u00e1ximo de 80 hs (72+8) de comienzo de s\u00edntomas al momento del inicio de la infusi\u00f3n. Esta excepci\u00f3n s\u00f3lo ser\u00e1 permitida en este rango horario nocturno.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administraci\u00f3n de la intervenci\u00f3n"
        },
        {
            "text": "Sobrecarga circulatoria asociada a transfusi\u00f3n (TACO) La sobrecarga circulatoria asociada a transfusi\u00f3n (transfusion-associated circulatory overload, TACO) es la complicaci\u00f3n pulmonar m\u00e1s frecuente y es un factor de riesgo independiente para morbimortalidad hospitalaria, con mayor incidencia en pacientes cr\u00edticos [58] . La frecuencia estimada de TACO var\u00eda del 1% a 5% seg\u00fan el sistema de hemovigilancia sea [59] , hasta los 8% en pacientes post quir\u00fargicos de avanzada, y 11% en pacientes cr\u00edticos [60 61 62] . Los factores de riesgo incluyen enfermedad transfusional [ 63 64 ]. La mayor\u00eda de los casos de TACO se previenen disminuyendo la velocidad de transfusi\u00f3n y la instauraci\u00f3n de las medidas habituales para sobrecarga h\u00eddrica en poblaciones susceptibles. La sobrecarga constituye un EA solicitado, pero de no mejorar en el curso de 120 minutos despu\u00e9s de la infusi\u00f3n o de requerir -a juicio de los profesionales responsables-el paso del paciente a cuidados intensivos por mala progresi\u00f3n cl\u00ednica a causa de dicha sobrecarga, deber\u00e1 informarse de inmediato como un EAS.",
            "cite_spans": [
                {
                    "start": 315,
                    "end": 319,
                    "text": "[58]",
                    "ref_id": "BIBREF175"
                },
                {
                    "start": 410,
                    "end": 414,
                    "text": "[59]",
                    "ref_id": "BIBREF176"
                },
                {
                    "start": 505,
                    "end": 511,
                    "text": "61 62]",
                    "ref_id": null
                },
                {
                    "start": 573,
                    "end": 578,
                    "text": "63 64",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Monitoreo de eventos adversos asociados a la transfusi\u00f3n de plasma"
        },
        {
            "text": "Criterios diagn\u00f3sticos de TACO [19] Durante o hasta 12 horas posteriores a la transfusi\u00f3n, TACO se caracteriza por la presencia de un total de 3 o m\u00e1s de los criterios listados: A. Compromiso respiratorio agudo o que empeora B. Evidencia de edema pulmonar agudo o que empeora basado en la cl\u00ednica y / o im\u00e1genes radiogr\u00e1ficas del t\u00f3rax y / u otra evaluaci\u00f3n no invasiva de la funci\u00f3n card\u00edaca (ecocardiograma) C. Evidencia de cambios cardiovasculares no explicados por la condici\u00f3n m\u00e9dica subyacente del paciente, incluido: taquicardia, hipertensi\u00f3n, presi\u00f3n de pulso ensanchada, distensi\u00f3n venosa yugular, silueta card\u00edaca agrandada y / o edema perif\u00e9rico T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020 24 D. Evidencia de sobrecarga de l\u00edquidos, incluyendo cualquiera de los siguientes: un balance positivo de l\u00edquidos; respuesta a la terapia diur\u00e9tica, o di\u00e1lisis combinada con mejor\u00eda cl\u00ednica; y variaci\u00f3n del peso del paciente E. Aumento del nivel de p\u00e9ptido natriur\u00e9tico de tipo B (por ejemplo, BNP o NT-pro BNP) por encima del rango de referencia espec\u00edfico del grupo de edad y mayor de 1,5 veces el valor de pre transfusi\u00f3n.",
            "cite_spans": [
                {
                    "start": 31,
                    "end": 35,
                    "text": "[19]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Monitoreo de eventos adversos asociados a la transfusi\u00f3n de plasma"
        },
        {
            "text": "Injuria Pulmonar Aguda Asociada a Transfusi\u00f3n (TRALI) Es un s\u00edndrome de dificultad respiratoria aguda, ser\u00e1 considerado un EAS y ocurre durante o dentro de las seis horas posteriores a la administraci\u00f3n de la transfusi\u00f3n. Estudios prospectivos de TRALI en diversas encontraron tasas de incidencia muy bajas (0,0008% a 0,001% de pacientes transfundidos) [19] despu\u00e9s de la implementaci\u00f3n de estrategias para prevenir la transfusi\u00f3n de componentes de la sangre obtenido de donantes femeninas mult\u00edparas. En nuestro estudio no se transfundir\u00e1 plasma convaleciente de mujeres mult\u00edparas. El tratamiento del paciente con TRALI incluye la interrupci\u00f3n inmediata de la transfusi\u00f3n.",
            "cite_spans": [
                {
                    "start": 353,
                    "end": 357,
                    "text": "[19]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Monitoreo de eventos adversos asociados a la transfusi\u00f3n de plasma"
        },
        {
            "text": "Criterios diagn\u00f3sticos de TRALI: [28] TRALI Tipo I: pacientes que no tienen factores de riesgo de SDRA y cumplen con los siguientes criterios: A. i. Inicio agudo ii. Hipoxemia (PaO 2 / FiO 2 2 <90% en aire ambiente). iii. Evidencia clara de edema pulmonar bilateral en im\u00e1genes (radiograf\u00eda de t\u00f3rax, tac o ecograf\u00eda) iv. No hay evidencia de hipertrofia ventricular izquierda o, si est\u00e1 presente, no es la principal contribuyente de la hipoxemia B. Inicio durante o dentro de las 6 horas de la transfusi\u00f3n C. Sin relaci\u00f3n temporal con un factor de riesgo alternativo para SDRA TRALI Tipo II: pacientes que tienen factores de riesgo de SDRA (pero que no han sido diagnosticados con SDRA) o que tienen SDRA leve existente (Pa / Fi de 200-300), pero cuyo estado respiratorio se deteriora y se considera que se debe a una transfusi\u00f3n basado en: a. Los resultados descritos en las categor\u00edas a y b de TRALI Tipo I, y b. Estado respiratorio estable en las 12 horas previas a la transfusi\u00f3n",
            "cite_spans": [
                {
                    "start": 33,
                    "end": 37,
                    "text": "[28]",
                    "ref_id": "BIBREF17"
                }
            ],
            "ref_spans": [],
            "section": "Monitoreo de eventos adversos asociados a la transfusi\u00f3n de plasma"
        },
        {
            "text": "Las reacciones al\u00e9rgicas ocurren en general durante o dentro de las 4 horas posteriores a la transfusi\u00f3n y est\u00e1n m\u00e1s frecuentemente asociadas a la transfusi\u00f3n de plaquetas (302 cada 100 000 unidades de plaquetas) [29] . Los s\u00edntomas son causados Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020 25 por mediadores como la histamina, liberados en la activaci\u00f3n de mastocitos y bas\u00f3filos [30] . En general la presentaci\u00f3n cl\u00ednica es leve (erupci\u00f3n cut\u00e1nea, prurito, urticaria, y angioedema localizado) y constituye un EA solicitado. Las reacciones transfusionales al\u00e9rgicas leves en general resuelven con la administraci\u00f3n del tratamiento habitual para reacciones al\u00e9rgicas, pudiendo reiniciar la infusi\u00f3n de la unidad. La transfusi\u00f3n debe suspenderse si los s\u00edntomas reaparecen. La incidencia de reacciones anafil\u00e1cticas es de 8/100,000 unidades de plaquetas transfundidas. Las reacciones m\u00e1s severas generalmente se presentan con broncoespasmo, dificultad respiratoria e hipotensi\u00f3n y constituyen un EAS y debe ser reportado como tal inmediatamente [31] [32] [33] [34] [35] .",
            "cite_spans": [
                {
                    "start": 213,
                    "end": 217,
                    "text": "[29]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 637,
                    "end": 641,
                    "text": "[30]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 1300,
                    "end": 1304,
                    "text": "[31]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 1305,
                    "end": 1309,
                    "text": "[32]",
                    "ref_id": null
                },
                {
                    "start": 1310,
                    "end": 1314,
                    "text": "[33]",
                    "ref_id": null
                },
                {
                    "start": 1315,
                    "end": 1319,
                    "text": "[34]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 1320,
                    "end": 1324,
                    "text": "[35]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Reacciones Al\u00e9rgicas Anafil\u00e1cticas"
        },
        {
            "text": "Reacciones transfusionales hemol\u00edticas agudas Las reacciones de transfusionales hemol\u00edticas agudas (RTHA) pueden ocurrir cuando se transfunden gl\u00f3bulos rojos incompatibles o en menor frecuencia, grandes cantidades de plasma incompatible con el ABO del paciente. El mecanismo fisiopatol\u00f3gico central es la hem\u00f3lisis intravascular y se considerar\u00e1 un EAS. Se presenta con fiebre repentina y escalofr\u00edos, dolor retroperitoneal y disnea, hemoglobinuria y hasta coagulaci\u00f3n intravascular diseminada, insuficiencia renal aguda y shock. Dado que la fiebre y los escalofr\u00edos pueden ser los \u00fanicos signos tempranos, es importante controlar al paciente durante la transfusi\u00f3n y detenerla transfusi\u00f3n inmediatamente si hay alg\u00fan cambio en los signos vitales o ante la aparici\u00f3n de s\u00edntomas inesperados. El tratamiento se basa en medidas de sost\u00e9n para mitigar los s\u00edntomas. La identificaci\u00f3n adecuada del paciente y el cumplimiento de todos los procesos relacionados con el manejo de muestras pre-transfusionales y con la administraci\u00f3n de la transfusi\u00f3n, son esenciales para prevenir la RTHA [36] .",
            "cite_spans": [
                {
                    "start": 1082,
                    "end": 1086,
                    "text": "[36]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Reacciones Al\u00e9rgicas Anafil\u00e1cticas"
        },
        {
            "text": "Infecciones Transmisibles por Transfusi\u00f3n [39] El riesgo de transmisi\u00f3n de enfermedades infecciosas por transfusiones se ha reducido dram\u00e1ticamente, secundario a los grandes avances en el testeo de las unidades, inactivaci\u00f3n de pat\u00f3genos para unidades de plasma y sus componentes [51] y a la implementaci\u00f3n de rigurosos m\u00e9todos de selecci\u00f3n de donantes. En nuestro medio, las muestras son testeadas para HBV, HCV, HIV, HTLV y Trypanosoma cruzi [52] . En Estados Unidos, el riesgo de adquirir HBV y HIV por transfusi\u00f3n es de 1:280.000 y 1:1.467.000, respectivamente [53 54] . Gracias al congelamiento de las muestras de plasma, la contaminaci\u00f3n de las mismas por pat\u00f3genos bacterianos y CMV es extremadamente rara. Hay solo una decena de casos entre los millones de transfusiones realizadas, reportados en Alemania y Canad\u00e1 de transmisi\u00f3n bacteriana. Se estima que la fuente potencial de esta contaminaci\u00f3n habr\u00edan sido los ba\u00f1os de agua utilizados para el descongelamiento de las unidades. Esto es f\u00e1cilmente evitable con la limpieza y esterilizaci\u00f3n correctas de los descongeladores [39] .",
            "cite_spans": [
                {
                    "start": 42,
                    "end": 46,
                    "text": "[39]",
                    "ref_id": null
                },
                {
                    "start": 280,
                    "end": 284,
                    "text": "[51]",
                    "ref_id": null
                },
                {
                    "start": 444,
                    "end": 448,
                    "text": "[52]",
                    "ref_id": "BIBREF171"
                },
                {
                    "start": 565,
                    "end": 572,
                    "text": "[53 54]",
                    "ref_id": null
                },
                {
                    "start": 1084,
                    "end": 1088,
                    "text": "[39]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Reacciones Al\u00e9rgicas Anafil\u00e1cticas"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020 26 12. Consideraciones \u00e9ticas",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Reacciones Al\u00e9rgicas Anafil\u00e1cticas"
        },
        {
            "text": "Este estudio se llevar\u00e1 a cabo de conformidad con el protocolo y con las siguientes consideraciones:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Declaraci\u00f3n de Buena Pr\u00e1ctica Cl\u00ednica"
        },
        {
            "text": "los principios \u00e9ticos que tienen su origen en la Declaraci\u00f3n de Helsinki, las pautas vigentes de las buenas pr\u00e1cticas cl\u00ednicas (Good Clinical Practice, GCP) del Consejo Internacional de Armonizaci\u00f3n (International Council of Harmonisation, ICH), las leyes y regulaciones vigentes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Declaraci\u00f3n de Buena Pr\u00e1ctica Cl\u00ednica"
        },
        {
            "text": "El protocolo, los formularios de Consentimiento Informado (FCI) y otros documentos relevantes han sido revisados y aprobados por Fundaci\u00f3n INFANT, las autoridades participantes y enviados al Comit\u00e9 de \u00c9tica (CE) para su evaluaci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Declaraci\u00f3n de Buena Pr\u00e1ctica Cl\u00ednica"
        },
        {
            "text": "Un CE debidamente constituido, como se describe en las pautas de ICH para GCP, debe revisar y aprobar:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comit\u00e9 de \u00e9tica (CE):"
        },
        {
            "text": "El protocolo, FCI y cualquier otro material que se proporcione a los participantes antes de que cualquier sujeto pueda ingresar en el estudio Cualquier enmienda o modificaci\u00f3n al protocolo de estudio o al FCI antes de la implementaci\u00f3n, a menos que el cambio sea necesario para eliminar un peligro inmediato para los pacientes, en cuyo caso el CE debe ser informado lo antes posible Adem\u00e1s, debe ser informado de cualquier evento que pueda afectar la seguridad de los pacientes o la realizaci\u00f3n continua del estudio cl\u00ednico.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comit\u00e9 de \u00e9tica (CE):"
        },
        {
            "text": "INFANT debe recibir una copia de la carta de aprobaci\u00f3n del CE antes de enviar los suministros de medicamentos al investigador de cada hospital. La carta de aprobaci\u00f3n debe incluir el t\u00edtulo del estudio, los documentos revisados y la fecha de la revisi\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comit\u00e9 de \u00e9tica (CE):"
        },
        {
            "text": "El investigador debe mantener en el archivo los registros de la revisi\u00f3n del CE y la aprobaci\u00f3n de todos los documentos del estudio",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Comit\u00e9 de \u00e9tica (CE):"
        },
        {
            "text": "El FCI utilizado por el investigador ser\u00e1 el aprobado por el CE correspondiente.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Proceso de Consentimiento Informado"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Proceso de Consentimiento Informado"
        },
        {
            "text": "Es responsabilidad del investigador o profesional delegado obtener el consentimiento informado por escrito de cada sujeto antes de su participaci\u00f3n en el estudio y despu\u00e9s de que los objetivos, procedimientos y riesgos potenciales del estudio se han explicado completamente en un lenguaje que el sujeto pueda entender. El FCI debe estar firmado y fechado por el investigador o personal delegado que realiz\u00f3 el proceso de toma de consentimiento.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "27"
        },
        {
            "text": "El investigador o personal delegado le explicar\u00e1 al participante la naturaleza del estudio y responder\u00e1 todas las preguntas sobre el estudio. Les informar\u00e1 que su participaci\u00f3n es voluntaria. El participante deber\u00e1 firmar el formulario de consentimiento informado (FCI) antes de que se realice cualquier actividad espec\u00edfica del estudio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "27"
        },
        {
            "text": "A los participantes que pueden entender pero que no pueden escribir y/o leer se les leer\u00e1 el CI en presencia de un testigo imparcial, que firmar\u00e1 y fechar\u00e1 el FCI para confirmar que se obtuvo el consentimiento informado.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "27"
        },
        {
            "text": "Se firmar\u00e1n dos ejemplares. El investigador debe conservar un ejemplar como parte del registro del estudio del paciente, y se debe entregar el otro ejemplar firmado al participante.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "27"
        },
        {
            "text": "Pacientes con vulnerabilidad cognitiva: Podr\u00e1n ser incluidos previa toma de consentimiento por parte de su representante seg\u00fan corresponda: a. Pacientes que posean una declaraci\u00f3n jur\u00eddica de incapacidad: deber\u00e1 ser quien haya sido designado como curador siempre que exista esa declaraci\u00f3n b. Pacientes que puedan tomar una decisi\u00f3n por si mismos previa asistencia de un \"apoyo\" seg\u00fan las disposiciones del C\u00f3digo Civil: por lo general el paciente puede designar a quien lo ayude a decidir. c. Pacientes sin declaraci\u00f3n judicial de incapacidad y que tampoco hayan designado un apoyo o representante: resultar\u00e1 de aplicaci\u00f3n la ley de derechos de los pacientes. Los medios para acreditar la representaci\u00f3n pueden consistir en cualquier documento que acredite la designaci\u00f3n como curador (si aplica) o bien cualquier directiva anticipada del paciente en donde establezca qui\u00e9n lo representa en temas de salud, o documentos que acrediten el parentesco seg\u00fan la Ley 26529.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "27"
        },
        {
            "text": "El investigador tomar\u00e1 todas las medidas apropiadas para garantizar que se mantenga el anonimato de cada sujeto del estudio en los registros para investigaci\u00f3n transmitidos fuera del centro de salud. Los documentos originales y esenciales del estudio deben Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Confidencialidad y Protecci\u00f3n de Datos Personales"
        },
        {
            "text": "28 mantenerse en estricta confidencialidad en cada centro de investigaci\u00f3n por el equipo del estudio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Confidencialidad y Protecci\u00f3n de Datos Personales"
        },
        {
            "text": "Los datos personales de los participantes se almacenar\u00e1n en el centro del estudio en un formato impreso y/o electr\u00f3nico protegidos por contrase\u00f1a o en un cuarto bajo llave, para garantizar el acceso exclusivo del personal autorizado del estudio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Confidencialidad y Protecci\u00f3n de Datos Personales"
        },
        {
            "text": "Para proteger los derechos y las libertades de las personas f\u00edsicas en relaci\u00f3n con el tratamiento de datos personales, se asignar\u00e1 a los participantes un c\u00f3digo alfanum\u00e9rico \u00fanico y espec\u00edfico. Los registros o conjuntos de datos de los participantes que se transfieran contendr\u00e1n el c\u00f3digo alfanum\u00e9rico; los nombres de los participantes no se transferir\u00e1n. Todos los dem\u00e1s datos identificables transferidos entre los investigadores se identificar\u00e1n mediante este c\u00f3digo \u00fanico y espec\u00edfico del participante. El centro del estudio mantendr\u00e1 una lista confidencial de los participantes que participaron en el estudio bajo estricta seguridad (protegidos por contrase\u00f1a o en un cuarto bajo llave), vinculando el c\u00f3digo alfanum\u00e9rico de cada participante con su identidad real.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Confidencialidad y Protecci\u00f3n de Datos Personales"
        },
        {
            "text": "Los registros y los documentos, incluidos los FCI firmados, respecto a la realizaci\u00f3n de este estudio, ser\u00e1n conservados por el investigador durante 15 a\u00f1os despu\u00e9s de la finalizaci\u00f3n del estudio, a menos que las regulaciones locales o las pol\u00edticas institucionales requieran un per\u00edodo de conservaci\u00f3n m\u00e1s prolongado. El investigador de cada instituci\u00f3n participante deber\u00e1 consultar con INFANT antes de descartar o destruir cualquier documento esencial del estudio despu\u00e9s de la finalizaci\u00f3n o interrupci\u00f3n del estudio. En caso de ser aprobado, los registros deben destruirse de manera que se garantice la confidencialidad.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Documentaci\u00f3n del Estudio"
        },
        {
            "text": "El monitor del estudio visitar\u00e1 cada sitio antes de inscribir al primer paciente y peri\u00f3dicamente durante el estudio de acuerdo con el Plan de Monitoreo del Estudio Aprobado.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoreo de sitios de estudio"
        },
        {
            "text": "El monitor recibir\u00e1 semanalmente de cada uno de los centros un informe con el n\u00famero de pacientes en periodo de pesquisa y enrolados y verificar\u00e1 que el envi\u00f3 de datos se encuentre al d\u00eda y completo, realizando de ser necesario seguimiento a cada uno de los centros.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoreo de sitios de estudio"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoreo de sitios de estudio"
        },
        {
            "text": "Cada centro contar\u00e1 con una persona designada por el Investigador a verificar procesos realizados bajo protocolo y datos originales y se documentar\u00e1 dicha verificaci\u00f3n por escrito.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "29"
        },
        {
            "text": "Las visitas de monitoreo y las actividades de monitoreo centralizado se realizar\u00e1n de acuerdo con todos los requisitos reglamentarios aplicables y normas vigentes en Argentina. Se entiende que el monitor contactar\u00e1 a cada investigador y a su equipo responsable regularmente y se le permitir\u00e1 verificar la generaci\u00f3n de los distintos registros del estudio.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "29"
        },
        {
            "text": "Ser\u00e1 responsabilidad del monitor inspeccionar los sistemas de captura de datos a intervalos regulares durante todo el estudio para verificar el cumplimiento del protocolo y la integridad, precisi\u00f3n y consistencia de los datos; y adhesi\u00f3n al ICH GCP y normativa local sobre la realizaci\u00f3n de investigaciones cl\u00ednicas. El monitor debe tener acceso a informes de laboratorio, medicaci\u00f3n de estudio, registros asociados con \u00e9l, y otros registros m\u00e9dicos necesario para verificar las entradas en el EDC.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "29"
        },
        {
            "text": "Se asignar\u00e1 un monitor no ciego cuyo rol estar\u00e1 limitado a auditar los datos de log\u00edstica manejo y registro del tratamiento de estudio de acuerdo con el protocolo aprobado y las instrucciones de tratamiento: recepci\u00f3n y condiciones de almacenaje randomizaci\u00f3n y administraci\u00f3n retorno o destrucci\u00f3n/ reconciliaci\u00f3n final",
            "cite_spans": [],
            "ref_spans": [],
            "section": "29"
        },
        {
            "text": "Se requiere que los investigadores preparen y mantengan registros de pacientes adecuados y precisos (documentos fuente).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Requisitos del documento fuente"
        },
        {
            "text": "El investigador debe mantener todos los documentos fuente en el archivo de los datos volcados al formulario del estudio (CRF). Algunos datos generados del estudio podr\u00e1n volcarse directamente en el sistema de EDC (captura directa de datos), previa aprobaci\u00f3n de dicho proceso por los Comit\u00e9s de \u00c9tica intervinientes. Los formularios de informes de casos y los documentos fuente deben estar disponibles en todo momento.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Requisitos del documento fuente"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Requisitos del formulario de informe de caso"
        },
        {
            "text": "Los datos del estudio obtenidos en el curso del estudio ser\u00e1n registrados en formularios de informes de casos (CRF) y enviados a INFANT en formato scan. Una vez recibidos ser\u00e1n archivados y procesados mediante el ingresados al del sistema EDC por personal capacitado de INFANT. Todos los CRF requeridos deben completarse para cada paciente inscrito en el estudio. El investigador debe conservar una copia del libro de casos de CRF de cada paciente como parte del registro del estudio y debe estar disponible en todo momento para su inspecci\u00f3n por parte de representantes autorizados del patrocinador y las autoridades reguladoras.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "30"
        },
        {
            "text": "Este estudio puede estar sujeto a una auditor\u00eda o inspecci\u00f3n de garant\u00eda de calidad. Si esto ocurre, el investigador es responsable de:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "16.. Auditorias e inspecciones"
        },
        {
            "text": "-Brindar acceso a todas las instalaciones, datos de estudio y documentos necesarios para la inspecci\u00f3n o auditor\u00eda. -Comunicar cualquier informaci\u00f3n que surja de la inspecci\u00f3n de las autoridades reguladoras a INFANT de inmediato. -Tomar todas las medidas apropiadas solicitadas por INFANT para resolver los problemas encontrados durante la auditor\u00eda o inspecci\u00f3n.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "16.. Auditorias e inspecciones"
        },
        {
            "text": "Los documentos sujetos a auditor\u00eda o inspecci\u00f3n incluyen, entre otros, todos los documentos fuente, CRF, registros m\u00e9dicos, correspondencia, FCI, archivos del CE, documentaci\u00f3n de certificaci\u00f3n y control de calidad de laboratorios de apoyo, y registros relevantes para el estudio que se mantienen Instalaciones de farmacia. Las condiciones de almacenamiento del material de estudio tambi\u00e9n est\u00e1n sujetas a inspecci\u00f3n. Adem\u00e1s, los representantes del patrocinador pueden observar la conducta de cualquier aspecto del estudio cl\u00ednico o sus actividades de apoyo tanto dentro como fuera de la instituci\u00f3n del investigador.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "16.. Auditorias e inspecciones"
        },
        {
            "text": "En todos los casos, se debe respetar la confidencialidad de los datos.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "16.. Auditorias e inspecciones"
        },
        {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Versi\u00f3n 6.0 02-noviembre-2020 32 s\u00edntomas de insuficiencia card\u00edaca est\u00e1n presentes incluso en reposo y aumentan con cualquier actividad f\u00edsica. Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2. Advisors: Dr. Daniel Stamboulian (FUNCEI)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "16.. Auditorias e inspecciones"
        },
        {
            "text": "SARS-CoV2 is a new and particularly aggressive virus for elderly individuals, who represent between 73% and 90% of fatal cases in different regions of the world [28, 30, 40] . Mortality, the need for intensive care, mechanical ventilation, oxygen requirements, and hospitalizations for respiratory disease increase markedly with advancing age in patients [2, 3, 29, 32, 46] . In fact, the frequency of death from disease due to SARS-CoV2 (COVID-19) is 8% in patients between 70 and 80 years old, and increases to 14.8% in those over 80 [23] . Specifically in hospitalized patients older than 75 years, mortality is 29.4% [24] , and in intensive care it amounts to an alarming 43.5% [25] . Several comorbidities associated with vascular and / or pulmonary disease worsen the prognosis of those infected even in patients younger than 70, including arterial hypertension, diabetes, obesity, and chronic obstructive pulmonary disease (COPD) [3, 23, 30, 31] . To date, the virus has caused more than 290,000 deaths worldwide, more than 300 of them in Argentina which is contained through a transitional strategy quarantine quasi-universal [4] . There is no specific treatment available yet. The results of the efficacy trials for SARS-CoV2 vaccines will be known within a minimum of 10-14 months.",
            "cite_spans": [
                {
                    "start": 161,
                    "end": 165,
                    "text": "[28,",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 166,
                    "end": 169,
                    "text": "30,",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 170,
                    "end": 173,
                    "text": "40]",
                    "ref_id": null
                },
                {
                    "start": 355,
                    "end": 358,
                    "text": "[2,",
                    "ref_id": null
                },
                {
                    "start": 359,
                    "end": 361,
                    "text": "3,",
                    "ref_id": null
                },
                {
                    "start": 362,
                    "end": 365,
                    "text": "29,",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 366,
                    "end": 369,
                    "text": "32,",
                    "ref_id": null
                },
                {
                    "start": 370,
                    "end": 373,
                    "text": "46]",
                    "ref_id": null
                },
                {
                    "start": 536,
                    "end": 540,
                    "text": "[23]",
                    "ref_id": null
                },
                {
                    "start": 621,
                    "end": 625,
                    "text": "[24]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 682,
                    "end": 686,
                    "text": "[25]",
                    "ref_id": null
                },
                {
                    "start": 937,
                    "end": 940,
                    "text": "[3,",
                    "ref_id": null
                },
                {
                    "start": 941,
                    "end": 944,
                    "text": "23,",
                    "ref_id": null
                },
                {
                    "start": 945,
                    "end": 948,
                    "text": "30,",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 949,
                    "end": 952,
                    "text": "31]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 1134,
                    "end": 1137,
                    "text": "[4]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "INTRODUCTION"
        },
        {
            "text": "SARS-CoV2 is an enveloped virus that contains single stranded RNA in the positive sense bound to a nucleoprotein (protein N), within a capsid composed of matrix proteins (protein M). The envelope contains spine-shaped glycoproteins (protein S) that bind to the cellular receptor ACE2 in humans and generate neutralizing antibodies [13] . Primary SARS-CoV2 infection, like other respiratory diseases, generates an antibody response with early production of IgM followed by specific IgG against viral proteins [14] . Detection of virus neutralizing antibodies is common, reaching high levels of up to 1: 21,500 PRNT50, mostly exceeding 1: 500 titers after 28 days of symptom onset in mild patients [41] . Approximately 5% of patients have neutralizing antibody levels <1:40, especially the younger ones [41] . A study of primary respiratory tract infection in rhesus macaques, using 10 6 pfu of SARS-CoV2 followed by a second intratracheal challenge using the same virus and doses 28 days later, demonstrated the absence of reinfection after an extensive evaluation by RT-PCR in tissues post-necropsy [42] . Neutralizing titers before the second inoculum ranged from 1:8-1:16 PRNT50 [42] . These findingslimited indeed, given the novelty of the problem -suggest that even low neutralizing antibody titers could prevent severe disease due to the virus.",
            "cite_spans": [
                {
                    "start": 331,
                    "end": 335,
                    "text": "[13]",
                    "ref_id": null
                },
                {
                    "start": 508,
                    "end": 512,
                    "text": "[14]",
                    "ref_id": null
                },
                {
                    "start": 696,
                    "end": 700,
                    "text": "[41]",
                    "ref_id": null
                },
                {
                    "start": 801,
                    "end": 805,
                    "text": "[41]",
                    "ref_id": null
                },
                {
                    "start": 1099,
                    "end": 1103,
                    "text": "[42]",
                    "ref_id": null
                },
                {
                    "start": 1181,
                    "end": 1185,
                    "text": "[42]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "INTRODUCTION"
        },
        {
            "text": "Protecting the populations most vulnerable to SARS-CoV2 is imperative, in the context of a highly infectious pathogen (R 0 estimated between 2 and 3.28) [27, 33, 34] . Its contagiousness rapidly overwhelms the health capacity of developed countries in different regions of the world [5] and threatens the health resources of developing countries [6] . Regions of Italy, Spain and the United States have been overwhelmed by the pandemic, which represents a serious threat to Argentina, coinciding with the beginning of the annual circulation of other lung pathogens, such as the common flu and respiratory syncytial virus [26] . Obviously, it would be impossible to respond to an avalanche of critically ill patients [7] , and any strategy aimed at reducing infections and the development of severe disease is directly aligned with the medical objective of saving lives and with the health needs of the country in order to provide the best possible care for those patients who need it.",
            "cite_spans": [
                {
                    "start": 153,
                    "end": 157,
                    "text": "[27,",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 158,
                    "end": 161,
                    "text": "33,",
                    "ref_id": null
                },
                {
                    "start": 162,
                    "end": 165,
                    "text": "34]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 283,
                    "end": 286,
                    "text": "[5]",
                    "ref_id": null
                },
                {
                    "start": 346,
                    "end": 349,
                    "text": "[6]",
                    "ref_id": null
                },
                {
                    "start": 621,
                    "end": 625,
                    "text": "[26]",
                    "ref_id": null
                },
                {
                    "start": 716,
                    "end": 719,
                    "text": "[7]",
                    "ref_id": "BIBREF128"
                }
            ],
            "ref_spans": [],
            "section": "INTRODUCTION"
        },
        {
            "text": "Post-exposure prophylaxis to viruses and treatment in early stages of disease, through defenses obtained in convalescent plasma, is a widespread practice with successful antecedents in the history of medicine at a national and global level. As early as 1960, Brunell et al. managed to prevent clinical varicella in siblings with sick parents, using anti-varicella zoster immunoglobulins obtained from the plasma of previously infected patients [8]. Today, for example, enriched immunoglobulin for measles is used in unvaccinated people who were in contact with a patient for the previous 6 days with an efficacy close to 100% [9, 52]; a similar product enriched for varicella zoster virus is administered to unvaccinated pregnant women, newborns, and immunosuppressed patients in contact with infected persons within 96 hours, reducing the incidence of severe disease by 90% [10, 53, 54] ; tetanus immunoglobulin supplements vaccination in soiled wound victims with incomplete primary immunization [43] ; gamma globulin against hepatitis B is used as prevention for newborns of infected mothers with an efficacy of 75% [44, 55] ; and rabies gamma globulin is ~ 100% effective in the prophylaxis of post-injury due to a rabid animal [11, 56] . Interventions using human immunity derived from convalescent plasma have been shown to be safe, have prevented countless cases of severe disease, and have preserved lives around the world.",
            "cite_spans": [
                {
                    "start": 875,
                    "end": 879,
                    "text": "[10,",
                    "ref_id": null
                },
                {
                    "start": 880,
                    "end": 883,
                    "text": "53,",
                    "ref_id": "BIBREF172"
                },
                {
                    "start": 884,
                    "end": 887,
                    "text": "54]",
                    "ref_id": "BIBREF173"
                },
                {
                    "start": 998,
                    "end": 1002,
                    "text": "[43]",
                    "ref_id": null
                },
                {
                    "start": 1119,
                    "end": 1123,
                    "text": "[44,",
                    "ref_id": null
                },
                {
                    "start": 1124,
                    "end": 1127,
                    "text": "55]",
                    "ref_id": null
                },
                {
                    "start": 1232,
                    "end": 1236,
                    "text": "[11,",
                    "ref_id": null
                },
                {
                    "start": 1237,
                    "end": 1240,
                    "text": "56]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "INTRODUCTION"
        },
        {
            "text": "The main objective of our study is to evaluate the efficacy of convalescent plasma in reducing the progression to severe disease in people between 65-74 years with at least one comorbidity and in all those years of age who present with mild symptoms of less than 48 hs of evolution at the time of screening and with an early diagnosis of COVID-19. Our central hypothesis is that a single dose convalescent plasma compared against placebo (saline at 0.9%) administered up to 72 hours after the onset of symptoms by SARS-COV2, prevent progression to severe respiratory disease in subjects 65-74 years with at least one comorbidity and irrespective of the presence of comorbidities.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "INTRODUCTION"
        },
        {
            "text": "To evaluate the efficacy of convalescent plasma, starting 12 hours after administration, in reducing the progression to severe respiratory disease in people between 65-74 years with at least one comorbidity and in all those 75 years with mild symptoms and a diagnosis of early COVID-19 until 15 days of administration of treatment (16-18 days of disease considering the pre-symptomatic period before enrollment).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Primary objective"
        },
        {
            "text": "The Secondary Objectives include determining if the administration of convalescent plasma up to 15 days or thereafter up to a maximum of 25 days of the administration of treatment in those still hospitalized:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Objectives"
        },
        {
            "text": "Reduces the need for oxygen support with maximal oxygen therapy (O 2 reservoir mask) and/or use of non-invasive respiratory support (NIV support including CPAP) and/or admission to ICU and/or requirement of invasive mechanical ventilation due to SARS-CoV2 in patients between 65-74 .",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Objectives"
        },
        {
            "text": "Reduces critical illness defined as (a) presence of acute respiratory failure 200 mm Hg.) and / or (b) shock (defined by need of vasoactive drugs to maintain MAP equal to or greater than 65 mm Hg) , and / or (c) multi-organ dysfunction syndrome (MODS ): acute kidney injury (defined by a creatinine increase two or more times from baseline or a creatinine increase of 0.3 mg / dl) , elevated liver enzymes (transaminases) greater than three times the upper normal value , acute cardiomyopathy (defined by troponin elevation above the normal level and/or new electrocardiographic or echocardiographic changes of myocardial damage) in patients 65-74 years with at least one comorbidity and in all those COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Objectives"
        },
        {
            "text": "Reduces mortality due to SARS-CoV2 in patients between 65-74 years with at COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Objectives"
        },
        {
            "text": "Decreases the length of oxygen support due to hypoxemia associated with COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Objectives"
        },
        {
            "text": "Describe the safety of convalescent plasma administration in patients between 65-COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Objectives"
        },
        {
            "text": "Explore the concentration of IgG anti-S SARS COV2 in plasma of participants associated with the absence of severe respiratory disease obtained at 24 hours of infusion.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Objectives"
        },
        {
            "text": "Explore whether, rather than protect against the severe respiratory disease, administration of convalescent plasma delays the onset of the disease.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exploratory Objectives"
        },
        {
            "text": "Explore the effects of convalescent plasma on primary humoral immune response against infection by SARS COV2 at 90 days post-illness.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exploratory Objectives"
        },
        {
            "text": "Explore whether the effects on respiratory and cardiovascular disease and long-term mortality were affected by the intervention at 12 months of enrollment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exploratory Objectives"
        },
        {
            "text": "Explore the correlation between viral load determined by RT-PCR at diagnosis and the response to plasma treatment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exploratory Objectives"
        },
        {
            "text": "Severe respiratory disease due to SARS-CoV2, confirmed by detection of viral RNA by RT-PCR, and defined by the presence of any of the following two variables in a nonsaturation in room air <93% [20, 21] . The primary endpoint will be determined from 12 hours of the start of the infusion until 15 days since administering treatment.",
            "cite_spans": [
                {
                    "start": 194,
                    "end": 198,
                    "text": "[20,",
                    "ref_id": null
                },
                {
                    "start": 199,
                    "end": 202,
                    "text": "21]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Primary Efficacy Assessment Criterion"
        },
        {
            "text": "Need for oxygen support with maximum oxygen therapy (O 2 reservoir mask) and/or non-invasive respiratory support (NIV support including CPAP) and/or admission to ICU and/or requirement of invasive mechanical ventilation, due to SARS-CoV2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Efficacy Assessment Criteria (up to 15 days or, thereafter, up to a maximum of 25 days after the administration of treatment if continued hospitalization)"
        },
        {
            "text": "Critical illness defined as (a) presence of acute respiratory failure (PaO2 / FiO2 200 mmHg.) and/or (b) shock, and/or (c) multi-organ dysfunction syndrome (MODS) according to criteria detailed in section 2.2: acute kidney injury, elevated liver enzymes, acute cardiomyopathy, due to SARS-Cov2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Efficacy Assessment Criteria (up to 15 days or, thereafter, up to a maximum of 25 days after the administration of treatment if continued hospitalization)"
        },
        {
            "text": "Mortality due to COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Efficacy Assessment Criteria (up to 15 days or, thereafter, up to a maximum of 25 days after the administration of treatment if continued hospitalization)"
        },
        {
            "text": "Our central hypothesis is that a convalescent plasma dose compared to placebo, and administered up to 72 hours from the onset of mild symptoms, will prevent progression to severe respiratory disease due to COVID-19 in patients between 65-74 years with at l with less than 48 hours of evolution and with mild symptoms.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hypothesis"
        },
        {
            "text": "The efficacy of an economically accessible therapeutic preparation against SARS-CoV2 analyzed by means of a randomized, double-blind study in vulnerable patients would allow its applicability to be immediately scaled up nationally and internationally through massive plasma donation campaigns in convalescent patients awaiting definitive solutions such as successful drugs, monoclonal antibodies, or vaccines [17] . Even if there is concentrated partial protection in the lower respiratory tract [18] , this same strategy could hypothetically allow immunization of subjects through controlled replication of the germ in the upper respiratory tract (as in the case of passive administration of antibodies against respiratory syncytial virus in infants [19] ).",
            "cite_spans": [
                {
                    "start": 409,
                    "end": 413,
                    "text": "[17]",
                    "ref_id": null
                },
                {
                    "start": 496,
                    "end": 500,
                    "text": "[18]",
                    "ref_id": null
                },
                {
                    "start": 751,
                    "end": 755,
                    "text": "[19]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Justification"
        },
        {
            "text": "A randomized, double-blind, placebo-controlled study to test the efficacy of convalescent plasma, administered up to 72 hours after the onset of symptoms, to prevent progression to severe respiratory disease. The study will be conducted in subjects aged 65presented with mild symptoms of less than 48 hours at the time of screening (as defined in section 5.1) and early diagnosis of COVID-19. Subjects will be followed for a minimum observation period of 15 days in which participants will remain under medical supervision daily to determine the primary endpoint. Monitoring will extend thereafter, up to 25 days if subjects remain symptomatic and hospitalized, to analyze secondary endpoints.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "STUDY DESIGN"
        },
        {
            "text": "The study is projected to incorporate an estimated maximum of 210 patients (see 9.0 Sample size). Participants will be randomized in a 1:1 ratio. Table 1 ). For each subject, participation in the study will last a minimum of 15 days or until the resolution of symptoms from the administration of the test article with a maximum of 25 days. Participating subjects will be monitored during and after administration of the test article to assess expected and unexpected safety events after plasma administration. A Data and Safety Monitoring Board will oversee the enrollment, efficacy, and safety of the participants throughout the study.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 146,
                    "end": 153,
                    "text": "Table 1",
                    "ref_id": "TABREF18"
                }
            ],
            "section": "STUDY DESIGN"
        },
        {
            "text": "The study will be conducted at the San Juan de Dios Hospital, the Simply Evita Hospital, the Dr. Carlos Bocalandro Hospital, the Evita Pueblo Hospital, in close coordination with health effectors of the provincial Ministry of Health and the Hospital Central Militar, the Sanatorio of Los Arcos, CEMIC, and the Research Center OSECAC and will not interfere with the care and standards of patient care established for notification and management of this disease.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "STUDY DESIGN"
        },
        {
            "text": "A subject must meet the following criteria to be included in the study:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria:"
        },
        {
            "text": "1. years or age between 65-74 years with at least one of the following comorbidities:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria:"
        },
        {
            "text": "a. Diagnosis of arterial hypertension under pharmacological treatment. b. Known diagnosis of diabetes in treatment with one or more of the available drugs (Appendix I). c. Obesity (BMI -Body mass indexd. Chronic obstructive pulmonary disease (COPD) treated with any of the available drugs (Appendix I). e. Cardiovascular disease defined as a) known diagnosis of coronary heart disease, b) history of ischemic stroke or hemorrhagic, or c) CHF (defined as EF f. Chronic kidney disease (defined as a reduction in GFR below 60 ml/min/1.73 m 2 ).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria:"
        },
        {
            "text": "2. Present for less than 48 hs : ( A ) axillary temperature 37,5\u00b0C or fever equivalence (defined as feeling cold and/or chills and/or unexplained sweating) , combined with (a ) dry cough and / or ( b) difficulty breathing and / or ( c) odynophagia and / or (d) anosmia and/or (e) dysgeusia and / or (e) any of the following symptoms: fatigue, anorexia, myalgia or rhinorrhea .",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria:"
        },
        {
            "text": "4. Being able, according to medical judgment, to understand and comply with the study procedures and to consent or not to their participation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SARS-CoV2 diagnosis confirmed by RT-PCR"
        },
        {
            "text": "A subject who meets any of the following criteria will be excluded from the study: immunosuppressants or other drugs that modify the immune system at the time of enrollment or within the 6 months prior to administration of study medication. An immunosuppressive dose of glucocorticoids will be defined as a systemic dose 13. Solid organ transplant. 14. Known chronic liver disease diagnosed with stage II-III-IV cirrhosis. 15. Chronic lung disease with oxygen requirement. 16 . Any other physical, psychiatric or social condition that may, at the discretion of the investigator, increase the risks of participation in the study for the participant or that may lead to the collection of incomplete or inaccurate safety data. Table 2) 5.2.a. Participating population and identification process of potential subjects.",
            "cite_spans": [
                {
                    "start": 473,
                    "end": 475,
                    "text": "16",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 724,
                    "end": 732,
                    "text": "Table 2)",
                    "ref_id": "TABREF3"
                }
            ],
            "section": "Exclusion Criteria"
        },
        {
            "text": "Subjects 65-74 years with at least one comorbid for less than 48 hours the following symptoms: ( a ) temperature 37,5\u00b0C or fever equivalence (defined by feeling cold or chills or unexplained sweating ) , combined with ( b ) dry cough and / or dyspnea and / or anosmia / dysgeusia and / or odynophagia and / or fatigue and / or anorexia and / or myalgias and / or rhinorrhea .",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study procedures ("
        },
        {
            "text": "Those patients who meet the inclusion criteria and do not meet any of the aforementioned exclusion criteria will be invited to participate in the research phase of the study in which, if they accept (expressing their agreement by signing the informed consent -research ANNEX), a sample of respiratory secretions is obtained by swabbing the nasopharynx and oropharynx (according to the procedure and regulations of the Argentinean Ministry of Health) to assay for RNA of SARS-COV2 by reverse transcriptase-polymerase chain reaction (RT-PCR).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study procedures ("
        },
        {
            "text": "The sample will be processed and analyzed by the laboratory designated for participating institutions daily, using the same RT-PCR test to assess the presence of RNA of SARS-COV2. This determination will be made as soon as possible (within a maximum of 24 hours) and under all the biosecurity standards indicated by the health authorities. The samples will be kept for later testing by RT-PCR for co-infections with influenza A and B, respiratory syncytial virus and other winter viral pathogens at the INFANT Foundation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study procedures ("
        },
        {
            "text": "If SARS-CoV2 RNA is detected in the respiratory sample, the candidate will be informed about the details of the study and eligibility will be verified again. The candidates may decide not to participate in the investigation by their free will and without any consequence whatsoever. In the event that the subject is interested in participating in the study, and after their consent is attested with the signing of the informed consent for participation (ANNEX), a unique identification number will be assigned. Once its alphanumeric code has been assigned, vital signs will be obtained and a complete physical examination will be performed to obtain the following demographic and clinical information [1-3, 25, 47-51]:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.b. Enrollment for participation in the study"
        },
        {
            "text": "-Sex -Age -Usual medications and those of the last 15 days. -History of smoking -Comorbidities of primary interest: arterial hypertension, diabetes, coronary heart disease, heart failure, history of stroke and AMI, COPD, chronic kidney disease, and obesity. -Secondary comorbidities: asthma, history of cancer, liver diseases, and neurological diseases.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.b. Enrollment for participation in the study"
        },
        {
            "text": "All participants with confirmed eligibility will be randomly assigned to a treatment group. The randomization of participating subjects will be conducted by the person in charge of randomizing the study using an electronic system. Once the patient is randomized, the person in charge of the allocation will communicate with a member of the Transfusion Medicine Central Team in the study who will remove the opaque bag treatment indicated in the freezer of the Central Laboratory. The",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.c. Random assignment"
        },
        {
            "text": "Transfusion Medicine team will proceed to take the cold bag to the hospital. There, he/she will complete the preparation of the masked product and administer the indicated treatment to the participating patient, using a venous access previously obtained by a member of the hospital team for the infusion. Only the person responsible for randomization and the physician in the Transfusion Medicine Central Team administering treatment will know the product administered to each patient (unblind). Neither the patient nor the researchers will have knowledge of the administered treatment, conducting a double-blind study. The unblinded team will keep a record of the product assignments and their administrations that will be kept confidential. In the eventual need to open the blind, such records may be used.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.c. Random assignment"
        },
        {
            "text": "The preparation and administration of the convalescent plasma or placebo (physiological solution) will be performed according to the ADMINISTRATIVE AND Once masked, the team of Transfusion Medicine will administer the product intravenously for 3 hours and up to 4 hours. After administration, local reactions at the injection site and systemic reactions will be monitored for 12 hours. This is a minimal risk study, since the administration of plasma and saline (placebo in this study) are a daily habit in medical practice. In the event of a medical emergency, when it is known that the treatment assignment may influence the medical care of the patient, the investigator or designee may request that the subject be unblinded for the emergency. However, prior to breaking the blind the investigator must make all reasonable efforts to discuss the decision to break the blind. The investigator is expected to provide a reason for the need to break the blind, based on a significant change in the participant's immediate or short-term medical care that will result from knowledge of the treatment assignment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.d. Preparation and administration of the test article"
        },
        {
            "text": "At 24 hours of completion of infusion of the treatment, a sample of 5 ml of venous blood will be obtained from all participants for titration of serum IgG anti-S SARS-COV2 and held at the Foundation INFANT. The assay will be performed by the ELISA method (COVIDAR IgG, Leloir / CONICET and Genetech IgG and sNT). Serum will be preserved to -20 C and transferred by a shuttle authorized for sample handling system transport biological the Foundation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.e. Taking a blood sample for titration of IgG anti-S SARS CoV2 in serum."
        },
        {
            "text": "We will perform one control daily from Day 0 and at least 15 days from the infusion and up to 25 days for those subjects who remain hospitalized with symptoms after day 15.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2. f. Daily clinical monitoring"
        },
        {
            "text": "Patients who are discharged prior to the day 15 will be monitored at home by a team of physicians trained for this purpose working in collaboration with the research centers. The following clinical information will be collected daily (using a questionnaire designed for this purpose) by study personnel and without interfering with the patient's medical care or altering the standards recommended by the health care authorities for the management of patients with COVID-19 : (a) respiratory rate (looking at the chest excursion for 30 seconds) , (b) oxygen saturation, (c) temperature, (d) central heart rate , (e) cough and duration, (f) sore throat and duration , (g) feeling of fever / chills, (h) need for supplemental oxygen provision and duration, (i) need for intensive care and duration, (j) need for non-invasive or invasive respiratory support and duration, (k) evidence of SDMO : according to criteria for acute kidney injury , criteria for elevated liver enzymes and criteria for acute cardiomyopathy (detailed in section 2.2) , (l) survival. ",
            "cite_spans": [
                {
                    "start": 569,
                    "end": 572,
                    "text": "(c)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "2. f. Daily clinical monitoring"
        },
        {
            "text": "Surveillance of adverse events X * (X)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring of transfusion X"
        },
        {
            "text": "Taking a blood sample after the infusion is complete",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring of transfusion X"
        },
        {
            "text": "Surveillance of respiratory symptoms X X We consider that the patient completes its participation when reaching day 15 (if the patient is already discharged), at the time of discharge between days 15 and 25, or at the expiration of day 25 if he/she continues hospitalized.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "hours"
        },
        {
            "text": "A Data Safety Monitoring Board (DSMB) will monitor the safety of the subjects throughout the study. The DSMB includes at least experienced members in managing internal medicine, infectious diseases, and a biostatistician with specific experience in the design, analysis and safety of clinical trials. The DSMB will operate under an approved plan and will have the responsibility to monitor the outcomes/end points, adverse events (AE) and serious adverse events (SAE), and recommend termination of the study if it appears at any point during the study that participants (or a subset of participants) are at undue risk as a result of their participation. The DSMB will meet (by teleconference) weekly to review the accumulated data on safety and efficacy and will conduct an interim analysis of the data. The DSMB will issue written recommendations based on its meetings regarding the continuity of the study. The minutes of each meeting will be recorded in documented minutes based on a preestablished work schedule. Any participant-specific protected health information reviewed by the DSMB will be kept completely confidential. Sessions will be closed without access to third parties.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data Safety Monitoring Board"
        },
        {
            "text": "The researcher at each institution and at a general level will supervise the safety of the study patient at his/her site(s) according to the requirements of this protocol and in accordance with current Good Clinical Practices (GCP). The investigator will monitor safety data at all study sites. Security monitoring will be carried out on an ongoing basis (for example, individual review of EA S, EAs and endpoints) and on a periodic cumulative basis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Security Monitoring"
        },
        {
            "text": "An AE is any unfavorable medical event in a patient who was administered a study drug that may or may not have a causal relationship to the study drug. Therefore, an AE is any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease that is temporarily associated with the use of a study drug, regardless of whether it is considered related to the study drug.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adverse event (AE)"
        },
        {
            "text": "An AE also includes any worsening (ie, any clinically significant change in frequency and / or intensity) of a pre-existing condition that is temporarily associated with the use of the investigational product.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adverse event (AE)"
        },
        {
            "text": "COVID-19 progression will not be considered an AE if it is clearly consistent with the typical progression pattern of the disease reported as an AE or SAE, as described in the appropriate protocol section.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adverse event (AE)"
        },
        {
            "text": "A SAE, by definition, is any unfavorable medical event that at any dose:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious adverse event (SAE)"
        },
        {
            "text": "Results in death: Includes all deaths, even those that appear to be unrelated to the study drug (for example, a car accident in which a patient is a passenger).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious adverse event (SAE)"
        },
        {
            "text": "It is life threatening: In the opinion of the investigator, the patient is at immediate risk of death at the time of the event. This does not include an AE which, if it had occurred in a more severe form, could have caused death.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious adverse event (SAE)"
        },
        {
            "text": "Requires hospitalization or extension of existing hospitalization. Hospitalization is defined as admission to a hospital or emergency room for more than 24 hours. Prolongation of existing hospitalization is defined as a hospital stay that is longer than originally planned for the event, or prolonged due to the development of a new AE as determined by the investigator or treating physician.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious adverse event (SAE)"
        },
        {
            "text": "Results in persistent or significant disability (substantial disruption of one's ability to carry out normal life functions).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious adverse event (SAE)"
        },
        {
            "text": "It is a major medical event -Major medical events may not immediately endanger life or result in death or hospitalization, but may endanger the patient or may require intervention to prevent one of the other serious outcomes listed above (for example, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias that do not result in hospitalization).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious adverse event (SAE)"
        },
        {
            "text": "In the case specific of this study we will consider AE or SAE , according to the detailed description in section 11.2, those that are initiated within 12 hours after administration of the IP and clinical exacerbations and deaths associated with these events. We will not consider as AE and SAEs those events occurring after 12 hours of initiation of treatment, that are consistent with the clinical course in patients infected with SARS COV2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious adverse event (SAE)"
        },
        {
            "text": "The reporting period for AE/SAE begins when the participant was initially included in the study (date of signature of informed consent for participation) and receives the infusion and continues for events that occur in the next 12 hours (see section 11.2 ) . During the follow up period, after the initial 12 hours of IP administration subjects will be monitored for the clinical outcome associated with primary and secondary endpoints.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adverse Event Collection Period"
        },
        {
            "text": "Subjects may leave the study at any time if they wish, but we will make every effort to monitor them during the stipulated period to guarantee their safety.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Leaving the Study Prematurely"
        },
        {
            "text": "Those patients who decide to drop out of the study prior to drug administration will be replaced, if necessary, to ensure an adequate number of evaluable patients.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Patient Replacement"
        },
        {
            "text": "There is significant uncertainty in the expected effect size of the intervention, and considering that the trial is expected to be completed in a relatively short period of time, the study is designed to have an interim analysis when the results of 50% of the subjects have been acquired.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Justification of the sample size and statistical analysis"
        },
        {
            "text": "Given the relative complexity of implementing this intervention, the minimally clinically important difference is established in a relative reduction of 40%, for an expected result rate of 50% in the control group that is reduced to 30% in the intervention group. A total sample size of 210 subjects (105 per test arm) will have 80% power, at a significance level (alpha) of 0.05 using a two-sided z-test with continuity correction. These results assume that 2 sequential tests are performed using the O'Brien-Fleming expenditure function to determine the limits of the test, as described in the Under the primary analysis strategy, we will use the Kaplan-Meier product cutoff distribution to compare treatment groups over time required to reach the primary outcome. An estimate of the relative risk and the 95% confidence interval will also be reported. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Justification of the sample size and statistical analysis"
        },
        {
            "text": "After donating plasma by apheresis or hemodonation, in addition to the samples obtained for routine blood bank controls, a dry tube of 5 mL of whole blood will be obtained, labeled with the identification given to the donor, identification of the Blood Bank and label that identifies the purpose of the \"PCC19\" study to perform the antibody titer. These will be assayed using the SARS CoV2 anti-protein S ELISA test, which in light of the existing data on protection against the virus allows an indirect extrapolation of the serum's neutralization capacity, optimized by the Leloir Institute in charge of Dr. Gamarnik, and currently used by health teams in Argentina to study immunity prevalence. Likewise, if possible, data will be correlated with the neutralizing antibody titer against a pseudovirus encoding protein S optimized by the same laboratory.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Anti-SARS Cov2 antibody titration"
        },
        {
            "text": "Tubes will be stored in a designated location within the Bank and shipped in an approved biological sample shipment to the INFANT Foundation (over 18 years of experience in testing) for assaying ELISAs and neutralizing antibodies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Anti-SARS Cov2 antibody titration"
        },
        {
            "text": "The titers obtained by S ELISA will then be classified and those that are above 1: 1,000 selected to provide convalescent plasma for this study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Anti-SARS Cov2 antibody titration"
        },
        {
            "text": "The additional high titer plasmas will also be stored to be sent to the C\u00f3rdoba Blood Products Center (UNC), which will produce gammaglobulin enriched with anti-SARS-CoV2 antibodies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Anti-SARS Cov2 antibody titration"
        },
        {
            "text": "Military Hospital, Hemocentro Buenos Aires Foundation, and Sarmiento Hematology Foundation) Plasma donation will be conducted through an apheresis procedure with equipment and disposable supplies approved for this purpose, during which it is recommended to extract a volume no greater than 15% of the donor's blood volume. The anticoagulant to be used will be ACD-A or similar. In cases where volume replacement is not performed, plasma extraction should not exceed 600 ml per procedure. The 48 hours interval must be respected between each procedure, not to exceed 2 donations in a week or 24 donations in a 12-month period. The PCC19 units can be separated into 250ml aliquots, respecting the closed circuit and following the indications of the current standard operating procedure.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Plasmapheresis (Institute of Hemotherapy of the Province in La Plata, Central"
        },
        {
            "text": "1-Plasma will be obtained with a Cobe Spectra equipment. 1.5 to 2 L of plasma will be extracted according to the donor's weight and tolerance to the procedure. In case of venous inaccessibility or opposition from the donor, between 400 and 500 ml of whole blood will be drawn (classic hemodonation) 2-The volume replacement will use NS and albumin solution.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hemodonation (CEMIC)"
        },
        {
            "text": "3-During the procedure the plasma will be transferred to transfer bags of similar volume each (approximately 500ml). 4-The bags will be labeled as detailed below. 5-They will be frozen in the -56\u00b0C Righi vertical ultrafreezer (labeled Freezer # I, identified with COVID-19 convalescent plasma label in the Blood Bank) separated on shelves by bag type (1, 2 or 3). 6-The convalescent plasma will remain stored until its use or expiration (1 year), with appropriate safety criteria. 7-Disposal will be conducted under stipulated security regulations. 8-Stored aliquots of serum / plasma frozen for future determinations at -80 \u00ba C in Eppendorf tubes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hemodonation (CEMIC)"
        },
        {
            "text": "All units of PC COVID-19 must comply with the labeling required for fresh frozen plasma from each Blood Bank and must also have a clear identification, which must include: \u00b7 \"Product Type: PC COVID-19\" \u00b7 \"Result of antibody titer for SARS-CoV-2\" (if available) \u00b7 \"CAUTION: product for research use only\" . \"PROTOCOL: INFANT Foundation -Serum enriched with anti SARS-CoV2 antibodies\"",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Labelled"
        },
        {
            "text": "Cold Chain of PCCOVID-19",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Labelled"
        },
        {
            "text": "1.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Labelled"
        },
        {
            "text": "The units are stored properly separated from the remaining plasma units and labelled for transfusional use in a place clearly identified for this purpose.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Labelled"
        },
        {
            "text": "The PCC19 units will be stored at temperatures below -25 \u00ba C, which allows a storage of 36 months and between -18 \u00ba C and -25 \u00ba C for 3 months of storage.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2."
        },
        {
            "text": "The units will be transported in a way to maintain the cold chain reliably.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "3."
        },
        {
            "text": "Plasma units should be stored between 2 \u00baC and 6\u00baC until 24 hours after thawing. After then, they should be discarded.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "4."
        },
        {
            "text": "The Blood Bank and the Transfusion Service of the requesting Institution will implement a registry system that guarantees traceability between donors and recipients. In this special situation, they must also have a specific registry as this is a transfusion therapy administered in an experimental context.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Traceability"
        },
        {
            "text": "After assessing vital signs and verifying eligibility, the unblinded team from the Medical Transfusion Center will be notified of the result of the randomization process and drive to the assigned hospital with the masked treatment product cold. On arrival, they will proceed again to check the code assigned for treatment with a member of the laboratory of Transfusion Medicine of the hospital (see 5.2.c).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administration of the intervention"
        },
        {
            "text": "Placebo will be a 250 ml of normal saline (0.9%) sterile, masked and administered in the same way and speed as plasma. To avoid bias and maintain the study blinded, plasma and saline 0.9% will be masked using an opaque bag and tape that will not allow to differentiate both products. Members of the Medical Transfusion Central Team will conduct the intervention with a member of the local team. Thus, both members of the Transfusion Medicine Central Team and the respective member of Transfusion Medicine at the hospitals will not be blind, while the rest of the team with delegated functions in the studies in each Center and the patients will be blind to the intervention.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administration of the intervention"
        },
        {
            "text": "To prepare the plasma, 250 ml bags will be thawed at 37 \u00b0C, according to the operating procedures of the Department of Transfusion Medicine at the Hospital. Plasma will be infused slowly (at least 3 hours and up to 4 hours) according to the hemodynamics of the patient and monitored for 12 hours and adverse effects early and late attributable to transfusion recorded.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administration of the intervention"
        },
        {
            "text": "Transfusion-associated circulatory overload (TACO) Transfusion-associated circulatory overload (TACO) is the most common pulmonary complication and is an independent risk factor for hospital morbidity and mortality, with a higher incidence in critically ill patients [58] . The estimated frequency of TACO varies from 1% to 5% depending on the hemovigilance system [59] , up to 8% in advanced post-surgical patients, and 11% in critically ill patients [60 61 62] . Risk factors include -transfusion fluid balance [63] [64] . Most cases of TACO are prevented by slowing the transfusion rate and establishing the usual measures for fluid overload in susceptible populations. Overload constitutes a requested AE, but if it does not improve within 120 minutes after the infusion or requires -in the opinion of the responsible professionals -transfer of the patient to intensive care due to poor clinical progression, should be reported immediately as a SAE.",
            "cite_spans": [
                {
                    "start": 267,
                    "end": 271,
                    "text": "[58]",
                    "ref_id": "BIBREF175"
                },
                {
                    "start": 365,
                    "end": 369,
                    "text": "[59]",
                    "ref_id": "BIBREF176"
                },
                {
                    "start": 456,
                    "end": 462,
                    "text": "61 62]",
                    "ref_id": null
                },
                {
                    "start": 513,
                    "end": 517,
                    "text": "[63]",
                    "ref_id": "BIBREF180"
                },
                {
                    "start": 518,
                    "end": 522,
                    "text": "[64]",
                    "ref_id": "BIBREF181"
                }
            ],
            "ref_spans": [],
            "section": "Monitoring of adverse events associated with plasma transfusion"
        },
        {
            "text": "Diagnostic criteria for TACO [19] During or up to 12 hours after the transfusion, TACO is characterized by the presence of a total of 3 or more of these criteria: A. Acute or worsening respiratory compromise B. Evidence of acute or worsening pulmonary edema based on clinical and / or chest radiographic images and / or other noninvasive assessment of cardiac function (echocardiogram) C. Evidence of cardiovascular changes not explained by the patient's underlying medical condition, including: tachycardia, hypertension, widened pulse pressure, jugular venous distention, enlarged cardiac silhouette, and/or peripheral edema. D. Evidence of fluid overload, including any of the following: a positive fluid balance; response to diuretic therapy, or dialysis combined with clinical improvement; and variation of the patient's weight. E. Increased level of B-type natriuretic peptide (eg, BNP or NT-pro BNP) above the agespecific reference range and greater than 1.5 times the pre-transfusion value.",
            "cite_spans": [
                {
                    "start": 29,
                    "end": 33,
                    "text": "[19]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Monitoring of adverse events associated with plasma transfusion"
        },
        {
            "text": "This is an acute respiratory distress syndrome, it will be considered a SAE and it occurs during or within six hours after the administration of the transfusion. Prospective studies of TRALI reported very low incidence rates (0.0008% to 0.001% of transfused patients) [19] after the implementation of strategies to prevent the transfusion of blood components obtained from multiparous female donors. In our study, multiparous women will not be invited to donate plasma. Treatment of a patient with TRALI involves immediate interruption of the transfusion.",
            "cite_spans": [
                {
                    "start": 268,
                    "end": 272,
                    "text": "[19]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Transfusion Associated Acute Pulmonary Injury (TRALI)"
        },
        {
            "text": "TRALI diagnostic criteria: [28] TRALI Type I: patients who do not have risk factors for ARDS and meet the following criteria: A. i. Acute onset ii. Hypoxemia (Pa O 2 / Fi O 2 2 <90% in room air). iii. Pulmonary edema with clear evidence of bilateral images ( CXR, CT or ultrasound) iv. There is no evidence of left ventricular hypertrophy or, if present, it is not the main contributor to hypoxemia. B. Initiation during or within 6 hours of transfusion. C. Temporarily unrelated to an alternative risk factor for ARDS. TRALI Type II: patients who have risk factors for ARDS (but have not been diagnosed with ARDS) or who have existing mild ARDS (Pa / Fi 200-300), but whose respiratory status is deteriorating and is considered to be due to a transfusion based on: a. The results described in categories a and b of TRALI Type I, and b. Stable respiratory status within 12 hours prior to transfusion",
            "cite_spans": [
                {
                    "start": 27,
                    "end": 31,
                    "text": "[28]",
                    "ref_id": "BIBREF17"
                }
            ],
            "ref_spans": [],
            "section": "Transfusion Associated Acute Pulmonary Injury (TRALI)"
        },
        {
            "text": "Allergic reactions generally occur during or within 4 hours of transfusion and are most frequently associated with platelet transfusions (302 per 100,000 platelet units) [29] . Symptoms are caused by mediators such as histamine, released in mast cell and basophil activation [30] . Frequently, the clinical presentation is mild (rash, pruritus, urticaria, and angioedema are localized) and they are a solicited AE. Mild allergic transfusion reactions generally resolve with the administration of the usual treatment for allergic reactions, being able to restart the infusion of the unit. The transfusion should be stopped if symptoms reappear. The incidence of anaphylactic reactions is 8 / 100,000 units of transfused platelets. The most severe reactions generally present with bronchospasm, respiratory distress, and hypotension and constitute a SAE and should be reported as such immediately [31] [32] [33] [34] [35] .",
            "cite_spans": [
                {
                    "start": 170,
                    "end": 174,
                    "text": "[29]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 275,
                    "end": 279,
                    "text": "[30]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 895,
                    "end": 899,
                    "text": "[31]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 900,
                    "end": 904,
                    "text": "[32]",
                    "ref_id": null
                },
                {
                    "start": 905,
                    "end": 909,
                    "text": "[33]",
                    "ref_id": null
                },
                {
                    "start": 910,
                    "end": 914,
                    "text": "[34]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 915,
                    "end": 919,
                    "text": "[35]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Allergic -Anaphylactic Reactions"
        },
        {
            "text": "Acute hemolytic transfusion reactions Acute hemolytic transfusion reactions (ATRs) can occur when incompatible red blood cells are transfused or, less frequently, large amounts of plasma incompatible with the patient's ABO are transfused. The central pathophysiological mechanism is intravascular hemolysis and is considered a SAE. It presents with sudden fever and chills, retroperitoneal pain and dyspnea, hemoglobinuria and even disseminated intravascular coagulation, acute renal failure, and shock. Since fever and chills may be the only early signs, it is important to monitor the patient during the transfusion and stop the transfusion immediately if there is any change in vital signs or unexpected symptoms appear. Treatment is based on supportive measures to alleviate symptoms. Proper patient identification and adherence to all procedures related to handling pretransfusion specimens and administration of transfusions are essential to prevent ATRs [36] .",
            "cite_spans": [
                {
                    "start": 961,
                    "end": 965,
                    "text": "[36]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Allergic -Anaphylactic Reactions"
        },
        {
            "text": "The risk of transmission of infectious diseases through transfusions has been dramatically reduced, secondary to the great advances in unit testing, and pathogen inactivation for plasma units and their components [51] and the implementation of rigorous donor selection methods. In our environment, the samples are tested for HBV, HCV, HIV, HTLV and Trypanosoma cruzi [52] . In the United States, the risk of acquiring HBV and HIV by transfusion is 1:280,000 and 1:1,467,000, respectively [53 54 ]. Due to freezing of plasma samples, contamination by bacterial pathogens and CMV is extremely rare. There are only a dozen cases among the millions of transfusions reported in Germany and Canada of bacterial transmission. It is estimated that the potential source of this contamination would have been the water baths used to defrost the units. This is easily avoidable with proper cleaning and sterilization of defrosters [39] .",
            "cite_spans": [
                {
                    "start": 213,
                    "end": 217,
                    "text": "[51]",
                    "ref_id": null
                },
                {
                    "start": 367,
                    "end": 371,
                    "text": "[52]",
                    "ref_id": "BIBREF171"
                },
                {
                    "start": 488,
                    "end": 494,
                    "text": "[53 54",
                    "ref_id": null
                },
                {
                    "start": 920,
                    "end": 924,
                    "text": "[39]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Transfusion Communicable Infections [39]"
        },
        {
            "text": "This study will be conducted in accordance with the protocol and with the following considerations: the ethical principles that have their origin in the Declaration of Helsinki, the current Good Clinical Practice (GCP) guidelines from the International Council of Harmonization (ICH), current laws and regulations.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statement of Good Clinical Practice"
        },
        {
            "text": "The protocol, the Informed Consent forms (ICF) and other relevant documents have been reviewed and approved by INFANT Foundation, the participating authorities and sent to the Ethics Committee (EC) for evaluation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statement of Good Clinical Practice"
        },
        {
            "text": "A properly constituted EC, as outlined in the ICH guidelines for GCP, must review and approve:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethics Committee (EC):"
        },
        {
            "text": "The protocol, ICF and any other materials that are provided to the participants before any subject can enter the study Any amendment or modification to the study protocol or to the CRF prior to implementation, unless the change is necessary to eliminate an immediate danger to patients, in which case the EC should be informed as soon as possible",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethics Committee (EC):"
        },
        {
            "text": "In addition, they must be informed of any event that may affect the safety of patients or the continued conduct of the clinical study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethics Committee (EC):"
        },
        {
            "text": "INFANT should receive a copy of the approval letter from the EC before sending drug supplies to the investigator at each hospital. The approval letter should include the title of the study, the documents reviewed, and the date of the review.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethics Committee (EC):"
        },
        {
            "text": "The investigator must keep on file the records of the EC review and approval of all study documents",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethics Committee (EC):"
        },
        {
            "text": "The ICF used by the researcher will be approved by the corresponding EC.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent Process"
        },
        {
            "text": "It is the responsibility of the investigator or delegated professional to obtain the written informed consent from each subject prior to their participation in the study and after the objectives, procedures, and potential risks of the study have been fully explained in language that the subject can understand. The ICF must be signed and dated by the researcher or delegated personnel who performed the consenting process.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent Process"
        },
        {
            "text": "The investigator or delegated staff will explain the nature of the study to the participant and answer all questions about the study. He/she will inform them that their participation is voluntary. The participant must sign the informed consent form (ICF) before any specific study activity takes place.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent Process"
        },
        {
            "text": "Participants who can understand but cannot write and / or read will have the IC read to them in the presence of an impartial witness, who will sign and date the ICF to confirm that informed consent was obtained.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent Process"
        },
        {
            "text": "Two copies will be signed. The investigator should keep one copy as part of the patient's study record, and the other signed copy should be given to the participant.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent Process"
        },
        {
            "text": "The investigator will take all appropriate measures to ensure that the anonymity of each study subject is maintained in research records transmitted outside the health center. The original and essential documents of the study must be kept in strict confidence at each research center by the study team.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Confidentiality and Protection of Personal Data"
        },
        {
            "text": "The personal data of the participants will be stored in the study center in a passwordprotected print and/or electronic format or in a locked room, to guarantee the exclusive access of authorized study personnel.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Confidentiality and Protection of Personal Data"
        },
        {
            "text": "To protect the rights and freedoms of natural persons in relation to the processing of personal data, a unique and specific alphanumeric code will be assigned to the participants. The records or data sets of the participants that are transferred will contain the alphanumeric code; the names of the participants will not be transferred. All other identifiable data transferred between researchers will be identified by this unique, participant-specific code. The study center will maintain a confidential list of participants who participated in the study under strict security (password protected or in a locked room), linking the alphanumeric code of each participant with their real identity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Confidentiality and Protection of Personal Data"
        },
        {
            "text": "Records and documents, including signed FCIs, regarding the conduct of this study will be retained by the investigator for 15 years after study completion, unless local regulations or institutional policies require a longer retention period. The investigator from each participating institution should consult with INFANT before discarding or destroying any essential study documents after study completion or interruption. If approved, records must be destroyed in a way that ensures confidentiality.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Documentation"
        },
        {
            "text": "The study monitor will visit each site prior to enrolling the first patient and periodically during the study in accordance with the Approved Study Monitoring Plan.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring of study sites"
        },
        {
            "text": "The monitor receives weekly reports from each of the centers with the number of patients in a period of research and enrolled.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring of study sites"
        },
        {
            "text": "Monitoring visits and centralized monitoring activities will be carried out in accordance with all applicable regulatory requirements and standards in force in Argentina. It is understood that the monitor will contact each researcher and their responsible team regularly and will be allowed to verify the generation of the different study records.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring of study sites"
        },
        {
            "text": "It will be the monitor's responsibility to inspect the data capture systems at regular intervals throughout the study to verify compliance with the protocol and the integrity, precision and consistency of the data; and adherence to the ICH GCP and local regulations on conducting clinical research. The monitor should have access to laboratory reports, study medication, records associated with it, and other medical records necessary to verify the entries in the EDC.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring of study sites"
        },
        {
            "text": "An unblinded monitor will be assigned whose role will be limited to auditing the logistic data, management and study treatment registration according to the approved protocol and treatment instructions:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring of study sites"
        },
        {
            "text": "reception and storage conditions randomization and administration return or destruction / final reconciliation",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring of study sites"
        },
        {
            "text": "Investigators are required to prepare and maintain adequate and accurate patient records (source documents).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Source document requirements"
        },
        {
            "text": "The researcher must keep all the source documents in the file of the data submitted to the study form (CRF). Some data generated from the study may be entered directly into the EDC system (direct data capture), after approval of the process by the Ethics Committees involved. Case report forms and source documents must be available at all times.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Source document requirements"
        },
        {
            "text": "Study data obtained in the course of the study will be recorded in case report forms (CRF) and sent to INFANT in scan format. Once received, they will be archived and processed by entering the EDC system by trained INFANT personnel. All required CRFs must be completed for each patient enrolled in the study. The investigator should retain a copy of each patient's CRF case book as part of the study record and should be available at all times for inspection by authorized representatives of the sponsor and regulatory authorities.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Case Report Form Requirements"
        },
        {
            "text": "This study may be subject to a quality assurance audit or inspection. If this occurs, the investigator is responsible for:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Audits and inspections"
        },
        {
            "text": "-Provide access to all facilities, study data and documents necessary for inspection or audit.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Audits and inspections"
        },
        {
            "text": "-Communicate any information arising from the inspection of the regulatory authorities to INFANT immediately. -Take all appropriate measures requested by INFANT to resolve the problems found during the audit or inspection.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Audits and inspections"
        },
        {
            "text": "Documents subject to audit or inspection include, but are not limited to, all source documents, CRF, medical records, correspondence, FCI, CE files, supporting laboratory quality control and certification documentation, and relevant records for the study being conducted. they maintain pharmacy facilities. The storage conditions of study material are also subject to inspection. Additionally, sponsor representatives may observe the conduct of any aspect of the clinical trial or its support activities both within and outside of the investigator's institution.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Audits and inspections"
        },
        {
            "text": "In all cases, the confidentiality of the data must be respected.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Audits and inspections"
        },
        {
            "text": "HEART FAILURE NYHA SCALE (NEW YORK HEART ASSOCIATION) FUNCTIONAL ASSESSMENT OF HEART FAILURE.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "ANNEX"
        },
        {
            "text": "Class I Without limitation of physical activity. Normal physical exercise does not cause fatigue, palpitations, or dyspnea.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "NYHA FUNCTIONAL CLASSIFICATION"
        },
        {
            "text": "Class II Slight limitation of physical activity. No symptoms at rest. Ordinary activity causes fatigue, palpitations, or dyspnea.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "NYHA FUNCTIONAL CLASSIFICATION"
        },
        {
            "text": "Class III Marked limitation of physical activity. No symptoms at rest. Less than ordinary physical activity causes fatigue, palpitations or dyspnea. Class IV Inability to carry out any physical activity; symptoms of heart failure are present even at rest and increase with any physical activity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "NYHA FUNCTIONAL CLASSIFICATION"
        },
        {
            "text": "Stage ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "CIRRHOSIS STAGES"
        },
        {
            "text": "Administrative and Technical Regulations, RM 797/13 -139/14 -1507/15 Directorate of Blood and Blood Products Ministry of Health of the Nation. http://www.msal.gob.ar/disahe/images/stories/pdf/normashemoterapia.pdf",
            "cite_spans": [],
            "ref_spans": [],
            "section": "96."
        },
        {
            "text": "SARS-CoV2 is a new and particularly aggressive virus for elderly individuals, who represent between 73% and 90% of fatal cases in different regions of the world [28, 30, 40] . Mortality, the need for intensive care, mechanical ventilation, oxygen requirements, and hospitalizations for respiratory disease increase markedly with advancing age in patients [2, 3, 29, 32, 46] . In fact, the frequency of death from disease due to SARS-CoV2 (COVID-19) is 8% in patients between 70 and 80 years old, and increases to 14.8% in those over 80 [23] . Specifically in hospitalized patients older than 75 years, mortality is 29.4% [24] , and in intensive care it amounts to an alarming 43.5% [25] . Several comorbidities associated with vascular and / or pulmonary disease worsen the prognosis of those infected even in patients younger than 70, including arterial hypertension, diabetes, obesity, and chronic obstructive pulmonary disease (COPD) [3, 23, 30, 31] . To date, the virus has caused more than 290,000 deaths worldwide, more than 300 of them in Argentina which is contained through a transitional strategy quarantine quasi-universal [4] . There is no specific treatment available yet. The results of the efficacy trials for SARS-CoV2 vaccines will be known within a minimum of 10-14 months.",
            "cite_spans": [
                {
                    "start": 161,
                    "end": 165,
                    "text": "[28,",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 166,
                    "end": 169,
                    "text": "30,",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 170,
                    "end": 173,
                    "text": "40]",
                    "ref_id": null
                },
                {
                    "start": 355,
                    "end": 358,
                    "text": "[2,",
                    "ref_id": null
                },
                {
                    "start": 359,
                    "end": 361,
                    "text": "3,",
                    "ref_id": null
                },
                {
                    "start": 362,
                    "end": 365,
                    "text": "29,",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 366,
                    "end": 369,
                    "text": "32,",
                    "ref_id": null
                },
                {
                    "start": 370,
                    "end": 373,
                    "text": "46]",
                    "ref_id": null
                },
                {
                    "start": 536,
                    "end": 540,
                    "text": "[23]",
                    "ref_id": null
                },
                {
                    "start": 621,
                    "end": 625,
                    "text": "[24]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 682,
                    "end": 686,
                    "text": "[25]",
                    "ref_id": null
                },
                {
                    "start": 937,
                    "end": 940,
                    "text": "[3,",
                    "ref_id": null
                },
                {
                    "start": 941,
                    "end": 944,
                    "text": "23,",
                    "ref_id": null
                },
                {
                    "start": 945,
                    "end": 948,
                    "text": "30,",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 949,
                    "end": 952,
                    "text": "31]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 1134,
                    "end": 1137,
                    "text": "[4]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "INTRODUCTION"
        },
        {
            "text": "SARS-CoV2 is an enveloped virus that contains single stranded RNA in the positive sense bound to a nucleoprotein (protein N), within a capsid composed of matrix proteins (protein M). The envelope contains spine-shaped glycoproteins (protein S) that bind to the cellular receptor ACE2 in humans and generate neutralizing antibodies [13] . Primary SARS-CoV2 infection, like other respiratory diseases, generates an antibody response with early production of IgM followed by specific IgG against viral proteins [14] . Detection of virus neutralizing antibodies is common, reaching high levels of up to 1: 21,500 PRNT50, mostly exceeding 1: 500 titers after 28 days of symptom onset in mild patients [41] . Approximately 5% of patients have neutralizing antibody levels <1:40, especially the younger ones [41] . A study of primary respiratory tract infection in rhesus macaques, using 10 6 pfu of SARS-CoV2 followed by a second intratracheal challenge using the same virus and doses 28 days later, demonstrated the absence of reinfection after an extensive evaluation by RT-PCR in tissues post-necropsy [42] . Neutralizing titers before the second inoculum ranged from 1:8-1:16 PRNT50 [42] . These findingslimited indeed, given the novelty of the problem -suggest that even low neutralizing antibody titers could prevent severe disease due to the virus.",
            "cite_spans": [
                {
                    "start": 331,
                    "end": 335,
                    "text": "[13]",
                    "ref_id": null
                },
                {
                    "start": 508,
                    "end": 512,
                    "text": "[14]",
                    "ref_id": null
                },
                {
                    "start": 696,
                    "end": 700,
                    "text": "[41]",
                    "ref_id": null
                },
                {
                    "start": 801,
                    "end": 805,
                    "text": "[41]",
                    "ref_id": null
                },
                {
                    "start": 1099,
                    "end": 1103,
                    "text": "[42]",
                    "ref_id": null
                },
                {
                    "start": 1181,
                    "end": 1185,
                    "text": "[42]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "INTRODUCTION"
        },
        {
            "text": "Protecting the populations most vulnerable to SARS-CoV2 is imperative, in the context of a highly infectious pathogen (R 0 estimated between 2 and 3.28) [27, 33, 34] . Its contagiousness rapidly overwhelms the health capacity of developed countries in different regions of the world [5] and threatens the health resources of developing countries [6] . Regions of Italy, Spain and the United States have been overwhelmed by the pandemic, which represents a serious threat to Argentina, coinciding with the beginning of the annual circulation of other lung pathogens, such as the common flu and respiratory syncytial virus [26] . Obviously, it would be impossible to respond to an avalanche of critically ill patients [7] , and any strategy aimed at reducing infections and the development of severe disease is directly aligned with the medical objective of saving lives and with the health needs of the country in order to provide the best possible care for those patients who need it.",
            "cite_spans": [
                {
                    "start": 153,
                    "end": 157,
                    "text": "[27,",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 158,
                    "end": 161,
                    "text": "33,",
                    "ref_id": null
                },
                {
                    "start": 162,
                    "end": 165,
                    "text": "34]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 283,
                    "end": 286,
                    "text": "[5]",
                    "ref_id": null
                },
                {
                    "start": 346,
                    "end": 349,
                    "text": "[6]",
                    "ref_id": null
                },
                {
                    "start": 621,
                    "end": 625,
                    "text": "[26]",
                    "ref_id": null
                },
                {
                    "start": 716,
                    "end": 719,
                    "text": "[7]",
                    "ref_id": "BIBREF128"
                }
            ],
            "ref_spans": [],
            "section": "INTRODUCTION"
        },
        {
            "text": "Post-exposure prophylaxis to viruses and treatment in early stages of disease, through defenses obtained in convalescent plasma, is a widespread practice with successful antecedents in the history of medicine at a national and global level. As early as 1960, Brunell et al. managed to prevent clinical varicella in siblings with sick parents, using anti-varicella zoster immunoglobulins obtained from the plasma of previously infected patients [8]. Today, for example, enriched immunoglobulin for measles is used in unvaccinated people who were in contact with a patient for the previous 6 days with an efficacy close to 100% [9, 52]; a similar product enriched for varicella zoster virus is administered to unvaccinated pregnant women, newborns, and immunosuppressed patients in contact with infected persons within 96 hours, reducing the incidence of severe disease by 90% [10, 53, 54] ; tetanus immunoglobulin supplements vaccination in soiled wound victims with incomplete primary immunization [43] ; gamma globulin against hepatitis B is used as prevention for newborns of infected mothers with an efficacy of 75% [44, 55] ; and rabies gamma globulin is ~ 100% effective in the prophylaxis of post-injury due to a rabid animal [11, 56] . Interventions using human immunity derived from convalescent plasma have been shown to be safe, have prevented countless cases of severe disease, and have preserved lives around the world.",
            "cite_spans": [
                {
                    "start": 875,
                    "end": 879,
                    "text": "[10,",
                    "ref_id": null
                },
                {
                    "start": 880,
                    "end": 883,
                    "text": "53,",
                    "ref_id": "BIBREF172"
                },
                {
                    "start": 884,
                    "end": 887,
                    "text": "54]",
                    "ref_id": "BIBREF173"
                },
                {
                    "start": 998,
                    "end": 1002,
                    "text": "[43]",
                    "ref_id": null
                },
                {
                    "start": 1119,
                    "end": 1123,
                    "text": "[44,",
                    "ref_id": null
                },
                {
                    "start": 1124,
                    "end": 1127,
                    "text": "55]",
                    "ref_id": null
                },
                {
                    "start": 1232,
                    "end": 1236,
                    "text": "[11,",
                    "ref_id": null
                },
                {
                    "start": 1237,
                    "end": 1240,
                    "text": "56]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "INTRODUCTION"
        },
        {
            "text": "The main objective of our study is to evaluate the efficacy of convalescent plasma in reducing the progression to severe disease in people between 65-74 years with at least one comorbidity and in all those years of age who present with mild symptoms of less than 48 hs of evolution at the time of screening and with an early diagnosis of COVID-19. Our central hypothesis is that a single dose convalescent plasma compared against placebo (saline at 0.9%) administered up to 72 hours after the onset of symptoms by SARS-COV2, prevent progression to severe respiratory disease in subjects 65-74 years with at least one comorbidity and irrespective of the presence of comorbidities.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "INTRODUCTION"
        },
        {
            "text": "To evaluate the efficacy of convalescent plasma, starting 12 hours after administration, in reducing the progression to severe respiratory disease in people between 65-74 years with at least one comorbidity and in all those 75 years with mild symptoms and a diagnosis of early COVID-19 until 15 days of administration of treatment (16-18 days of disease considering the pre-symptomatic period before enrollment).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Primary objective"
        },
        {
            "text": "The Secondary Objectives include determining if the administration of convalescent plasma up to 15 days or thereafter up to a maximum of 25 days of the administration of treatment in those still hospitalized:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Objectives"
        },
        {
            "text": "Reduces the need for oxygen support with maximal oxygen therapy (O 2 reservoir mask) and/or use of non-invasive respiratory support (NIV support including CPAP) and/or admission to ICU and/or requirement of invasive mechanical ventilation due to SARS-CoV2 in patients between 65-74 .",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Objectives"
        },
        {
            "text": "Reduces critical illness defined as (a) presence of acute respiratory failure 200 mm Hg.) and / or (b) shock (defined by need of vasoactive drugs to maintain MAP equal to or greater than 65 mm Hg) , and / or (c) multi-organ dysfunction syndrome (MODS ): acute kidney injury (defined by a creatinine increase two or more times from baseline or a creatinine increase of 0.3 mg / dl) , elevated liver enzymes (transaminases) greater than three times the upper normal value , acute cardiomyopathy (defined by troponin elevation above the normal level and/or new electrocardiographic or echocardiographic changes of myocardial damage) in patients 65-74 years with at least one comorbidity and in all those -19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Objectives"
        },
        {
            "text": "Reduces mortality due to SARS-CoV2 in patients between 65-74 years with at -19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Objectives"
        },
        {
            "text": "Decreases the length of oxygen support due to hypoxemia associated with COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Objectives"
        },
        {
            "text": "Describe the safety of convalescent plasma administration in patients between 65-COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Objectives"
        },
        {
            "text": "Explore the concentration of IgG anti-S SARS COV2 in plasma of participants associated with the absence of severe respiratory disease obtained at 24 hours of infusion.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Objectives"
        },
        {
            "text": "Explore whether, rather than protect against the severe respiratory disease, administration of convalescent plasma delays the onset of the disease.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exploratory Objectives"
        },
        {
            "text": "Explore the effects of convalescent plasma on primary humoral immune response against infection by SARS COV2 at 90 days post-illness.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exploratory Objectives"
        },
        {
            "text": "Explore whether the effects on respiratory and cardiovascular disease and long-term mortality were affected by the intervention at 12 months of enrollment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exploratory Objectives"
        },
        {
            "text": "Explore the correlation between viral load determined by RT-PCR at diagnosis and the response to plasma treatment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exploratory Objectives"
        },
        {
            "text": "Severe respiratory disease due to SARS-CoV2, confirmed by detection of viral RNA by RT-PCR, and defined by the presence of any of the following two variables in a nonsaturation in room air <93% [20, 21] . The primary endpoint will be determined from 12 hours of the start of the infusion until 15 days since administering treatment. Need for oxygen support with maximum oxygen therapy (O 2 reservoir mask) and/or non-invasive respiratory support (NIV support including CPAP) and/or admission to ICU and/or requirement of invasive mechanical ventilation, due to SARS-CoV2.",
            "cite_spans": [
                {
                    "start": 194,
                    "end": 198,
                    "text": "[20,",
                    "ref_id": null
                },
                {
                    "start": 199,
                    "end": 202,
                    "text": "21]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Primary Efficacy Assessment Criterion"
        },
        {
            "text": "Critical illness defined as (a) presence of acute respiratory failure (PaO2 / FiO2 200 mmHg.) and/or (b) shock, and/or (c) multi-organ dysfunction syndrome (MODS) according to criteria detailed in section 2.2: acute kidney injury, elevated liver enzymes, acute cardiomyopathy, due to SARS-Cov2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Efficacy"
        },
        {
            "text": "Mortality due to COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Efficacy"
        },
        {
            "text": "Combination of the secondary efficacy endpoints # 1 (need for oxygen support covid-19).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Efficacy"
        },
        {
            "text": "Duration of oxygen requirement in patients with COVID-19 due to O 2 saturation in room air <93%.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Secondary Efficacy"
        },
        {
            "text": "Our central hypothesis is that a convalescent plasma dose compared to placebo, and administered up to 72 hours from the onset of mild symptoms, will prevent progression to severe respiratory disease due to covid-19 in patients between 65-74 years with at l with less than 48 hours of evolution and with mild symptoms.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hypothesis"
        },
        {
            "text": "The efficacy of an economically accessible therapeutic preparation against SARS-CoV2 analyzed by means of a randomized, double-blind study in vulnerable patients would allow its applicability to be immediately scaled up nationally and internationally through massive plasma donation campaigns in convalescent patients awaiting definitive solutions such as successful drugs, monoclonal antibodies, or vaccines [17] . Even if there is concentrated partial protection in the lower respiratory tract [18] , this same strategy could hypothetically allow immunization of subjects through controlled replication of the germ in the upper respiratory tract (as in the case of passive administration of antibodies against respiratory syncytial virus in infants [19] ).",
            "cite_spans": [
                {
                    "start": 409,
                    "end": 413,
                    "text": "[17]",
                    "ref_id": null
                },
                {
                    "start": 496,
                    "end": 500,
                    "text": "[18]",
                    "ref_id": null
                },
                {
                    "start": 751,
                    "end": 755,
                    "text": "[19]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Justification"
        },
        {
            "text": "A randomized, double-blind, placebo-controlled study to test the efficacy of convalescent plasma, administered up to 72 hours after the onset of symptoms, to prevent progression to severe respiratory disease. The study will be conducted in subjects aged 65presented with mild symptoms of less than 48 hours at the time of screening (as defined in section 5.1) and early diagnosis of COVID-19. Subjects will be followed for a minimum observation period of 15 days in which participants will remain under medical supervision daily to determine the primary endpoint. Monitoring will extend thereafter, up to 25 days if subjects remain symptomatic and hospitalized, to analyze secondary endpoints.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "STUDY DESIGN"
        },
        {
            "text": "The study is projected to incorporate an estimated maximum of 210 patients (see 9.0 Sample size). Participants will be randomized in a 1:1 ratio. Table 1 ). For each subject, participation in the study will last a minimum of 15 days or until the resolution of symptoms from the administration of the test article with a maximum of 25 days. Participating subjects will be monitored during and after administration of the test article to assess expected and unexpected safety events after plasma administration. A Data and Safety Monitoring Board will oversee the enrollment, efficacy, and safety of the participants throughout the study.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 146,
                    "end": 153,
                    "text": "Table 1",
                    "ref_id": "TABREF18"
                }
            ],
            "section": "STUDY DESIGN"
        },
        {
            "text": "The study will be conducted at the MOBILE-COVID TEAM. Given the context of the COVID-19 situation in the AMBA with the reduction in the availability of beds and the overload of hospital staff added to the exponential increase in severe cases, mildly symptomatic patients without oxygen requirements and from nursing homes find it extremely difficult (almost impossible) to be admitted to the hospitals. Therefore, to facilitate the incorporation of the main potential beneficiaries of this intervention to the study (that is, the most vulnerable elderly) and given the enormous existing public health need to provide therapeutic alternatives against this scourge, a COVID-Mobile unit will be added to monitor volunteers in COVID-PAMI centers where the administration of the investigational product (now clearly demonstrated as safe in publications in thousands of patients) are performed to the same standards and the same equipment as in all other research sites. The COVID-Mobile team will record the evolution of these participants who are under the care of doctors and health personnel from PAMI on site. Any transfer of these patients to centers of greater complexity due to the natural evolution of their disease will be the decision of the treating physicians of the PAMI, and the mobile research team will limit itself to continuing to collect data on their clinical progress in the same way as it does today when a patient is transferred or receives an early discharge from another institution.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "STUDY DESIGN"
        },
        {
            "text": "A subject must meet the following criteria to be included in the study:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria:"
        },
        {
            "text": "8. Previous diagnosis of CHRONIC LYMPHOPROLIFERATIVE SYNDROMES. (WHO classification: peripheral B lymphocyte lymphomas, T lymphocyte and NK cell lymphomas, Hodgkin lymphoma). 9. KNOWN HYPERSENSITIVITY to the administration of immunoglobulins, plasma, monoclonal antibodies and / or vaccines. 10. Active cancer, defined as receiving or having received or receiving chemotherapy, radiotherapy, or new designer or monoclonal drug treatments in the last six months. 11. Known HIV, HBV, or HCV infection. 12. Chronic administration (defined as more than 14 calendar days) of immunosuppressants or other drugs that modify the immune system at the time of enrollment or within the 6 months prior to administration of study medication. An immunosuppressive dose of glucocorticoids will be defined as a systemic dose 13. Solid organ transplant. 14. Known chronic liver disease diagnosed with stage II-III-IV cirrhosis. 15. Chronic lung disease with oxygen requirement. 16 . Any other physical, psychiatric or social condition that may, at the discretion of the investigator, increase the risks of participation in the study for the participant or that may lead to the collection of incomplete or inaccurate safety data. 17. Patients who are receiving any type of anticoagulant therapy orally: family of dicoumarins (Warfarin such as Acenocoumarol) or direct acting anticoagulants (DOAC) (Rivaroxaban, Dabigatran, Apixaban) as well as those who are receiving heparin in any of its types for anticoagulant therapy purposes. (Table 2) 5.2.a. Participating population and identification process of potential subjects.",
            "cite_spans": [
                {
                    "start": 960,
                    "end": 962,
                    "text": "16",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 1513,
                    "end": 1522,
                    "text": "(Table 2)",
                    "ref_id": "TABREF3"
                }
            ],
            "section": "Inclusion Criteria:"
        },
        {
            "text": "Subjects 65-74 years for less than 48 hours the following symptoms: ( a ) temperature 37,5\u00b0C or fever equivalence (defined by feeling cold or chills or unexplained sweating ) , combined with ( b ) dry cough and / or dyspnea and / or anosmia / dysgeusia and / or odynophagia and / or fatigue and / or anorexia and / or myalgias and / or rhinorrhea .",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study procedures"
        },
        {
            "text": "Those patients who meet the inclusion criteria and do not meet any of the aforementioned exclusion criteria will be invited to participate in the research phase of the study in which, if they accept (expressing their agreement by signing the informed consent -research ANNEX), a sample of respiratory secretions is obtained by swabbing the nasopharynx and oropharynx (according to the procedure and regulations of the Argentinean Ministry of Health) to assay for RNA of SARS-COV2 by reverse transcriptase-polymerase chain reaction (RT-PCR).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study procedures"
        },
        {
            "text": "The sample will be processed and analyzed by the laboratory designated for participating institutions daily, using the same RT-PCR test to assess the presence of RNA of SARS-COV2. This determination will be made as soon as possible (within a maximum of 24 hours) and under all the biosecurity standards indicated by the health authorities. The samples will be kept for later testing by RT-PCR for co-infections with influenza A and B, respiratory syncytial virus and other winter viral pathogens at the INFANT Foundation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study procedures"
        },
        {
            "text": "Patients who already have a positive result ( + ) considered valid by MOH standards will be invited to participate in the research phase of the study and will not be swabbed again .",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study procedures"
        },
        {
            "text": "If SARS-Co V 2 RNA is detected in the respiratory sample, the candidate will be informed about the details of the study and eligibility will be verified again. The candidates may decide not to participate in the investigation by their free will and without any consequence whatsoever. In the event that the subject is interested in participating in the study, and after their consent is attested with the signing of the informed consent for participation (ANNEX), a unique identification number will be assigned. Once its alphanumeric code has been assigned, vital signs will be obtained and a complete physical examination will be performed to obtain the following demographic and clinical information [1-3, 25, 47-51]:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2 .b. Enrollment for participation in the study"
        },
        {
            "text": "-Sex -Age -Usual medications and those of the last 15 days.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2 .b. Enrollment for participation in the study"
        },
        {
            "text": "-History of smoking -Comorbidities of primary interest: arterial hypertension, diabetes, coronary heart disease, heart failure, history of stroke and AMI, COPD, chronic kidney disease, and obesity. -Secondary comorbidities: asthma, history of cancer, liver diseases, and neurological diseases.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2 .b. Enrollment for participation in the study"
        },
        {
            "text": "All participants with confirmed eligibility will be randomly assigned to a treatment group. The randomization of participating subjects will be conducted by the person in charge of randomizing the study using an electronic system. Once the patient is randomized, the person in charge of the allocation will communicate with a member of the Transfusion Medicine Central Team in the study who will remove the opaque bag treatment indicated in the freezer of the Central Laboratory. The Transfusion Medicine team will proceed to take the cold bag to the hospital. There, he/she will complete the preparation of the masked product and administer the indicated treatment to the participating patient, using a venous access previously obtained by a member of the hospital team for the infusion. Only the person responsible for randomization and the physician in the Transfusion Medicine Central Team administering treatment will know the product administered to each patient (unblind). Neither the patient nor the researchers will have knowledge of the administered treatment, conducting a double-blind study. The unblind team will keep a record of the product assignments and their administrations that will be kept confidential. In the eventual need to open the blind, such records may be used.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "5.2.c. Random assignment"
        },
        {
            "text": "The preparation and administration of the convalescent plasma or placebo (physiological solution) will be performed according to the ADMINISTRATIVE AND TECHNICAL REGULATIONS RM 797/13 -139/14 -1507/15 Directorate of Blood and Hemoderivatives Ministry of Health of the Nation. ( http://www.msal.gob.ar/disahe/images/stories/pdf/normas-hemoterapia.pdf ).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2 .d. Preparation and administration of the test article"
        },
        {
            "text": "Once masked, the team of Transfusion Medicine will administered the product intravenously for 1.5 hours and up to 2 hours. After administration, local reactions at the injection site and systemic reactions will be monitored for 12 hours. This is a minimal risk study, since the administration of plasma and saline (placebo in this study) are a daily habit in medical practice. In the event of a medical emergency, when it is known that the treatment assignment may influence the medical care of the patient, the investigator or designee may request that the subject be unblinded for the emergency. However, prior to breaking the blind the investigator must make all reasonable efforts to discuss the decision to break the blind. The investigator is expected to provide a reason for the need to break the blind, based on a significant change in the participant's immediate or short-term medical care that will result from knowledge of the treatment assignment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2 .d. Preparation and administration of the test article"
        },
        {
            "text": "At 24 hours of completion of infusion of the treatment, a sample of 5 ml of venous blood will be obtained from all participants for titration of serum IgG anti-S SARS-COV2 and held at the Foundation INFANT. The assay will be performed by the ELISA method (COVIDAR IgG, Leloir / CONICET and Genetech IgG and sNT). Serum will be preserved to -20 C and transferred by a shuttle authorized for sample handling system transport biological the Foundation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2 .e. Taking a blood sample for titration of IgG anti-S SARS CoV2 in serum."
        },
        {
            "text": "Window for sample collection: +/-4 hours. The sample may be taken within a minimum period of 20 hours and a maximum of 28 hours after the administration of the Research Product is complete.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2 .e. Taking a blood sample for titration of IgG anti-S SARS CoV2 in serum."
        },
        {
            "text": "We will perform one control daily from Day 0 and at least 15 days from the infusion and up to 25 days for those subjects who remain hospitalized with symptoms after day 15.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2. f. Daily clinical monitoring"
        },
        {
            "text": "Patients who are discharged prior to the day 15 will be monitored at home by a team of physicians trained for this purpose working in collaboration with the research centers. The following clinical information will be collected daily (using a questionnaire designed for this purpose) by study personnel and without interfering with the patient's medical care or altering the standards recommended by the health care authorities for the management of patients with COVID-19 : (a) respiratory rate (looking at the chest excursion for 30 seconds) , (b) oxygen saturation, (c) temperature, (d) central heart rate , (e) cough and duration, (f) sore throat and duration , (g) feeling of fever / chills, (h) need for supplemental oxygen provision and duration, (i) need for intensive care and duration, (j) need for non-invasive or invasive respiratory support and duration, (k) evidence of SDMO : according to criteria for acute kidney injury , criteria for elevated liver enzymes and criteria for acute cardiomyopathy (detailed in section 2.2) , (l) survival. (1) This procedure will not be required if a result is available by a valid method at the time of patient screening.",
            "cite_spans": [
                {
                    "start": 569,
                    "end": 572,
                    "text": "(c)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "2. f. Daily clinical monitoring"
        },
        {
            "text": "We consider that the patient completes its participation when reaching day 15 (if the patient is already discharged), at the time of discharge between days 15 and 25, or at the expiration of day 25 if he/she continues hospitalized.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2. f. Daily clinical monitoring"
        },
        {
            "text": "A Data Safety Monitoring Board (DSMB) will monitor the safety of the subjects throughout the study. The DSMB includes at least experienced members in managing internal medicine, infectious diseases, and a biostatistician with specific experience in the design, analysis and safety of clinical trials. The DSMB will operate under an approved plan and will have the responsibility to monitor the outcomes/end points, adverse events (AE) and serious adverse events (SAE) , and recommend termination of the study if it appears at any point during the study that participants (or a subset of participants) are at undue risk as a result of their participation. The DSMB will meet (by teleconference) weekly to review the accumulated data on safety and efficacy and will conduct an interim analysis of the data. The DSMB will issue written recommendations based on its meetings regarding the continuity of the study. The minutes of each meeting will be recorded in documented minutes based on a preestablished work schedule. Any participant-specific protected health information reviewed by the DSMB will be kept completely confidential. Sessions will be closed without access to third parties.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data Safety Monitoring Board"
        },
        {
            "text": "The researcher at each institution and at a general level will supervise the safety of the study patient at his/her site(s) according to the requirements of this protocol and in accordance with current Good Clinical Practices (GCP). The investigator will monitor safety data at all study sites. Security monitoring will be carried out on an ongoing basis (for example, individual review of EA S, EAs and endpoints) and on a periodic cumulative basis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Security Monitoring"
        },
        {
            "text": "An AE is any unfavorable medical event in a patient who was administered a study drug that may or may not have a causal relationship to the study drug. Therefore, an AE is any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease that is temporarily associated with the use of a study drug, regardless of whether it is considered related to the study drug.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adverse event (AE)"
        },
        {
            "text": "An AE also includes any worsening (ie, any clinically significant change in frequency and / or intensity) of a pre-existing condition that is temporarily associated with the use of the investigational product. reported as an AE or SAE, as described in the appropriate protocol section.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adverse event (AE)"
        },
        {
            "text": "A SAE, by definition, is any unfavorable medical event that at any dose:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious adverse event (SAE)"
        },
        {
            "text": "Results in death: Includes all deaths, even those that appear to be unrelated to the study drug (for example, a car accident in which a patient is a passenger).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious adverse event (SAE)"
        },
        {
            "text": "It is life threatening: In the opinion of the investigator, the patient is at immediate risk of death at the time of the event. This does not include an AE which, if it had occurred in a more severe form, could have caused death.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious adverse event (SAE)"
        },
        {
            "text": "Requires hospitalization or extension of existing hospitalization. Hospitalization is defined as admission to a hospital or emergency room for more than 24 hours. Prolongation of existing hospitalization is defined as a hospital stay that is longer than originally planned for the event, or prolonged due to the development of a new AE as determined by the investigator or treating physician.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious adverse event (SAE)"
        },
        {
            "text": "Results in persistent or significant disability (substantial disruption of one's ability to carry out normal life functions).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious adverse event (SAE)"
        },
        {
            "text": "It is a major medical event -Major medical events may not immediately endanger life or result in death or hospitalization, but may endanger the patient or may require intervention to prevent one of the other serious outcomes listed above (for example, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias that do not result in hospitalization).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious adverse event (SAE)"
        },
        {
            "text": "In the case specific of this study we will consider AE or SAE , according to the detailed description in section 11.2, those that are initiated within 12 hours after administration of the IP and clinical exacerbations and deaths associated with these events. We will not consider as AE and SAEs those events occurring after 12 hours of initiation of treatment, that are consistent with the clinical course in patients infected with SARS COV2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Serious adverse event (SAE)"
        },
        {
            "text": "The reporting period for AE/SAE begins when the participant was initially included in the study (date of signature of informed consent for participation) and receives the infusion and continues for events that occur in the next 12 hours (see section 11.2 ) . During the follow up period, after the initial 12 hours of IP administration subjects will be monitored for the clinical outcome associated with primary and secondary endpoints.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Adverse Event Collection Period"
        },
        {
            "text": "Subjects may leave the study at any time if they wish, but we will make every effort to monitor them during the stipulated period to guarantee their safety .",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Leaving the Study Prematurely"
        },
        {
            "text": "Those patients who decide to drop out of the study prior to drug administration will be replaced, if necessary, to ensure an adequate number of evaluable patients.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Patient Replacement"
        },
        {
            "text": "There is significant uncertainty in the expected effect size of the intervention, and considering that the trial is expected to be completed in a relatively short period of time, the study is designed to have an interim analysis when the results of 50% of the subjects have been acquired.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Justification of the sample size and statistical analysis"
        },
        {
            "text": "Given the relative complexity of implementing this intervention, the minimally clinically important difference is established in a relative reduction of 40%, for an expected result rate of 50% in the control group that is reduced to 30% in the intervention group. A total sample size of 210 subjects (105 per test arm) will have 80% power, at a significance level (alpha) of 0.05 using a two-sided z-test with continuity correction. These results assume that 2 sequential tests are performed using the O'Brien-Fleming expenditure function to determine the limits of the test, as described in the Under the primary analysis strategy, we will use the Kaplan-Meier product cutoff distribution to compare treatment groups over time required to reach the primary outcome. An estimate of the relative risk and the 95% confidence interval will also be reported.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Justification of the sample size and statistical analysis"
        },
        {
            "text": "Based on a recommendation of the DSMB, we will also conduct an analysis stratified by age (65-74 years and years) and adjust the statistical analysis by those significant risk factors whose distribution between groups can affect the outcome. In order to donate plasma, the patient must comply with the conditions determined to date ( https://www.boletinoficial.gob.ar/detalleAviso/primera/227976/20200418 ) or follow updates from the Ministry of Health.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Justification of the sample size and statistical analysis"
        },
        {
            "text": "After donating plasma by apheresis or hemodonation, in addition to the samples obtained for routine blood bank controls, a dry tube of 5 mL of whole blood will be obtained, labeled with the identification given to the donor, identification of the Blood Bank and label that identifies the purpose of the \"PCC19\" study to perform the antibody titer. These will be asaayed using the SARS CoV2 anti-protein S ELISA test, which in light of the existing data on protection against the virus allows an indirect extrapolation of the serum's neutralization capacity, optimized by the Leloir Institute in charge of Dr. Gamarnik, and currently used by health teams in Argentina to study immunity prevalence. Likewise, if possible, data will be correlated with the neutralizing antibody titer against a pseudovirus encoding protein S optimized by the same laboratory.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Anti-SARS Cov2 antibody titration"
        },
        {
            "text": "Tubes will be stored in a designated location within the Bank and shipped in an approved biological sample shipment to the INFANT Foundation (over 18 years of experience in testing) for assaying ELISAs and neutralizing antibodies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Anti-SARS Cov2 antibody titration"
        },
        {
            "text": "The titers obtained by S ELISA will then be classified and those that are above 1: 1,000 selected to provide convalescent plasma for this study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Anti-SARS Cov2 antibody titration"
        },
        {
            "text": "The additional high titer plasmas will also be stored to be sent to the C\u00f3rdoba Blood Products Center (UNC), which will produce gammaglobulin enriched with anti-SARS-CoV2 antibodies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Anti-SARS Cov2 antibody titration"
        },
        {
            "text": "Plasmapheresis (Institute of Hemotherapy of the Province in La Plata, Central Military Hospital, Hemocentro Buenos Aires Foundation, and Sarmiento Hematology Foundation) Plasma donation will be conducted through an apheresis procedure with equipment and disposable supplies approved for this purpose, during which it is recommended to extract a volume no greater than 15% of the donor's blood volume. The anticoagulant to be used will be ACD-A or similar. In cases where volume replacement is not performed, plasma extraction should not exceed 600 ml per procedure. The 48 hours interval must be respected between each procedure, not to exceed 2 donations in a week or 24 donations in a 12-month period. The PCC19 units can be separated into 250ml aliquots, respecting the closed circuit and following the indications of the current standard operating procedure.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Anti-SARS Cov2 antibody titration"
        },
        {
            "text": "1-Plasma will be obatined with a Cobe Spectra equipment. 1.5 to 2 L of plasma will be extracted according to the donor's weight and tolerance to the procedure. In case of venous inaccessibility or opposition from the donor, between 400 and 500 ml of whole blood will be drawn (classic hemodonation) 2-The volume replacement will use NS and albumin solution. 3-During the procedure the plasma will be transferred to transfer bags of similar volume each (approximately 500ml). 4-The bags will be labeled as detailed below. 5-They will be frozen in the -56\u00b0C Righi vertical ultrafreezer (labeled Freezer # I, identified with COVID-19 convalescent plasma label in the Blood Bank) separated on shelves by bag type (1, 2 or 3). 6-The convalescent plasma will remain stored until its use or expiration (1 year), with appropriate safety criteria. 7-Disposal will be conducted under stipulated security regulations. 8-Stored aliquots of serum / plasma frozen for future determinations at -80 \u00ba C in Eppendorf tubes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Hemodonation (CEMIC)"
        },
        {
            "text": "All units of PC COVID-19 must comply with the labeling required for fresh frozen plasma from each Blood Bank and must also have a clear identification, which must include:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Labelled"
        },
        {
            "text": "\u00b7 \"Product Type: PC COVID-19\" \u00b7 \"Result of antibody titer for SARS-CoV-2\" (if available) \u00b7 \"CAUTION: product for research use only\" . \"PROTOCOL: INFANT Foundation -Serum enriched with anti SARS-CoV2 antibodies\"",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Labelled"
        },
        {
            "text": "Cold Chain of PCCOVID-19",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Labelled"
        },
        {
            "text": "1.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Labelled"
        },
        {
            "text": "The units are stored properly separated from the remaining plasma units and labelled for transfusional use in a place clearly identified for this purpose.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Labelled"
        },
        {
            "text": "The PCC19 units will be stored at temperatures below -25 \u00ba C, which allows a storage of 36 months and between -18 \u00ba C and -25 \u00ba C for 3 months of storage.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2."
        },
        {
            "text": "The units will be transported in a way to maintain the cold chain reliably.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "3."
        },
        {
            "text": "Plasma units should be stored between 2 \u00baC and 6\u00baC until 24 hours after thawing. After then, they should be discarded.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "4."
        },
        {
            "text": "The Blood Bank and the Transfusion Service of the requesting Institution will implement a registry system that guarantees traceability between donors and recipients. In this special situation, they must also have a specific registry as this is a transfusion therapy administered in an experimental context.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Traceability"
        },
        {
            "text": "After assessing vital signs and verifying eligibility, the unblinded team from the Medical Transfusion Center will be notified of the result of the randomization process and drive to the assigned hospital with the masked treatment product cold. On arrival, they will proceed again to check the code assigned for treatment with a member of the laboratory of Transfusion Medicine of the hospital (see 5.2.c).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administration of the intervention"
        },
        {
            "text": "Placebo will be a 250 ml of normal saline (0.9%) sterile, masked and administered in the same way and speed as plasma. To avoid bias and maintain the study blinded, plasma and saline 0.9% will be masked using an opaque bag and tape that will not allow to differentiate both products. Members of the Medical Transfusion Central Team will conduct the intervention with a member of the local team. Thus, both members of the Transfusion Medicine Central Team and the respective member of Transfusion Medicine at the hospitals will not be blind, while the rest of the team with delegated functions in the studies in each Center and the patients will be blind to the intervention.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administration of the intervention"
        },
        {
            "text": "To prepare the plasma, 250 ml bags will be thawed at 37 \u00b0 C, according to the operating procedures of the Department of Transfusion Medicine at the Hospital. Plasma will be infused slowly (at least 1.5 hours and up to 2 hours) according to the hemodynamics of the patient and monitored for 12 hours and adverse effects early and late attributable to transfusion recorded.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administration of the intervention"
        },
        {
            "text": "Night window for the passage of the research product: between 8:00 p.m. and 8:00 a.m., a window of +8 hours will be tolerated for the passage of the research product. A maximum of 80 hours (72 + 8) from onset of symptoms will be allowed in these cases before starting the infusion. This exception will only be allowed in this night time.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Administration of the intervention"
        },
        {
            "text": "Transfusion-associated circulatory overload (TACO) Transfusion-associated circulatory overload (TACO) is the most common pulmonary complication and is an independent risk factor for hospital morbidity and mortality, with a higher incidence in critically ill patients [58] . The estimated frequency of TACO varies from 1% to 5% depending on the hemovigilance system [59] , up to 8% in advanced post-surgical patients, and 11% in critically ill patients [60 61 62] . Risk factors include -transfusion fluid balance [63] [64] . Most cases of TACO are prevented by slowing the transfusion rate and establishing the usual measures for fluid overload in susceptible populations. Overload constitutes a requested AE, but if it does not improve within 120 minutes after the infusion or requires -in the opinion of the responsible professionalstransfer of the patient to intensive care due to poor clinical progression, should be reported immediately as a SAE.",
            "cite_spans": [
                {
                    "start": 267,
                    "end": 271,
                    "text": "[58]",
                    "ref_id": "BIBREF175"
                },
                {
                    "start": 365,
                    "end": 369,
                    "text": "[59]",
                    "ref_id": "BIBREF176"
                },
                {
                    "start": 456,
                    "end": 462,
                    "text": "61 62]",
                    "ref_id": null
                },
                {
                    "start": 513,
                    "end": 517,
                    "text": "[63]",
                    "ref_id": "BIBREF180"
                },
                {
                    "start": 518,
                    "end": 522,
                    "text": "[64]",
                    "ref_id": "BIBREF181"
                }
            ],
            "ref_spans": [],
            "section": "Monitoring of adverse events associated with plasma transfusion"
        },
        {
            "text": "Diagnostic criteria for TACO [19] During or up to 12 hours after the transfusion, TACO is characterized by the presence of a total of 3 or more of these criteria: A. Acute or worsening respiratory compromise B. Evidence of acute or worsening pulmonary edema based on clinical and / or chest radiographic images and / or other noninvasive assessment of cardiac function (echocardiogram) C. Evidence of cardiovascular changes not explained by the patient's underlying medical condition, including: tachycardia, hypertension, widened pulse pressure, jugular venous distention, enlarged cardiac silhouette, and/or peripheral edema. D. Evidence of fluid overload, including any of the following: a positive fluid balance; response to diuretic therapy, or dialysis combined with clinical improvement; and variation of the patient's weight. E. Increased level of B-type natriuretic peptide (eg, BNP or NT-pro BNP) above the agespecific reference range and greater than 1.5 times the pre-transfusion value.",
            "cite_spans": [
                {
                    "start": 29,
                    "end": 33,
                    "text": "[19]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Monitoring of adverse events associated with plasma transfusion"
        },
        {
            "text": "Transfusion Associated Acute Pulmonary Injury (TRALI) This is an acute respiratory distress syndrome, it will be considered a SAE and it occurs during or within six hours after the administration of the transfusion. Prospective studies of TRALI reported very low incidence rates (0.0008% to 0.001% of transfused patients) [19] after the implementation of strategies to prevent the transfusion of blood components obtained from multiparous female donors. In our study, multiparous women will not be invited to donate plasma. Treatment of a patient with TRALI involves immediate interruption of the transfusion.",
            "cite_spans": [
                {
                    "start": 322,
                    "end": 326,
                    "text": "[19]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Monitoring of adverse events associated with plasma transfusion"
        },
        {
            "text": "TRALI diagnostic criteria: [28] TRALI Type I: patients who do not have risk factors for ARDS and meet the following criteria: A. i. Acute onset ii. Hypoxemia (Pa O 2 / Fi O 2 2 <90% in room air). iii. Pulmonary edema with clear evidence of bilateral images ( CXR, CT or ultrasound) iv. There is no evidence of left ventricular hypertrophy or, if present, it is not the main contributor to hypoxemia. B. Initiation during or within 6 hours of transfusion. C. Temporarily unrelated to an alternative risk factor for ARDS. TRALI Type II: patients who have risk factors for ARDS (but have not been diagnosed with ARDS) or who have existing mild ARDS (Pa / Fi 200-300), but whose respiratory status is deteriorating and is considered to be due to a transfusion based on: a. The results described in categories a and b of TRALI Type I, and b. Stable respiratory status within 12 hours prior to transfusion Allergic -Anaphylactic Reactions Allergic reactions generally occur during or within 4 hours of transfusion and are most frequently associated with platelet transfusions (302 per 100,000 platelet units) [29] . Symptoms are caused by mediators such as histamine, released in mast cell and basophil activation [30] . Frequently, the clinical presentation is mild (rash, pruritus, urticaria, and angioedema are localized) and they are a solicited AE. Mild allergic transfusion reactions generally resolve with the administration of the usual treatment for allergic reactions, being able to restart the infusion of the unit. The transfusion should be stopped if symptoms reappear. The incidence of anaphylactic reactions is 8 / 100,000 units of transfused platelets. The most severe reactions generally present with bronchospasm, respiratory distress, and hypotension and constitute a SAE and should be reported as such immediately [31] [32] [33] [34] [35] .",
            "cite_spans": [
                {
                    "start": 27,
                    "end": 31,
                    "text": "[28]",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 1103,
                    "end": 1107,
                    "text": "[29]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 1208,
                    "end": 1212,
                    "text": "[30]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 1828,
                    "end": 1832,
                    "text": "[31]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 1833,
                    "end": 1837,
                    "text": "[32]",
                    "ref_id": null
                },
                {
                    "start": 1838,
                    "end": 1842,
                    "text": "[33]",
                    "ref_id": null
                },
                {
                    "start": 1843,
                    "end": 1847,
                    "text": "[34]",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 1848,
                    "end": 1852,
                    "text": "[35]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Monitoring of adverse events associated with plasma transfusion"
        },
        {
            "text": "Acute hemolytic transfusion reactions Acute hemolytic transfusion reactions (ATRs) can occur when incompatible red blood cells are transfused or, less frequently, large amounts of plasma incompatible with the patient's ABO are transfused. The central pathophysiological mechanism is intravascular hemolysis and is considered a SAE. It presents with sudden fever and chills, retroperitoneal pain and dyspnea, hemoglobinuria and even disseminated intravascular coagulation, acute renal failure, and shock. Since fever and chills may be the only early signs, it is important to monitor the patient during the transfusion and stop the transfusion immediately if there is any change in vital signs or unexpected symptoms appear. Treatment is based on supportive measures to alleviate symptoms. Proper patient identification and adherence to all procedures related to handling pretransfusion specimens and administration of transfusions are essential to prevent ATRs [36] .",
            "cite_spans": [
                {
                    "start": 961,
                    "end": 965,
                    "text": "[36]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Monitoring of adverse events associated with plasma transfusion"
        },
        {
            "text": "The risk of transmission of infectious diseases through transfusions has been dramatically reduced, secondary to the great advances in unit testing, and pathogen inactivation for plasma units and their components [51] and the implementation of rigorous donor selection methods. In our environment, the samples are tested for HBV, HCV, HIV, HTLV and Trypanosoma cruzi [52] . In the United States, the risk of acquiring HBV and HIV by transfusion is 1:280,000 and 1:1,467,000, respectively [53 54 ]. Due to freezing of plasma samples, contamination by bacterial pathogens and CMV is extremely rare. There are only a dozen cases among the millions of transfusions reported in Germany and Canada of bacterial transmission. It is estimated that the potential source of this contamination would have been the water baths used to defrost the units. This is easily avoidable with proper cleaning and sterilization of defrosters [39] .",
            "cite_spans": [
                {
                    "start": 213,
                    "end": 217,
                    "text": "[51]",
                    "ref_id": null
                },
                {
                    "start": 367,
                    "end": 371,
                    "text": "[52]",
                    "ref_id": "BIBREF171"
                },
                {
                    "start": 488,
                    "end": 494,
                    "text": "[53 54",
                    "ref_id": null
                },
                {
                    "start": 920,
                    "end": 924,
                    "text": "[39]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Transfusion Communicable Infections [39]"
        },
        {
            "text": "This study will be conducted in accordance with the protocol and with the following considerations:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statement of Good Clinical Practice"
        },
        {
            "text": "the ethical principles that have their origin in the Declaration of Helsinki, the current Good Clinical Practice (GCP) guidelines from the International Council of Harmonization (ICH), current laws and regulations.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statement of Good Clinical Practice"
        },
        {
            "text": "The protocol, the Informed Consent forms (ICF) and other relevant documents have been reviewed and approved by INFANT Foundation, the participating authorities and sent to the Ethics Committee (EC) for evaluation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statement of Good Clinical Practice"
        },
        {
            "text": "A properly constituted EC, as outlined in the ICH guidelines for GCP, must review and approve:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethics Committee (EC):"
        },
        {
            "text": "The protocol, ICF and any other materials that are provided to the participants before any subject can enter the study Any amendment or modification to the study protocol or to the CRF prior to implementation, unless the change is necessary to eliminate an immediate danger to patients, in which case the EC should be informed as soon as possible",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethics Committee (EC):"
        },
        {
            "text": "In addition, they must be informed of any event that may affect the safety of patients or the continued conduct of the clinical study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethics Committee (EC):"
        },
        {
            "text": "INFANT should receive a copy of the approval letter from the EC before sending drug supplies to the investigator at each hospital. The approval letter should include the title of the study, the documents reviewed, and the date of the review.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethics Committee (EC):"
        },
        {
            "text": "The investigator must keep on file the records of the EC review and approval of all study documents",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethics Committee (EC):"
        },
        {
            "text": "The ICF used by the researcher will be approved by the corresponding EC.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent Process"
        },
        {
            "text": "It is the responsibility of the investigator or delegated professional to obtain the written informed consent from each subject prior to their participation in the study and after the objectives, procedures, and potential risks of the study have been fully explained in language that the subject can understand. The ICF must be signed and dated by the researcher or delegated personnel who performed the consenting process.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent Process"
        },
        {
            "text": "The investigator or delegated staff will explain the nature of the study to the participant and answer all questions about the study. He/she will inform them that their participation is voluntary. The participant must sign the informed consent form (ICF) before any specific study activity takes place.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent Process"
        },
        {
            "text": "Participants who can understand but cannot write and / or read will have the IC read to them in the presence of an impartial witness, who will sign and date the ICF to confirm that informed consent was obtained.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent Process"
        },
        {
            "text": "Two copies will be signed. The investigator should keep one copy as part of the patient's study record, and the other signed copy should be given to the participant.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent Process"
        },
        {
            "text": "Patients with cognitive vulnerability: They may be included after obtaining informed consent from their legal representative as appropriate: to. Patients who have a statement of disability: duty of who has been designated as curator whenever there is such a statement. b. Patients who can decide for themselves prior assistance of a \"support\" person according to provisions of the Law: usually the patient can designate who can help him/her decide. c. Patients without a judicial declaration of incapacity and who have not appointed a support or representative either: the patients' rights law will apply. The means to prove the representation can consist of any document that proves the appointment as curator (if applicable) or any advance directive of the patient where it establishes who represents him in health matters, or documents that prove the relationship according to Law 26529.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Informed Consent Process"
        },
        {
            "text": "The investigator will take all appropriate measures to ensure that the anonymity of each study subject is maintained in research records transmitted outside the health center. The original and essential documents of the study must be kept in strict confidence at each research center by the study team.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Confidentiality and Protection of Personal Data"
        },
        {
            "text": "The personal data of the participants will be stored in the study center in a passwordprotected print and/or electronic format or in a locked room, to guarantee the exclusive access of authorized study personnel.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Confidentiality and Protection of Personal Data"
        },
        {
            "text": "To protect the rights and freedoms of natural persons in relation to the processing of personal data, a unique and specific alphanumeric code will be assigned to the participants. The records or data sets of the participants that are transferred will contain the alphanumeric code; the names of the participants will not be transferred. All other identifiable data transferred between researchers will be identified by this unique, participant-specific code. The study center will maintain a confidential list of participants who participated in the study under strict security (password protected or in a locked room), linking the alphanumeric code of each participant with their real identity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Confidentiality and Protection of Personal Data"
        },
        {
            "text": "Records and documents, including signed FCIs, regarding the conduct of this study will be retained by the investigator for 15 years after study completion, unless local regulations or institutional policies require a longer retention period. The investigator from each participating institution should consult with INFANT before discarding or destroying any essential study documents after study completion or interruption. If approved, records must be destroyed in a way that ensures confidentiality.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Documentation"
        },
        {
            "text": "The study monitor will visit each site prior to enrolling the first patient and periodically during the study in accordance with the Approved Study Monitoring Plan.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring of study sites"
        },
        {
            "text": "The monitor receives weekly reports from each of the centers with the number of patients in a period of research and enrolled.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring of study sites"
        },
        {
            "text": "Monitoring visits and centralized monitoring activities will be carried out in accordance with all applicable regulatory requirements and standards in force in Argentina. It is understood that the monitor will contact each researcher and their responsible team regularly and will be allowed to verify the generation of the different study records.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring of study sites"
        },
        {
            "text": "It will be the monitor's responsibility to inspect the data capture systems at regular intervals throughout the study to verify compliance with the protocol and the integrity, precision and consistency of the data; and adherence to the ICH GCP and local regulations on conducting clinical research. The monitor should have access to laboratory reports, study medication, records associated with it, and other medical records necessary to verify the entries in the EDC.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring of study sites"
        },
        {
            "text": "An unblinded monitor will be assigned whose role will be limited to auditing the logistic data, management and study treatment registration according to the approved protocol and treatment instructions: reception and storage conditions randomization and administration return or destruction / final reconciliation",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Monitoring of study sites"
        },
        {
            "text": "Investigators are required to prepare and maintain adequate and accurate patient records (source documents).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Source document requirements"
        },
        {
            "text": "The researcher must keep all the source documents in the file of the data submitted to the study form (CRF). Some data generated from the study may be entered directly into the EDC system (direct data capture), after approval of the process by the Ethics Committees involved. Case report forms and source documents must be available at all times.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Source document requirements"
        },
        {
            "text": "Study data obtained in the course of the study will be recorded in case report forms (CRF) and sent to INFANT in scan format. Once received, they will be archived and processed by entering the EDC system by trained INFANT personnel. All required CRFs must be completed for each patient enrolled in the study. The investigator should retain a copy of each patient's CRF case book as part of the study record and should be available at all times for inspection by authorized representatives of the sponsor and regulatory authorities.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Case Report Form Requirements"
        },
        {
            "text": "This study may be subject to a quality assurance audit or inspection. If this occurs, the investigator is responsible for:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Audits and inspections"
        },
        {
            "text": "-Provide access to all facilities, study data and documents necessary for inspection or audit. -Communicate any information arising from the inspection of the regulatory authorities to INFANT immediately. -Take all appropriate measures requested by INFANT to resolve the problems found during the audit or inspection.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Audits and inspections"
        },
        {
            "text": "Documents subject to audit or inspection include, but are not limited to, all source documents, CRF, medical records, correspondence, FCI, CE files, supporting laboratory quality control and certification documentation, and relevant records for the study being conducted. they maintain pharmacy facilities. The storage conditions of study material are also subject to inspection. Additionally, sponsor representatives may observe the conduct of any aspect of the clinical trial or its support activities both within and outside of the investigator's institution.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Audits and inspections"
        },
        {
            "text": "In all cases, the confidentiality of the data must be respected. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Audits and inspections"
        },
        {
            "text": "To evaluate the efficacy of convalescent plasma, from 12 hours of administration, in reducing progression to severe respiratory disease in subjects between 65-74 years of age with at least one comorbidity or old, with mild symptomatology and with early COVID-19 diagnosis up to 15 days of treatment administration (16-18 days of disease considering the symptomatic period previous enrollment) in an interim analysis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "Secondary outcomes include determining if convalescent plasma administration up to 15 days, or from there up to a maximum of 25 days since treatment administration if the patient remains in hospital, achieve to:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "To reduce the need of respiratory support with maximum oxygen therapy (oxygen reservoir mask) and/or the use of non-invasive respiratory support (NIV support, including CPAP) and/or admission to the intensive care unit (ICU) and/or invasive mechanical ventilation assistance because of SARS-CoV2 in patients between 65-74 years of age with at least one comorbidity or in with COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "To reduce critical systemic illness defined as (a) presence of acute respiratory failure d by the need of support with vasoactive drugs to maintain the mean arterial pressure multiorganic shock syndrome: acute renal injury (defined by creatinine increase two or more times from baseline or creatinine increase of 0.3 mg/dl), increase of hepatic enzymes (transaminase) in three or more times the normal range, acute cardiomyopathy (define by the increase of troponin above normal range and/ or new electrocardiographic or echocardiographic abnormalities due to myocardial damage) due to SARS-Cov2 in patients between 65-74 years of age with at least one comorbidity or in with COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "To reduce the mortality due to SARS-Cov2 in patients between 65-74 years of age with at least one comorbidity or in all patients years old with COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "To describe the safety of convalescent plasma administration in patients between 65-74 years of age with at least one comorbidity or in all patients old with COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "To explore the concentration of anti-SARS-CoV2 in the plasma of the participants associated with the absence of severe respiratory disease obtained 24 hours after infusion.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "September 11 th -Version 1.0 4 EFFECTIVENESS ASSESSMENT CRITERIA Primary criteria of effectiveness evaluation Severe respiratory disease due to SARS-CoV2, confirmed by viral ARN detection with RT-PCR, and defined by the presence of any of the following two variables in a non-exclusive way: (a) per minute (b) O2 sat<93% at room air. The primary endpoint will be determined from 12 hours from the start of the infusion until 15 days since the administration of the treatment (12h 15 d).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "Secondary criteria of effectiveness evaluation (Up to 15 days or from there up to a maximum of 25 days since treatment administration if the patient remains in hospital).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "Need of respiratory support with maximum oxygen therapy (oxygen reservoir mask) and/or the use of non-invasive respiratory support (NIV support including CPAP) and/or admission to the intensive care unit (ICU) and/or invasive mechanical ventilation assistance due to SARS-CoV2. Critical systemic illness defined as: (a) presence of acute respiratory failure ( and/ or (b) shock and/or (c) multiorganic shock syndrome, acute renal injury, increase of hepatic enzymes and acute cardiomyopathy due of SARS-Cov2. Mortality due to SARS-Cov2. Combination of secondary criteria of effectiveness evaluation, #1 (Need of Mortality due to SARS-Cov2). Duration of oxygen support requirement in patients with COVID-19 due to O2 sat<93% at room air.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "The socio-demographic characteristics, vital signs and comorbidities of primary and secondary interest of the participants will be described. For both primary and secondary outcomes the proportion by treatment group and the relative risk with its 95% confidence interval will be reported.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "STATISTICAL ANALYSIS"
        },
        {
            "text": "The analysis will be made over two populations: 1) Intention-to-treat (ITT). All the randomized patients with follow-up until 15 days from transfusion beginning date (or since randomization if they had not received treatment) will be included. 2) Modified intention-to-treat (mITT). All the randomized patients with follow-up until 15 days from transfusion beginning date will be included, with the exception of patients with the following conditions: a. Has not received the treatment b. Has lost eligibility criteria between randomization and treatment administration, regardless if they had received the treatment. (I.e., those patients who, in advance or at the time of starting treatment, had already developed severe disease, primary outcome of the study).",
            "cite_spans": [
                {
                    "start": 332,
                    "end": 334,
                    "text": "15",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "STATISTICAL ANALYSIS"
        },
        {
            "text": "Note: The inclusion of this result in this interim analysis is subject to EC confirmation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "STATISTICAL ANALYSIS"
        },
        {
            "text": "Given the relative complexity of implementing this intervention, the minimally clinically important difference was set at a 40% relative reduction for an expected outcome rate of 50% in the control group reduced to 30% in the intervention group.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SAMPLE SIZE AND DETENTION RULES ACCORDING THE PROTOCOL."
        },
        {
            "text": "A total sample size of 210 subjects (105 per trial arm) was estimated to have 80% power at a significance level (alpha) of 0.05 using a two-sided z-test with continuity correction. The study protocol contemplates the execution of an interim analysis when a 50% of the projected sample sized is achieved. There is significant uncertainty in the expected effect size of the intervention, and considering that the trial is expected to be completed in a relatively short period of time, the study is designed to have an interim analysis when the results of 50% of the subjects have been acquired. These results assume that 2 sequential tests are performed using the O'Brien Fleming expense function to determine the test limits, as described in the ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SAMPLE SIZE AND DETENTION RULES ACCORDING THE PROTOCOL."
        },
        {
            "text": "Combination of secondary criteria of effectiveness evaluation-(4) or (9) or (13) Need of respiratory support with oxygen and/or the use of non-invasive respiratory support and/or admission to the ICU and/or critical systemic illness or mortality due to COVID-19 from 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SAMPLE SIZE AND DETENTION RULES ACCORDING THE PROTOCOL."
        },
        {
            "text": "Duration of oxygen support requirement in patients with COVID-19 due to O2 sat<93% at room air.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SAMPLE SIZE AND DETENTION RULES ACCORDING THE PROTOCOL."
        },
        {
            "text": "Oxygen support (Form 7, variable 14) Loss of eligibility criteria between randomization and treatment administration (n=XX) Shock -Multiorganic shock syndrome -Mortality due to SARS-CoV2 Support with maximum oxygen therapy and/ or non-invasive respiratory support and/or admission to UCI and/or invasive mechanical ventilation assistance requirement and/or severe disease and/or mortality Duration in days of the oxygen support requirement * Duration in days of the oxygen support requirement * Table 2 : Secondary outcomes definition. 9 Table 2 : Secondary outcomes definition (cont.) 11 Table 3 : Adverse events definition 12 RESULT TABLES 13 ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 495,
                    "end": 502,
                    "text": "Table 2",
                    "ref_id": "TABREF3"
                },
                {
                    "start": 538,
                    "end": 545,
                    "text": "Table 2",
                    "ref_id": "TABREF3"
                },
                {
                    "start": 589,
                    "end": 596,
                    "text": "Table 3",
                    "ref_id": "TABREF35"
                }
            ],
            "section": "Number of days that oxygen support was required"
        },
        {
            "text": "To evaluate the efficacy of convalescent plasma, from 12 hours of administration, in reducing progression to severe respiratory disease in subjects between 65-74 years of age with at least one comorbidity or old, with mild symptomatology and with early COVID-19 diagnosis up to 15 days of treatment administration (16-18 days of disease considering the symptomatic period previous enrollment).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "Secondary outcomes include determining if convalescent plasma administration up to 15 days, or from there up to a maximum of 25 days since treatment administration if the patient remains in hospital, achieve to:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "To reduce the need of respiratory support with maximum oxygen therapy (oxygen reservoir mask) and/or the use of non-invasive respiratory support (NIV support, including CPAP) and/or admission to the intensive care unit (ICU) and/or invasive mechanical ventilation assistance because of SARS-CoV2 in patients between 65-74 years of age with at least one comorbidity or in with COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "To reduce critical systemic illness defined as (a) presence of acute respiratory failure d by the need of support with vasoactive drugs to maintain the mean arterial pressure multiorganic shock syndrome: acute renal injury (defined by creatinine increase two or more times from baseline or creatinine increase of 0.3 mg/dl), increase of hepatic enzymes (transaminase) in three or more times the normal range, acute cardiomyopathy (define by the increase of troponin above normal range and/ or new electrocardiographic or echocardiographic abnormalities due to myocardial damage) due to SARS-Cov2 in patients between 65-74 years of age with at least one comorbidity or in with COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "To reduce the mortality due to SARS-Cov2 in patients between 65-74 years of age with at least one comorbidity or in all patients old with COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "To describe the safety of convalescent plasma administration in patients between 65-74 years of age with at least one comorbidity or in all patients old with COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "To explore the concentration of anti-SARS-CoV2 in the plasma of the participants associated with the absence of severe respiratory disease obtained 24 hours after infusion.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "OBJETIVES"
        },
        {
            "text": "Primary criteria of effectiveness evaluation Severe respiratory disease due to SARS-CoV2, confirmed by viral ARN detection with RT-PCR, and defined by the presence of any of the following two variables in a non-exclusive way: (a) per minute (b) O2 sat<93% at room air. The primary endpoint will be ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "EFFECTIVENESS ASSESSMENT CRITERIA"
        },
        {
            "text": "Combination of secondary criteria of effectiveness evaluation-(4) or (9) or (13) Need of respiratory support with oxygen and/or the use of non-invasive respiratory support and/or admission to the ICU and/or critical systemic illness or mortality due to COVID-19 from 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "EFFECTIVENESS ASSESSMENT CRITERIA"
        },
        {
            "text": "Duration of oxygen support requirement in patients with COVID-19 due to O2 sat<93% at room air.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "EFFECTIVENESS ASSESSMENT CRITERIA"
        },
        {
            "text": "Oxygen support (Form 7, variable 14) Presence of tetany (hyperventilation) during the infusion and between 12 hours after.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Number of days that oxygen support was required"
        },
        {
            "text": "-Yes (the event was registered) -No (The event was not registered) -Multiorganic shock syndrome -Mortality due to SARS-CoV2 Support with maximum oxygen therapy and/ or non-invasive respiratory support and/or admission to UCI and/or invasive mechanical ventilation assistance requirement and/or severe disease and/or mortality Duration in days of the oxygen support requirement * Duration in days of the oxygen support requirement * * Median and quartiles (quartile 1 quartile 3)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Number of days that oxygen support was required"
        },
        {
            "text": "Only those who oxygen required were considered (n=in Group A y n=in Group B) Only those who oxygen required and survived were considered (n=in Group A y n=in Group B) Acute respiratory failure -Shock -Multiorganic shock syndrome -Mortality due to SARS-CoV2 Support with maximum oxygen therapy and/ or non-invasive respiratory support and/or admission to UCI and/or invasive mechanical ventilation assistance requirement and/or severe disease and/or mortality Duration in days of the oxygen support requirement * Duration in days of the oxygen support requirement * * Median and quartiles (quartile 1 quartile 3)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Number of days that oxygen support was required"
        },
        {
            "text": "Only those who oxygen required were considered (n=in Group A y n=in Group B) Only those who oxygen required and survived were considered (n=in Group A y n=in Group B) Figure 5 : Kaplan-Meier survival curve. Time to support with maximum oxygen therapy and/ or non-invasive respiratory support and/or admission to UCI and/or invasive mechanical ventilation assistance requirement by treatment group-ITT analysis -Mortality due to SARS-CoV2 Support with maximum oxygen therapy and/ or non-invasive respiratory support and/or admission to UCI and/or invasive mechanical ventilation assistance requirement and/or severe disease and/or mortality Duration in days of the oxygen support requirement * Duration in days of the oxygen support requirement * Acute respiratory failure -Shock -Multiorganic shock syndrome -Mortality due to SARS-CoV2 Support with maximum oxygen therapy and/ or non-invasive respiratory support and/or admission to UCI and/or invasive mechanical ventilation assistance requirement and/or severe disease and/or mortality Duration in days of the oxygen support requirement * Duration in days of the oxygen support requirement * * Median and quartiles (quartile 1 quartile 3)",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 167,
                    "end": 175,
                    "text": "Figure 5",
                    "ref_id": null
                }
            ],
            "section": "Number of days that oxygen support was required"
        },
        {
            "text": "Only those who oxygen required were considered (n=in Group A y n=in Group B) Only those who oxygen required and survived were considered (n=in Group A y n=in Group B) Figure 12 : Kaplan-Meier survival curve. Time to support with maximum oxygen therapy and/ or non-invasive respiratory support and/or admission to UCI and/or invasive mechanical ventilation assistance requirement by treatment group ITTm analysis Final analysis plan, translated to English. As recommended by the DSMB the analysis plan was updated to include a stratified analysis by age (65-74 years and . The final analysis plan was also expanded to be in line with the analysis plan section of the protocol that included a time to event analysis of the primary outcome.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 167,
                    "end": 176,
                    "text": "Figure 12",
                    "ref_id": "FIGREF15"
                }
            ],
            "section": "Number of days that oxygen support was required"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Genotype and phenotype of COVID-19: Their roles in pathogenesis",
            "authors": [
                {
                    "first": "Leila",
                    "middle": [],
                    "last": "Mousavizadeha",
                    "suffix": ""
                },
                {
                    "first": "Sorayya",
                    "middle": [],
                    "last": "Ghasemi",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Microbiol Immunol Infect",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.jmii.2020.03.022"
                ]
            }
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Severe Acute Respi Responses in Coronavirus Disease",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Nisreen",
                    "suffix": ""
                },
                {
                    "first": "Marcel",
                    "middle": [
                        "A"
                    ],
                    "last": "Okba1",
                    "suffix": ""
                },
                {
                    "first": "Wentao",
                    "middle": [],
                    "last": "M\u00fcller1",
                    "suffix": ""
                },
                {
                    "first": "Chunyan",
                    "middle": [],
                    "last": "Li1",
                    "suffix": ""
                },
                {
                    "first": "Corine",
                    "middle": [
                        "H"
                    ],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Victor",
                    "middle": [
                        "M"
                    ],
                    "last": "Geurtsvankessel",
                    "suffix": ""
                },
                {
                    "first": "Mart",
                    "middle": [
                        "M"
                    ],
                    "last": "Corman",
                    "suffix": ""
                },
                {
                    "first": "Reina",
                    "middle": [
                        "S"
                    ],
                    "last": "Lamers",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Sikkema",
                    "suffix": ""
                },
                {
                    "first": "Felicity",
                    "middle": [
                        "D"
                    ],
                    "last": "Erwin De Bruin",
                    "suffix": ""
                },
                {
                    "first": "Yazdan",
                    "middle": [],
                    "last": "Chandler",
                    "suffix": ""
                },
                {
                    "first": "Quentin",
                    "middle": [
                        "Le"
                    ],
                    "last": "Yazdanpanah",
                    "suffix": ""
                },
                {
                    "first": "Diane",
                    "middle": [],
                    "last": "Hingrat",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Descamps",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Patients. Emerg Infect Dis",
            "volume": "26",
            "issn": "7",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.3201/eid2607.200841"
                ]
            }
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma",
            "authors": [
                {
                    "first": "Chenguang",
                    "middle": [],
                    "last": "Shen",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Phd1; Zhaoqin",
                    "suffix": ""
                },
                {
                    "first": "Phd1; Fang",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": ";",
                    "middle": [],
                    "last": "Phd1",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1001/jama.2020.4783"
                ]
            }
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Organ-protective Effect of Angiotensin-converting Enzyme 2 and its Effect on the Prognosis of COVID-19",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "G.-Q",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Journal of Medical Virology",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1002/jmv.25785"
                ]
            }
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Deployment of convalescent plasma for the prevention and treatment of COVID-19",
            "authors": [
                {
                    "first": "Evan",
                    "middle": [
                        "M"
                    ],
                    "last": "Bloch",
                    "suffix": ""
                },
                {
                    "first": "Jeffrey",
                    "middle": [
                        "A"
                    ],
                    "last": "Bailey",
                    "suffix": ""
                },
                {
                    "first": "Aaron",
                    "middle": [
                        "A R"
                    ],
                    "last": "Tobian",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Clin Invest",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1172/JCI138745"
                ]
            }
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses",
            "authors": [
                {
                    "first": "Didier",
                    "middle": [],
                    "last": "Raoult",
                    "suffix": ""
                },
                {
                    "first": "Alimuddin",
                    "middle": [],
                    "last": "Zumla",
                    "suffix": ""
                },
                {
                    "first": "Franco",
                    "middle": [],
                    "last": "Locatelli",
                    "suffix": ""
                },
                {
                    "first": "Giuseppe",
                    "middle": [],
                    "last": "Ippolito",
                    "suffix": ""
                },
                {
                    "first": "Guido",
                    "middle": [],
                    "last": "Kroemer",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Stress",
            "volume": "4",
            "issn": "4",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.15698/cst2020.04.216"
                ]
            }
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "COVID-19 with Different Severity: A Multi-center Study of Clinical Feature",
            "authors": [
                {
                    "first": "Yunfei",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "doi.org/10.1164/rccm.202002-0445OC"
                ]
            }
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Fan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Gu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Tu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "1054--1062",
            "other_ids": {
                "DOI": [
                    "10.1016/S0140-6736(20)30566-3"
                ]
            }
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Is forced oscillation technique the next respiratory function test of choice in childhood asthma",
            "authors": [
                {
                    "first": "Afaf",
                    "middle": [],
                    "last": "Alblooshi",
                    "suffix": ""
                },
                {
                    "first": "Alia",
                    "middle": [],
                    "last": "Alkalbani",
                    "suffix": ""
                },
                {
                    "first": "Ghaya",
                    "middle": [],
                    "last": "Albadi",
                    "suffix": ""
                },
                {
                    "first": "Hassib",
                    "middle": [],
                    "last": "Narchi",
                    "suffix": ""
                },
                {
                    "first": "Graham",
                    "middle": [],
                    "last": "Hall",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "World J Methodol",
            "volume": "7",
            "issn": "4",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.5662/wjm.v7.i4.129"
                ]
            }
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 COVID-NET, 14 States",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Garg",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Kim",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Whitaker",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "MMWR Morb Mortal Wkly Rep",
            "volume": "69",
            "issn": "",
            "pages": "458--464",
            "other_ids": {
                "DOI": [
                    "10.15585/mmwr.mm6915e3"
                ]
            }
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "COVID-19 with Different Severity: A Multi-center Study of Clinical Features",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Feng",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Am. J. Respir. Crit. Care Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1164/rccm.202002-0445OC"
                ]
            }
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Grasselli",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Zangrillo",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Zanella",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Italy. JAMA",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1001/jama.2020.5394"
                ]
            }
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2",
            "authors": [],
            "year": 2020,
            "venue": "Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)",
            "volume": "",
            "issn": "",
            "pages": "16--24",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "source/coronaviruse/who-china-joint-mission-on-COVID-19-final-report",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Division of Risk assessment and International cooperation",
            "authors": [],
            "year": 2020,
            "venue": "Republic of Korea",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "M"
                    ],
                    "last": "Leung",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1038/s41591-020-0822-7"
                ]
            }
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "COVID-19) in the EU/EEA and the UK eighth update",
            "authors": [],
            "year": null,
            "venue": "Coronavirus disease 2019",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Immediate and Near Future Prediction of COVID-19 Patients in the U.S. Population Aged 65+ With the Prior Medical Conditions of Hypertension, Cardiovascular and Lung Diseases: Methods, Models and Acute Care Estimates",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Dai",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Mo",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Ma",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Luo",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Xiong",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "The Journals of Gerontology: Series A",
            "volume": "089",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1093/gerona/glaa089"
                ]
            }
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus Infected Pneumonia",
            "authors": [
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2001316NEJMoa2001316"
                ]
            }
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "The reproductive number of COVID-19 is higher compared to SARS coronavirus",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "Gayle",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Wilder-Smith",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Rockl\u00f6v",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Travel Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1093/jtm/taaa021"
                ]
            }
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Duan",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.16.20036145"
                ]
            }
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Hypertension Prevalence and Control Among Adults: United States",
            "authors": [
                {
                    "first": "Cheryl",
                    "middle": [
                        "D"
                    ],
                    "last": "Fryar",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S P H"
                    ],
                    "last": "Yechiam Ostchega",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "N"
                    ],
                    "last": "Craig",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Hales",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "P H"
                    ],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Deanna",
                    "middle": [],
                    "last": "Kruszon-Moran",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "DEPARTMENT OF HEALTH AND HUMAN SERVICES. Center for Disease Control and Prevention",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "Department of Health and Human Services, Center for Disease Control and Prevention. National Diabetes Statistics Report, Estimates of Diabetes and Its Burden in the United States",
            "authors": [
                {
                    "first": "U",
                    "middle": [
                        "S"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "Prevalence of Obesity and Severe Obesity Among Adults: United States",
            "authors": [
                {
                    "first": "Craig",
                    "middle": [
                        "M"
                    ],
                    "last": "Hales",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Margaret",
                    "middle": [
                        "D"
                    ],
                    "last": "Carroll",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S P H"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Cheryl",
                    "middle": [
                        "D"
                    ],
                    "last": "Fryar",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S P H"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Cynthia",
                    "middle": [
                        "L"
                    ],
                    "last": "Ogden",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "DEPARTMENT OF HEALTH AND HUMAN SERVICES. Center for Disease Control and Prevention",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Chronic Obstructive Pulmonary Disease Among Adults Aged 18 and Over in the United States",
            "authors": [
                {
                    "first": "Lara",
                    "middle": [
                        "J"
                    ],
                    "last": "Akinbami",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Sc",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "COVID-19) Daily Data Summary, NYC Health",
            "authors": [],
            "year": 2019,
            "venue": "Coronavirus Disease",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Jinghe Huang medRxiv 2020.03.30",
            "authors": [
                {
                    "first": "Aojie",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Mei",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Qimin",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Jun",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Shuai",
                    "middle": [],
                    "last": "Xia",
                    "suffix": ""
                },
                {
                    "first": "Yun",
                    "middle": [],
                    "last": "Ling",
                    "suffix": ""
                },
                {
                    "first": "Yuling",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Jingna",
                    "middle": [],
                    "last": "Xun",
                    "suffix": ""
                },
                {
                    "first": "Shibo",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "Hongzhou",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "Yumei",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Wen",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications Fan Wu",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.30.20047365"
                ]
            }
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "SARS-CoV-2 infected rhesus macaques",
            "authors": [
                {
                    "first": "Linlin",
                    "middle": [],
                    "last": "Bao",
                    "suffix": ""
                },
                {
                    "first": "Wei",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                },
                {
                    "first": "Hong",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "Chong",
                    "middle": [],
                    "last": "Xiao",
                    "suffix": ""
                },
                {
                    "first": "Jiayi",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Jing",
                    "middle": [],
                    "last": "Xue",
                    "suffix": ""
                },
                {
                    "first": "Qi",
                    "middle": [],
                    "last": "Lv",
                    "suffix": ""
                },
                {
                    "first": "Jiangning",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Pin",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "Yanfeng",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "Feifei",
                    "middle": [],
                    "last": "Qi",
                    "suffix": ""
                },
                {
                    "first": "Yajin",
                    "middle": [],
                    "last": "Qu",
                    "suffix": ""
                },
                {
                    "first": "Fengdi",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Zhiguang",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                },
                {
                    "first": "Haisheng",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "Shuran",
                    "middle": [],
                    "last": "Gong",
                    "suffix": ""
                },
                {
                    "first": "Mingya",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Guanpeng",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Shunyi",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Zhiqi",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                },
                {
                    "first": "Wenjie",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Yunlin",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                },
                {
                    "first": "Linna",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Xing",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Qiang",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.13.990226"
                ]
            }
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "Tetanus Disease, Treatment, Management",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Rhinesmith",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Fu",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Pediatrics in Review",
            "volume": "39",
            "issn": "8",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1542/pir.2017-0238"
                ]
            }
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "Hepatitis A, B, and C",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Christenson",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Manaloor",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Pediatrics in Review",
            "volume": "37",
            "issn": "10",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1542/pir.2015-0075"
                ]
            }
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "The pandemic pipeline",
            "authors": [
                {
                    "first": "John",
                    "middle": [],
                    "last": "Hodgson",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Nature Biotechnology",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1038/d41587-020-00005-z"
                ]
            }
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "for the China Medical Treatment Expert Group for COVID-19. Clinical Characteristics of Coronavirus Disease 2019 in China",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Ni",
                    "suffix": ""
                },
                {
                    "first": "Yu",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Ou",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Shan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Lei",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "S C"
                    ],
                    "last": "Hui",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Zeng",
                    "suffix": ""
                },
                {
                    "first": "K.-Y",
                    "middle": [],
                    "last": "Yuen",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Jin-Lin",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Peng",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Ya-Hua",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Peng",
                    "suffix": ""
                },
                {
                    "first": "Jian-Ming",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Qiu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Luo",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Ye",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Zhong",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "The New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2002032"
                ]
            }
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Epidemiology of COVID-19 in a Long-Term Care Facility",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Temet",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "Mcmichael",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Dustin",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "Currie",
                    "suffix": ""
                },
                {
                    "first": "Shauna",
                    "middle": [],
                    "last": "Clark",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "N"
                    ],
                    "last": "Sargis Pogosjans",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "P H"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Meagan",
                    "middle": [],
                    "last": "Kay",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "V M"
                    ],
                    "last": "Noah",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Schwartz",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "James",
                    "middle": [],
                    "last": "Lewis",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Baer",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "Vance Kawakami",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "V M"
                    ],
                    "last": "Margaret",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Lukoff",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Jessica",
                    "middle": [],
                    "last": "Ferro",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "P H"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Claire",
                    "middle": [],
                    "last": "Brostrom-Smith",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S N"
                    ],
                    "last": "Thomas",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Rea",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Michael",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Sayre",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Francis",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Riedo",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Denny Russell",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "S"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Brian",
                    "middle": [],
                    "last": "Hiatt",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "S"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Patricia",
                    "middle": [],
                    "last": "Montgomery",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "P H"
                    ],
                    "last": "Agam",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Rao",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Eric",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Chow",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Farrell Tobolowsky",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "O"
                    ],
                    "last": "Michael",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Hughes",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "P H"
                    ],
                    "last": "Ana",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Bardossy",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Lisa",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Oakley",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Jesica",
                    "middle": [
                        "R"
                    ],
                    "last": "Jacobs",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "Nimalie",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Stone",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Sujan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Reddy",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "John",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Jernigan",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Margaret",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Honein",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "Thomas",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Clark",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Jeffrey",
                    "middle": [
                        "S"
                    ],
                    "last": "Duchin",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "The New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2005412"
                ]
            }
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "Spread of SARS-CoV-2 in the Icelandic Population",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "R"
                    ],
                    "last": "Gretarsdottir",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "R"
                    ],
                    "last": "Gudmundsson",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Gunnarsdottir",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Gylfason",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Holm Masson",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Jonsdottir",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Thorsteinsdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Stefansson",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2006100"
                ]
            }
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "Severe Acute Respi Responses in Coronavirus Disease",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Nisreen",
                    "suffix": ""
                },
                {
                    "first": "Marcel",
                    "middle": [
                        "A"
                    ],
                    "last": "Okba1",
                    "suffix": ""
                },
                {
                    "first": "Wentao",
                    "middle": [],
                    "last": "M\u00fcller1",
                    "suffix": ""
                },
                {
                    "first": "Chunyan",
                    "middle": [],
                    "last": "Li1",
                    "suffix": ""
                },
                {
                    "first": "Corine",
                    "middle": [
                        "H"
                    ],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Victor",
                    "middle": [
                        "M"
                    ],
                    "last": "Geurtsvankessel",
                    "suffix": ""
                },
                {
                    "first": "Mart",
                    "middle": [
                        "M"
                    ],
                    "last": "Corman",
                    "suffix": ""
                },
                {
                    "first": "Reina",
                    "middle": [
                        "S"
                    ],
                    "last": "Lamers",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Sikkema",
                    "suffix": ""
                },
                {
                    "first": "Felicity",
                    "middle": [
                        "D"
                    ],
                    "last": "Erwin De Bruin",
                    "suffix": ""
                },
                {
                    "first": "Yazdan",
                    "middle": [],
                    "last": "Chandler",
                    "suffix": ""
                },
                {
                    "first": "Quentin",
                    "middle": [
                        "Le"
                    ],
                    "last": "Yazdanpanah",
                    "suffix": ""
                },
                {
                    "first": "Diane",
                    "middle": [],
                    "last": "Hingrat",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Descamps",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Patients. Emerg Infect Dis",
            "volume": "26",
            "issn": "7",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.3201/eid2607.200841"
                ]
            }
        },
        "BIBREF43": {
            "ref_id": "b43",
            "title": "Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma",
            "authors": [
                {
                    "first": "Chenguang",
                    "middle": [],
                    "last": "Shen",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Phd1; Zhaoqin",
                    "suffix": ""
                },
                {
                    "first": "Phd1; Fang",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": ";",
                    "middle": [],
                    "last": "Phd1",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1001/jama.2020.4783"
                ]
            }
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "Organ-protective Effect of Angiotensin-converting Enzyme 2 and its Effect on the Prognosis of COVID-19",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "G.-Q",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Journal of Medical Virology",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1002/jmv.25785"
                ]
            }
        },
        "BIBREF45": {
            "ref_id": "b45",
            "title": "Deployment of convalescent plasma for the prevention and treatment of COVID-19",
            "authors": [
                {
                    "first": "Evan",
                    "middle": [
                        "M"
                    ],
                    "last": "Bloch",
                    "suffix": ""
                },
                {
                    "first": "Jeffrey",
                    "middle": [
                        "A"
                    ],
                    "last": "Bailey",
                    "suffix": ""
                },
                {
                    "first": "Aaron",
                    "middle": [
                        "A R"
                    ],
                    "last": "Tobian",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Clin Invest",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1172/JCI138745"
                ]
            }
        },
        "BIBREF46": {
            "ref_id": "b46",
            "title": "Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses",
            "authors": [
                {
                    "first": "Didier",
                    "middle": [],
                    "last": "Raoult",
                    "suffix": ""
                },
                {
                    "first": "Alimuddin",
                    "middle": [],
                    "last": "Zumla",
                    "suffix": ""
                },
                {
                    "first": "Franco",
                    "middle": [],
                    "last": "Locatelli",
                    "suffix": ""
                },
                {
                    "first": "Giuseppe",
                    "middle": [],
                    "last": "Ippolito",
                    "suffix": ""
                },
                {
                    "first": "Guido",
                    "middle": [],
                    "last": "Kroemer",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Stress",
            "volume": "4",
            "issn": "4",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.15698/cst2020.04.216"
                ]
            }
        },
        "BIBREF47": {
            "ref_id": "b47",
            "title": "Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Groothuis",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Simoes",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Levin",
                    "suffix": ""
                }
            ],
            "year": 1993,
            "venue": "N Engl J Med",
            "volume": "329",
            "issn": "21",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "152430.10.1056/NEJM199311183292102"
                ]
            }
        },
        "BIBREF51": {
            "ref_id": "b51",
            "title": "COVID-19 with Different Severity: A Multi-center Study of Clinical Feature",
            "authors": [
                {
                    "first": "Yunfei",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "doi.org/10.1164/rccm.202002-0445OC"
                ]
            }
        },
        "BIBREF52": {
            "ref_id": "b52",
            "title": "COVID-19) Daily Data Summary, NYC Health",
            "authors": [],
            "year": 2019,
            "venue": "Coronavirus Disease",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF53": {
            "ref_id": "b53",
            "title": "Jinghe Huang medRxiv 2020.03.30",
            "authors": [
                {
                    "first": "Aojie",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Mei",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Qimin",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Jun",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Shuai",
                    "middle": [],
                    "last": "Xia",
                    "suffix": ""
                },
                {
                    "first": "Yun",
                    "middle": [],
                    "last": "Ling",
                    "suffix": ""
                },
                {
                    "first": "Yuling",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Jingna",
                    "middle": [],
                    "last": "Xun",
                    "suffix": ""
                },
                {
                    "first": "Shibo",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "Hongzhou",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "Yumei",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Wen",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications Fan Wu",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.30.20047365"
                ]
            }
        },
        "BIBREF54": {
            "ref_id": "b54",
            "title": "SARS-CoV-2 infected rhesus macaques",
            "authors": [
                {
                    "first": "Linlin",
                    "middle": [],
                    "last": "Bao",
                    "suffix": ""
                },
                {
                    "first": "Wei",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                },
                {
                    "first": "Hong",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "Chong",
                    "middle": [],
                    "last": "Xiao",
                    "suffix": ""
                },
                {
                    "first": "Jiayi",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Jing",
                    "middle": [],
                    "last": "Xue",
                    "suffix": ""
                },
                {
                    "first": "Qi",
                    "middle": [],
                    "last": "Lv",
                    "suffix": ""
                },
                {
                    "first": "Jiangning",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Pin",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "Yanfeng",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "Feifei",
                    "middle": [],
                    "last": "Qi",
                    "suffix": ""
                },
                {
                    "first": "Yajin",
                    "middle": [],
                    "last": "Qu",
                    "suffix": ""
                },
                {
                    "first": "Fengdi",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Zhiguang",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                },
                {
                    "first": "Haisheng",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "Shuran",
                    "middle": [],
                    "last": "Gong",
                    "suffix": ""
                },
                {
                    "first": "Mingya",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Guanpeng",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Shunyi",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Zhiqi",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                },
                {
                    "first": "Wenjie",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Yunlin",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                },
                {
                    "first": "Linna",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Xing",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Qiang",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.13.990226"
                ]
            }
        },
        "BIBREF55": {
            "ref_id": "b55",
            "title": "Tetanus Disease, Treatment, Management",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Rhinesmith",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Fu",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Pediatrics in Review",
            "volume": "39",
            "issn": "8",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1542/pir.2017-0238"
                ]
            }
        },
        "BIBREF56": {
            "ref_id": "b56",
            "title": "Hepatitis A, B, and C",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Christenson",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Manaloor",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Pediatrics in Review",
            "volume": "37",
            "issn": "10",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1542/pir.2015-0075"
                ]
            }
        },
        "BIBREF57": {
            "ref_id": "b57",
            "title": "The pandemic pipeline",
            "authors": [
                {
                    "first": "John",
                    "middle": [],
                    "last": "Hodgson",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Nature Biotechnology",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1038/d41587-020-00005-z"
                ]
            }
        },
        "BIBREF58": {
            "ref_id": "b58",
            "title": "Polack (INFANT) T\u00edtulo: Evaluaci\u00f3n de la eficacia de la administraci\u00f3n de plasma de convaleciente de COVID-19 en la disminuci\u00f3n de la progresi\u00f3n a enfermedad severa en adultos mayores con s\u00edntomas leves por SARS-CoV2",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF59": {
            "ref_id": "b59",
            "title": "for the China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Ni",
                    "suffix": ""
                },
                {
                    "first": "Yu",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Ou",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Shan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Lei",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "S C"
                    ],
                    "last": "Hui",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Zeng",
                    "suffix": ""
                },
                {
                    "first": "K.-Y",
                    "middle": [],
                    "last": "Yuen",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Jin-Lin",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Peng",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Ya-Hua",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Peng",
                    "suffix": ""
                },
                {
                    "first": "Jian-Ming",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Qiu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Luo",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Ye",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Zhong",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "The New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2002032"
                ]
            }
        },
        "BIBREF60": {
            "ref_id": "b60",
            "title": "Epidemiology of Covid-19 in a Long-Term Care Facility",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Temet",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "Mcmichael",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Dustin",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "Currie",
                    "suffix": ""
                },
                {
                    "first": "Shauna",
                    "middle": [],
                    "last": "Clark",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "N"
                    ],
                    "last": "Sargis Pogosjans",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "P H"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Meagan",
                    "middle": [],
                    "last": "Kay",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "V M"
                    ],
                    "last": "Noah",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Schwartz",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "James",
                    "middle": [],
                    "last": "Lewis",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Baer",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "Vance Kawakami",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "V M"
                    ],
                    "last": "Margaret",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Lukoff",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Jessica",
                    "middle": [],
                    "last": "Ferro",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "P H"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Claire",
                    "middle": [],
                    "last": "Brostrom-Smith",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S N"
                    ],
                    "last": "Thomas",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Rea",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Michael",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Sayre",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Francis",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Riedo",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Denny Russell",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "S"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Brian",
                    "middle": [],
                    "last": "Hiatt",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "S"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Patricia",
                    "middle": [],
                    "last": "Montgomery",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "P H"
                    ],
                    "last": "Agam",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Rao",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Eric",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Chow",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Farrell Tobolowsky",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "O"
                    ],
                    "last": "Michael",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Hughes",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "P H"
                    ],
                    "last": "Ana",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Bardossy",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Lisa",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Oakley",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Jesica",
                    "middle": [
                        "R"
                    ],
                    "last": "Jacobs",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "Nimalie",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Stone",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Sujan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Reddy",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "John",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Jernigan",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Margaret",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Honein",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "Thomas",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Clark",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Jeffrey",
                    "middle": [
                        "S"
                    ],
                    "last": "Duchin",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "The New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2005412"
                ]
            }
        },
        "BIBREF62": {
            "ref_id": "b62",
            "title": "Spread of SARS-CoV-2 in the Icelandic Population",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "R"
                    ],
                    "last": "Gretarsdottir",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "R"
                    ],
                    "last": "Gudmundsson",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Gunnarsdottir",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Gylfason",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "O"
                    ],
                    "last": "Holm",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Jensson",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Jonasdottir",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "S"
                    ],
                    "last": "Jonsson",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Josefsdottir",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "N"
                    ],
                    "last": "Kristjansson",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Magnusdottir",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Le Roux",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Sigmundsdottir",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "E"
                    ],
                    "last": "Sveinbjornsson",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Sveinsdottir",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Sveinsdottir",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "Thorbjornsso"
                    ],
                    "last": "Thorarensen",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Thorsteinsdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Stefansson",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2006100"
                ]
            }
        },
        "BIBREF65": {
            "ref_id": "b65",
            "title": "Bin Cao. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",
            "authors": [
                {
                    "first": "Fei",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "*",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Ting",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "*",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Ronghui",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "*",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Guohui",
                    "middle": [],
                    "last": "Fan",
                    "suffix": ""
                },
                {
                    "first": "*",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Ying",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "*",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Zhibo",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "*",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Jie",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                },
                {
                    "first": "*",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Yeming",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Bin",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                },
                {
                    "first": "Xiaoying",
                    "middle": [],
                    "last": "Gu",
                    "suffix": ""
                },
                {
                    "first": "Lulu",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Yuan",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "Hui",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Xudong",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "Jiuyang",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "Shengjin",
                    "middle": [],
                    "last": "Tu",
                    "suffix": ""
                },
                {
                    "first": "Yi",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Hua",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "20",
            "pages": "30566--30569",
            "other_ids": {}
        },
        "BIBREF66": {
            "ref_id": "b66",
            "title": "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Qu",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Gong",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "20",
            "pages": "30211--30218",
            "other_ids": {}
        },
        "BIBREF67": {
            "ref_id": "b67",
            "title": "Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Garg",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Kim",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Whitaker",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "MMWR Morb Mortal Wkly Rep",
            "volume": "69",
            "issn": "",
            "pages": "458--464",
            "other_ids": {
                "DOI": [
                    "10.15585/mmwr.mm6915e34.MinistryofHealthofArgentina.www.argentina.gob.ar/salud/coronavirus-COVID-19"
                ]
            }
        },
        "BIBREF68": {
            "ref_id": "b68",
            "title": "Goodarz Kolifarhood , 1,3 Mohammad Aghaali , 1 Hossein Mozafar Saadati , 1 Niloufar Taherpour , 1 Sajjad Rahimi , 1,2 Neda Izadi , 3 and Seyed Saeed Hashemi Nazari 4, * . Epidemiological and Clinical Aspects of COVID-19; a Narrative Review",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Willan",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "King",
                    "suffix": ""
                },
                {
                    "first": "Jeffery",
                    "middle": [],
                    "last": "Aj",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Bienz",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Orenstein",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Wa",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Heymann",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Dl",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Ellis",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Rj",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Rosenberg",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Rl",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Nakano",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "A"
                    ],
                    "last": "Halsey",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Witte",
                    "suffix": ""
                }
            ],
            "year": 1981,
            "venue": "m1117. doi: 10.1136 / bmj.m1117 6",
            "volume": "8",
            "issn": "",
            "pages": "80697--80706",
            "other_ids": {
                "PMID": [
                    "32259130"
                ],
                "PMCID": [
                    "PMC7117787"
                ]
            }
        },
        "BIBREF69": {
            "ref_id": "b69",
            "title": "Diagnosis, antiviral therapy, and prophylaxis of varicellazoster virus infections",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Sauerbrei",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Eur J Clin Microbiol Infect Dis",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF70": {
            "ref_id": "b70",
            "title": "Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis, The PREVENT Study Group *",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Mk Diallo",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "O"
                    ],
                    "last": "Diallo",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Dicko",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Richard",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Espi\u00e9",
                    "suffix": ""
                }
            ],
            "year": 1997,
            "venue": "BMC Infect Dis",
            "volume": "19",
            "issn": "1",
            "pages": "93--99",
            "other_ids": {}
        },
        "BIBREF71": {
            "ref_id": "b71",
            "title": "Genotype and phenotype of COVID-19: Their roles in pathogenesis",
            "authors": [
                {
                    "first": "Leila",
                    "middle": [],
                    "last": "Mousavizadeh A",
                    "suffix": ""
                },
                {
                    "first": "Sorayya",
                    "middle": [],
                    "last": "Ghasemi",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Microbiol Immunol Infect",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF74": {
            "ref_id": "b74",
            "title": "Severe Acute Respiratory Syndrome Coronavirus 2",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Haagmans",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF75": {
            "ref_id": "b75",
            "title": "Coronavirus Disease 2019 Patients. Emerg Infect Dis",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Antibody",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "26",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF76": {
            "ref_id": "b76",
            "title": "Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma",
            "authors": [
                {
                    "first": "Chenguang",
                    "middle": [],
                    "last": "Shen",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Phd1; Zhaoqin",
                    "suffix": ""
                },
                {
                    "first": "Phd1; Fang",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": ";",
                    "middle": [],
                    "last": "Phd1",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF77": {
            "ref_id": "b77",
            "title": "Organ-protective Effect of Angiotensin-converting Enzyme 2 and its Effect on the Prognosis of COVID-19",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "G.-Q",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Journal of Medical Virology",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF78": {
            "ref_id": "b78",
            "title": "Deployment of convalescent plasma for the prevention and treatment of COVID-19",
            "authors": [
                {
                    "first": "Evan",
                    "middle": [
                        "M"
                    ],
                    "last": "Bloch",
                    "suffix": ""
                },
                {
                    "first": "Jeffrey",
                    "middle": [
                        "A"
                    ],
                    "last": "Bailey",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "R"
                    ],
                    "last": "Aaron",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Tobian",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Clin Invest",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1172/JCI138745"
                ]
            }
        },
        "BIBREF79": {
            "ref_id": "b79",
            "title": "Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses",
            "authors": [
                {
                    "first": "Didier",
                    "middle": [],
                    "last": "Raoult",
                    "suffix": ""
                },
                {
                    "first": "Alimuddin",
                    "middle": [],
                    "last": "Zumla",
                    "suffix": ""
                },
                {
                    "first": "Franco",
                    "middle": [],
                    "last": "Locatelli",
                    "suffix": ""
                },
                {
                    "first": "Giuseppe",
                    "middle": [],
                    "last": "Ippolito",
                    "suffix": ""
                },
                {
                    "first": "Guido",
                    "middle": [],
                    "last": "Kroemer",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Stress",
            "volume": "4",
            "issn": "4",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF80": {
            "ref_id": "b80",
            "title": "19-pandemic-eighth-update 31. Immediate and Near Future Prediction of COVID-19 Patients in the US Population Aged 65+ With the Prior Medical Conditions of Hypertension, Cardiovascular and Lung Diseases: Methods, Models and Acute Care Estimates",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Groothuis",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Simoes",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Levin",
                    "suffix": ""
                }
            ],
            "year": 1993,
            "venue": "Nature Medicine",
            "volume": "329",
            "issn": "21",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.04.12.20062166"
                ]
            }
        },
        "BIBREF81": {
            "ref_id": "b81",
            "title": "Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Dai",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Mo",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Ma",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Luo",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Xiong",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "The Journals of Gerontology: Series A",
            "volume": "089",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1093/gerona/glaa089"
                ]
            }
        },
        "BIBREF82": {
            "ref_id": "b82",
            "title": "Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus Infected Pneumonia",
            "authors": [
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF83": {
            "ref_id": "b83",
            "title": "The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Duan",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.16.20036145"
                ]
            }
        },
        "BIBREF85": {
            "ref_id": "b85",
            "title": "US Department of Health and Human Services, Center for Disease Control and Prevention. National Diabetes Statistics Report, Estimates of Diabetes and Its Burden in the United States 38",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Us",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Services ; Craig",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Hales",
                    "suffix": ""
                },
                {
                    "first": "Margaret",
                    "middle": [
                        "D"
                    ],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Carroll",
                    "suffix": ""
                },
                {
                    "first": "Cheryl",
                    "middle": [
                        "D"
                    ],
                    "last": "Msph",
                    "suffix": ""
                },
                {
                    "first": "Msph",
                    "middle": [],
                    "last": "Fryar",
                    "suffix": ""
                },
                {
                    "first": "Cynthia",
                    "middle": [
                        "L"
                    ],
                    "last": "Ogden",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Ph.D. Prevalence of Obesity and Severe Obesity Among Adults: United States",
            "volume": "37",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF86": {
            "ref_id": "b86",
            "title": "Chronic Obstructive Pulmonary Disease Among Adults Aged 18 and Over in the United States",
            "authors": [
                {
                    "first": "Lara",
                    "middle": [
                        "J"
                    ],
                    "last": "Akinbami",
                    "suffix": ""
                },
                {
                    "first": "Xiang",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Sc",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF87": {
            "ref_id": "b87",
            "title": "Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications Fan Wu",
            "authors": [
                {
                    "first": "Aojie",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Mei",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Qimin",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Jun",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Shuai",
                    "middle": [],
                    "last": "Xia",
                    "suffix": ""
                },
                {
                    "first": "Yun",
                    "middle": [],
                    "last": "Ling",
                    "suffix": ""
                },
                {
                    "first": "Yuling",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Jingna",
                    "middle": [],
                    "last": "Xun",
                    "suffix": ""
                },
                {
                    "first": "Shibo",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "Hongzhou",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "Yumei",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Wen ; Linlin",
                    "suffix": ""
                },
                {
                    "first": "Wei",
                    "middle": [],
                    "last": "Bao",
                    "suffix": ""
                },
                {
                    "first": "Hong",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                },
                {
                    "first": "Chong",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "Jiayi",
                    "middle": [],
                    "last": "Xiao",
                    "suffix": ""
                },
                {
                    "first": "Jing",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Qi",
                    "middle": [],
                    "last": "Xue",
                    "suffix": ""
                },
                {
                    "first": "Jiangning",
                    "middle": [],
                    "last": "Lv",
                    "suffix": ""
                },
                {
                    "first": "Pin",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Yanfeng",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "Feifei",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "Yajin",
                    "middle": [],
                    "last": "Qi",
                    "suffix": ""
                },
                {
                    "first": "Fengdi",
                    "middle": [],
                    "last": "Qu",
                    "suffix": ""
                },
                {
                    "first": "Zhiguang",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Haisheng",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                },
                {
                    "first": "Shuran",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "Mingya",
                    "middle": [],
                    "last": "Gong",
                    "suffix": ""
                },
                {
                    "first": "Guanpeng",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Shunyi",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Zhiqi",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Wenjie",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                },
                {
                    "first": "Yunlin",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Linna",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                },
                {
                    "first": "Xing",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Qiang",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Wei ; Rhinesmith",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Fu",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Coronavirus Disease 2019 (COVID-19) Daily Data Summary, NYC Health",
            "volume": "39",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.30.2004736542"
                ]
            }
        },
        "BIBREF88": {
            "ref_id": "b88",
            "title": "Hepatitis A, B, and C",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Christenson",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Manaloor",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Jj",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Pediatrics in Review",
            "volume": "37",
            "issn": "10",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF89": {
            "ref_id": "b89",
            "title": "The pandemic pipeline",
            "authors": [
                {
                    "first": "John",
                    "middle": [],
                    "last": "Hodgson",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Nature Biotechnology",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF91": {
            "ref_id": "b91",
            "title": "Clinical Characteristics of Coronavirus Disease 2019 in China",
            "authors": [],
            "year": null,
            "venue": "The New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF93": {
            "ref_id": "b93",
            "title": "Spread of SARS-CoV-2 in the Icelandic Population",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Duchin",
                    "suffix": ""
                },
                {
                    "first": ";",
                    "middle": [],
                    "last": "Epidemiology",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Df Gudbjartsson",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Helgason",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Jonsson",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Magnusson",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Melsted",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Norddahl",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Saemundsdottir",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Sigurdsson",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Sulem",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Agustsdottir",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Eiriksdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Fridriksdottir",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Gardarsdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Georgsson",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Gretarsdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Kr Gudmundsson",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Gunnarsdottir",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Gylfason",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Holm",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Bo Jensson",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Jonasdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Jonsson",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Josefsdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Kristjansson",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Magnusdottir",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Le Roux",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Sigmundsdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Sveinbjornsson",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Sveinsdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Sveinsdottir",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Thorarensen",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Thorbjornsson",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "L\u00f6ve",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Masson",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Jonsdottir",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "M\u00f6ller",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Gudnason",
                    "suffix": ""
                },
                {
                    "first": "U",
                    "middle": [],
                    "last": "Kristinsson",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Thorsteinsdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Stefansson",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF97": {
            "ref_id": "b97",
            "title": "Novel Coronavirus in the United States",
            "authors": [],
            "year": null,
            "venue": "New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF99": {
            "ref_id": "b99",
            "title": "MD COVID-19 in Critically Ill Patients in the Seattle Region",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Greninger",
                    "suffix": ""
                },
                {
                    "first": "Sudhakar",
                    "middle": [],
                    "last": "Pipavath",
                    "suffix": ""
                },
                {
                    "first": "Mark",
                    "middle": [
                        "M"
                    ],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Wurfel",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "Laura",
                    "middle": [],
                    "last": "Evans",
                    "suffix": ""
                },
                {
                    "first": "Patricia",
                    "middle": [
                        "A"
                    ],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Kritek",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "Eoin"
                    ],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "West",
                    "suffix": ""
                },
                {
                    "first": "Mph",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "Andrew",
                    "middle": [],
                    "last": "Luks",
                    "suffix": ""
                },
                {
                    "first": "Anthony",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Gerbino",
                    "suffix": ""
                },
                {
                    "first": "Chris",
                    "middle": [
                        "R"
                    ],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Dale",
                    "suffix": ""
                },
                {
                    "first": "Jason",
                    "middle": [
                        "D"
                    ],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Goldman",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "O&apos;",
                    "middle": [],
                    "last": "Shane",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Mahony",
                    "suffix": ""
                },
                {
                    "first": "Carmen",
                    "middle": [],
                    "last": "Mikacenic",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Case Series New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF100": {
            "ref_id": "b100",
            "title": "Clinical Characteristics of Coronavirus Disease 2019 in China",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Ni",
                    "suffix": ""
                },
                {
                    "first": "Yu",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Ou",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Shan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Lei",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Hui",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "K.-Y",
                    "middle": [],
                    "last": "Zeng",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Yuen",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                },
                {
                    "first": "Jin-Lin",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Peng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "Ya-Hua",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "Jian-Ming",
                    "middle": [],
                    "last": "Peng",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Qiu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Luo",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ye",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Zhong",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF101": {
            "ref_id": "b101",
            "title": "Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "R"
                    ],
                    "last": "Harvey",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "V"
                    ],
                    "last": "Basavaraju",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "W"
                    ],
                    "last": "Chung",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Kuehnert",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Transfusion",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF102": {
            "ref_id": "b102",
            "title": "Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Hirayama",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Br J Haematol",
            "volume": "160",
            "issn": "",
            "pages": "434--478",
            "other_ids": {}
        },
        "BIBREF103": {
            "ref_id": "b103",
            "title": "Hemovigilance Module Surveillance Protocol v2.1.3. Atlanta: Centers for Disease Control and Prevention",
            "authors": [
                {
                    "first": "Cdc",
                    "middle": [],
                    "last": "Nhsn Biovigilance",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Component",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF104": {
            "ref_id": "b104",
            "title": "and the World Allergy Organization. World Allergy Organization anaphylaxis guidelines: summary",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "E"
                    ],
                    "last": "Simons",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "R"
                    ],
                    "last": "Ardusso",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "B"
                    ],
                    "last": "Bilo",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "J Allergy Clin Immunol",
            "volume": "127",
            "issn": "",
            "pages": "1--22",
            "other_ids": {}
        },
        "BIBREF105": {
            "ref_id": "b105",
            "title": "and the BCSH Blood Transfusion Task Force. Guideline on the investigation and management of acute transfusion reactions. Prepared by the BCSH Blood Transfusion Task Force",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Tinegate",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Birchall",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Gray",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Br J Haematol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF106": {
            "ref_id": "b106",
            "title": "Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "Y"
                    ],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Curry",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "R"
                    ],
                    "last": "Pesola",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Ann Emerg Med",
            "volume": "36",
            "issn": "",
            "pages": "462--68",
            "other_ids": {}
        },
        "BIBREF107": {
            "ref_id": "b107",
            "title": "Histamine antagonists in the treatment of acute allergic reactions",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "W"
                    ],
                    "last": "Runge",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Martinez",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "M"
                    ],
                    "last": "Caravati",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "G"
                    ],
                    "last": "Williamson",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "C"
                    ],
                    "last": "Hartsell",
                    "suffix": ""
                }
            ],
            "year": 1992,
            "venue": "Ann Emerg Med",
            "volume": "21",
            "issn": "",
            "pages": "237--427",
            "other_ids": {}
        },
        "BIBREF108": {
            "ref_id": "b108",
            "title": "Technical Manual, 18th edn",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Fung",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Grossman",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "D"
                    ],
                    "last": "Hillyer",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Westhoff",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF109": {
            "ref_id": "b109",
            "title": "Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Pandey",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "N"
                    ],
                    "last": "Vyas",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "U"
                    ],
                    "last": "Wieding",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Vehmeyer",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Dittman",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Hiddemann",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "K\u00f6hler",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Lanzer",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zou",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "A"
                    ],
                    "last": "Dorsey",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "P"
                    ],
                    "last": "Notari",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Foster",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "E"
                    ],
                    "last": "Krysztof",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Musavi",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "Y"
                    ],
                    "last": "Dodd",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "L"
                    ],
                    "last": "Stramer",
                    "suffix": ""
                }
            ],
            "year": 1994,
            "venue": "65S 79S",
            "volume": "52",
            "issn": "",
            "pages": "1495--504",
            "other_ids": {}
        },
        "BIBREF110": {
            "ref_id": "b110",
            "title": "Current incidence and residual risk of hepatitis B infection among blood donors in the United States",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zou",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "L"
                    ],
                    "last": "Stramer",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "P"
                    ],
                    "last": "Notari",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "C"
                    ],
                    "last": "Kuhns",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Krysztof",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Musavi",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "T"
                    ],
                    "last": "Fang",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "Y"
                    ],
                    "last": "Dodd",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Transfusion",
            "volume": "49",
            "issn": "",
            "pages": "1609--1629",
            "other_ids": {}
        },
        "BIBREF111": {
            "ref_id": "b111",
            "title": "Polack (INFANT) Title : Evaluation of the efficacy of COVID-19 convalescent plasma administration in reducing the progression to severe disease in older adults with mild symptoms due to SARS-CoV2 (ENGLISH VERSION FROM SPANISH). Version 6",
            "authors": [],
            "year": 2002,
            "venue": "Principal Investigator of the Program: Dr. Fernando P",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF112": {
            "ref_id": "b112",
            "title": "EVALUATION OF THE EFFICACY OF COVID-19 CONVALESCENT PLASMA ADMINISTRATION IN REDUCING THE PROGRESSION TO SEVERE DISEASE IN OLDER ADULTS WITH MILD SYMPTOMS DUE TO SARS-COV2",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF113": {
            "ref_id": "b113",
            "title": "Hospital Central de San Isidro Principal Investigator: Dr. Ramiro Larrea Dr. Carlos Bocalandro Hospital Principal Investigator: Dr. An\u00edbal Rondan Principal Investigator Simply Evita Hospital: Dra. Valeria Fern\u00e1ndez Vi\u00f1a Evita Pueblo Hospital Principal Investigator: Dra. Sandra Azc\u00e1rate San Juan de Dios Hospital Principal Investigator: Dra. Ivonne Ritou COVID-PAMI Centers Principal Investigator: Dr. Gonzalo Perez Marc Principal Investigator of the Program: Dr. Fernando P. Polack (INFANT)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF114": {
            "ref_id": "b114",
            "title": "Juan Sebasti\u00e1n Riera (Ministry of Health of the Province of Buenos Aires), Dr. Enio Garc\u00eda (Ministry of Health of the Province of Buenos Aires), Dr. Juan Canela (Ministry of Health of the Province of Buenos Aires), Dr. Mario Rovere (Ministry of Health of the Province of Buenos Aires",
            "authors": [],
            "year": null,
            "venue": "Dr. Dami\u00e1n Alvarez Paggi (INFANT / CONICET), Dr. Sebasti\u00e1n Esperante (INFANT / CONICET) , Dr. Federico Dimase (HMC), Dr. Susana Pastor Arg\u00fcello (HMC) , Dr. Juan Molinos (Olivos Clinic), Dr. Pablo Cruz (Galician Center), Dra. Mar\u00eda Dolores Silveyra (Anchorena Sanatorium), Dr. Alfonso Raggio",
            "volume": "1",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF115": {
            "ref_id": "b115",
            "title": "Obesity (BMI -Body mass indexd. Chronic obstructive pulmonary disease (COPD) treated with any of the available drugs (Appendix I)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF116": {
            "ref_id": "b116",
            "title": "Cardiovascular disease defined as a) known diagnosis of coronary heart disease, b) history of ischemic stroke or hemorrhagic, or c) ICC (defined as FE f. Chronic kidney disease (defined as a reduction in GFR below 60 ml/min/1.73 m 2 )",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF117": {
            "ref_id": "b117",
            "title": "5\u00b0C or fever equivalence (defined as feeling cold and/or chills and/or unexplained sweating) , combined with (a ) dry cough and / or ( b) difficulty breathing and / or ( c) odynophagia and / or (d) anosmia and/or (e) dysgeusia and / or (e) any of the following symptoms : fatigue, anorexia, myalgia or rhinorrhea",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "37",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF118": {
            "ref_id": "b118",
            "title": "SARS-CoV2 diagnosis confirmed by RT-PCR",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF119": {
            "ref_id": "b119",
            "title": "Being able, according to medical judgment, to understand and comply with the study procedures and to consent or not to their participation",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF120": {
            "ref_id": "b120",
            "title": "Provide informed consent",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF121": {
            "ref_id": "b121",
            "title": "Patients with cognitive vulnerability with support in decision-making by their representative, can be included as detailed below. (see section 12)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF122": {
            "ref_id": "b122",
            "title": "the study: 1. Present at the time of inclusion SEVERE RESPIRATORY DISEASE defined ambient air <93%",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF123": {
            "ref_id": "b123",
            "title": "HEART FAILURE in functional class III and IV (according to the functional classification of the",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF124": {
            "ref_id": "b124",
            "title": "Known diagnosis of CHRONIC KIDNEY INSUFFICIENCY in filtration stages G4 and G5 (according to KDIGO classification)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF125": {
            "ref_id": "b125",
            "title": "Previous diagnosis of PRIMARY HYPOGAMMAGLOBULINEMIA (congenital and hereditary)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF126": {
            "ref_id": "b126",
            "title": "Previous diagnosis of MONOCLONAL GAMMOPATHIES (multiple myeloma, Waldenstr\u00f6m macroglobulinemia, primary amyloidosis, heavy chain disease, among others)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF127": {
            "ref_id": "b127",
            "title": "Previous diagnosis of SELECTIVE DEFICIENCY OF IgA",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF128": {
            "ref_id": "b128",
            "title": "Previous diagnosis of MYELODYSPLASIC SYNDROMES",
            "authors": [],
            "year": null,
            "venue": "WHO classification: refractory thrombocytopenia (TR), refractory anemia (RA)",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF129": {
            "ref_id": "b129",
            "title": "Bin Cao. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",
            "authors": [
                {
                    "first": "Fei",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "*",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Ting",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "*",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Ronghui",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "*",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Guohui",
                    "middle": [],
                    "last": "Fan",
                    "suffix": ""
                },
                {
                    "first": "*",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Ying",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "*",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Zhibo",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "*",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Jie",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                },
                {
                    "first": "*",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Yeming",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Bin",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                },
                {
                    "first": "Xiaoying",
                    "middle": [],
                    "last": "Gu",
                    "suffix": ""
                },
                {
                    "first": "Lulu",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Yuan",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "Hui",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Xudong",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "Jiuyang",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "Shengjin",
                    "middle": [],
                    "last": "Tu",
                    "suffix": ""
                },
                {
                    "first": "Yi",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Hua",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "20",
            "pages": "30566--30569",
            "other_ids": {}
        },
        "BIBREF130": {
            "ref_id": "b130",
            "title": "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Qu",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Gong",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "20",
            "pages": "30211--30218",
            "other_ids": {}
        },
        "BIBREF131": {
            "ref_id": "b131",
            "title": "Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Garg",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Kim",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Whitaker",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "MMWR Morb Mortal Wkly Rep",
            "volume": "69",
            "issn": "",
            "pages": "458--464",
            "other_ids": {
                "DOI": [
                    "10.15585/mmwr.mm6915e34.MinistryofHealthofArgentina.www.argentina.gob.ar/salud/coronavirus-COVID-19"
                ]
            }
        },
        "BIBREF132": {
            "ref_id": "b132",
            "title": "Goodarz Kolifarhood , 1,3 Mohammad Aghaali , 1 Hossein Mozafar Saadati , 1 Niloufar Taherpour , 1 Sajjad Rahimi , 1,2 Neda Izadi , 3 and Seyed Saeed Hashemi Nazari 4, * . Epidemiological and Clinical Aspects of COVID-19; a Narrative Review",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Willan",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "King",
                    "suffix": ""
                },
                {
                    "first": "Jeffery",
                    "middle": [],
                    "last": "Aj",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Bienz",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Orenstein",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Wa",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Heymann",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Dl",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Ellis",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Rj",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Rosenberg",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Rl",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Nakano",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "A"
                    ],
                    "last": "Halsey",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Witte",
                    "suffix": ""
                }
            ],
            "year": 1981,
            "venue": "m1117. doi: 10.1136 / bmj.m1117 6",
            "volume": "8",
            "issn": "",
            "pages": "80697--80706",
            "other_ids": {
                "PMID": [
                    "32259130"
                ],
                "PMCID": [
                    "PMC7117787"
                ]
            }
        },
        "BIBREF133": {
            "ref_id": "b133",
            "title": "Diagnosis, antiviral therapy, and prophylaxis of varicellazoster virus infections",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Sauerbrei",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Eur J Clin Microbiol Infect Dis",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF134": {
            "ref_id": "b134",
            "title": "Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis, The PREVENT Study Group *",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Mk Diallo",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "O"
                    ],
                    "last": "Diallo",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Dicko",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Richard",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Espi\u00e9",
                    "suffix": ""
                }
            ],
            "year": 1997,
            "venue": "BMC Infect Dis",
            "volume": "19",
            "issn": "1",
            "pages": "93--99",
            "other_ids": {}
        },
        "BIBREF135": {
            "ref_id": "b135",
            "title": "Genotype and phenotype of COVID-19: Their roles in pathogenesis",
            "authors": [
                {
                    "first": "Leila",
                    "middle": [],
                    "last": "Mousavizadeh A",
                    "suffix": ""
                },
                {
                    "first": "Sorayya",
                    "middle": [],
                    "last": "Ghasemi",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Microbiol Immunol Infect",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF137": {
            "ref_id": "b137",
            "title": "Antibody Responses in Coronavirus Disease",
            "authors": [
                {
                    "first": "Erwin",
                    "middle": [],
                    "last": "Sikkema",
                    "suffix": ""
                },
                {
                    "first": "Felicity",
                    "middle": [
                        "D"
                    ],
                    "last": "De Bruin",
                    "suffix": ""
                },
                {
                    "first": "Yazdan",
                    "middle": [],
                    "last": "Chandler",
                    "suffix": ""
                },
                {
                    "first": "Quentin",
                    "middle": [
                        "Le"
                    ],
                    "last": "Yazdanpanah",
                    "suffix": ""
                },
                {
                    "first": "Diane",
                    "middle": [],
                    "last": "Hingrat",
                    "suffix": ""
                },
                {
                    "first": "Nadhira",
                    "middle": [],
                    "last": "Descamps",
                    "suffix": ""
                },
                {
                    "first": "Chantal",
                    "middle": [],
                    "last": "Houhou-Fidouh",
                    "suffix": ""
                },
                {
                    "first": "Berend-Jan",
                    "middle": [],
                    "last": "Bem Reusken",
                    "suffix": ""
                },
                {
                    "first": "Christian",
                    "middle": [],
                    "last": "Bosch",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Drosten",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "G"
                    ],
                    "last": "Marion",
                    "suffix": ""
                },
                {
                    "first": "Bart",
                    "middle": [
                        "L"
                    ],
                    "last": "Koopmans",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Haagmans",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Patients. Emerg Infect Dis",
            "volume": "26",
            "issn": "7",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF138": {
            "ref_id": "b138",
            "title": "Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma",
            "authors": [
                {
                    "first": "Chenguang",
                    "middle": [],
                    "last": "Shen",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Phd1; Zhaoqin",
                    "suffix": ""
                },
                {
                    "first": "Phd1; Fang",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": ";",
                    "middle": [],
                    "last": "Phd1",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF139": {
            "ref_id": "b139",
            "title": "Organ-protective Effect of Angiotensin-converting Enzyme 2 and its Effect on the Prognosis of COVID-19",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "G.-Q",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Journal of Medical Virology",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF140": {
            "ref_id": "b140",
            "title": "Deployment of convalescent plasma for the prevention and treatment of COVID-19",
            "authors": [
                {
                    "first": "Evan",
                    "middle": [
                        "M"
                    ],
                    "last": "Bloch",
                    "suffix": ""
                },
                {
                    "first": "Jeffrey",
                    "middle": [
                        "A"
                    ],
                    "last": "Bailey",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "R"
                    ],
                    "last": "Aaron",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Tobian",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Clin Invest",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1172/JCI138745"
                ]
            }
        },
        "BIBREF141": {
            "ref_id": "b141",
            "title": "Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses",
            "authors": [
                {
                    "first": "Didier",
                    "middle": [],
                    "last": "Raoult",
                    "suffix": ""
                },
                {
                    "first": "Alimuddin",
                    "middle": [],
                    "last": "Zumla",
                    "suffix": ""
                },
                {
                    "first": "Franco",
                    "middle": [],
                    "last": "Locatelli",
                    "suffix": ""
                },
                {
                    "first": "Giuseppe",
                    "middle": [],
                    "last": "Ippolito",
                    "suffix": ""
                },
                {
                    "first": "Guido",
                    "middle": [],
                    "last": "Kroemer",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Stress",
            "volume": "4",
            "issn": "4",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF142": {
            "ref_id": "b142",
            "title": "Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Groothuis",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Simoes",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Levin",
                    "suffix": ""
                }
            ],
            "year": 1993,
            "venue": "N Engl J Med",
            "volume": "329",
            "issn": "21",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF145": {
            "ref_id": "b145",
            "title": "COVID-19 with Different Severity: A Multi-center Study of Clinical Feature",
            "authors": [
                {
                    "first": "Yunfei",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "doi.org/10.1164/rccm.202002-0445OC"
                ]
            }
        },
        "BIBREF146": {
            "ref_id": "b146",
            "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Fan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Gu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Tu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "1054--1062",
            "other_ids": {}
        },
        "BIBREF147": {
            "ref_id": "b147",
            "title": "Is forced oscillation technique the next respiratory function test of choice in childhood asthma",
            "authors": [
                {
                    "first": "Afaf",
                    "middle": [],
                    "last": "Alblooshi",
                    "suffix": ""
                },
                {
                    "first": "Alia",
                    "middle": [],
                    "last": "Alkalbani",
                    "suffix": ""
                },
                {
                    "first": "Ghaya",
                    "middle": [],
                    "last": "Albadi",
                    "suffix": ""
                },
                {
                    "first": "Hassib",
                    "middle": [],
                    "last": "Narchi",
                    "suffix": ""
                },
                {
                    "first": "Graham",
                    "middle": [],
                    "last": "Hall",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "World J Methodol",
            "volume": "7",
            "issn": "4",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF148": {
            "ref_id": "b148",
            "title": "Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Garg",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Kim",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Whitaker",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Am. J. Respir. Crit. Care Med",
            "volume": "69",
            "issn": "",
            "pages": "458--464",
            "other_ids": {
                "DOI": [
                    "10.15585/mmwr.mm6915e324"
                ]
            }
        },
        "BIBREF149": {
            "ref_id": "b149",
            "title": "doi: 10.1001 / jama.2020.5394 26. Integrated Surveillance Bulletin. National Directorate of Epidemiology and Analysis of the Health Situation. N \u00b0 424 -EW 39",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Grasselli",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Zangrillo",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Zanella",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)",
            "volume": "",
            "issn": "",
            "pages": "16--24",
            "other_ids": {}
        },
        "BIBREF150": {
            "ref_id": "b150",
            "title": "Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nature Medicine. doi: 10.1038 / s41591-020-0822-7 30. Coronavirus disease 2019 (COVID-19) in the EU / EEA and the UKeighth update",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "T"
                    ],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Leung",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Bushman",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Kishore",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Niehus",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "De Salazar ; Arni Sr Srinivasa",
                    "suffix": ""
                },
                {
                    "first": "Douglas",
                    "middle": [
                        "D"
                    ],
                    "last": "Rao",
                    "suffix": ""
                },
                {
                    "first": "Adam",
                    "middle": [
                        "E"
                    ],
                    "last": "Miller",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Berman",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.04.12.20062166"
                ]
            }
        },
        "BIBREF151": {
            "ref_id": "b151",
            "title": "Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Dai",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Mo",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Ma",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Luo",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Xiong",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "The Journals of Gerontology: Series A",
            "volume": "089",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1093/gerona/glaa089"
                ]
            }
        },
        "BIBREF152": {
            "ref_id": "b152",
            "title": "Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus Infected Pneumonia",
            "authors": [
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF153": {
            "ref_id": "b153",
            "title": "The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Duan",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.16.20036145"
                ]
            }
        },
        "BIBREF155": {
            "ref_id": "b155",
            "title": "US Department of Health and Human Services, Center for Disease Control and Prevention. National Diabetes Statistics Report, Estimates of Diabetes and Its Burden in the United States 38",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Us",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Services ; Craig",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Hales",
                    "suffix": ""
                },
                {
                    "first": "Margaret",
                    "middle": [
                        "D"
                    ],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Carroll",
                    "suffix": ""
                },
                {
                    "first": "Cheryl",
                    "middle": [
                        "D"
                    ],
                    "last": "Msph",
                    "suffix": ""
                },
                {
                    "first": "Msph",
                    "middle": [],
                    "last": "Fryar",
                    "suffix": ""
                },
                {
                    "first": "Cynthia",
                    "middle": [
                        "L"
                    ],
                    "last": "Ogden",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Ph.D. Prevalence of Obesity and Severe Obesity Among Adults: United States",
            "volume": "37",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF156": {
            "ref_id": "b156",
            "title": "Chronic Obstructive Pulmonary Disease Among Adults Aged 18 and Over in the United States",
            "authors": [
                {
                    "first": "Lara",
                    "middle": [
                        "J"
                    ],
                    "last": "Akinbami",
                    "suffix": ""
                },
                {
                    "first": "Xiang",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Sc",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF157": {
            "ref_id": "b157",
            "title": "Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications Fan Wu",
            "authors": [
                {
                    "first": "Aojie",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Mei",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Qimin",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Jun",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Shuai",
                    "middle": [],
                    "last": "Xia",
                    "suffix": ""
                },
                {
                    "first": "Yun",
                    "middle": [],
                    "last": "Ling",
                    "suffix": ""
                },
                {
                    "first": "Yuling",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Jingna",
                    "middle": [],
                    "last": "Xun",
                    "suffix": ""
                },
                {
                    "first": "Shibo",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "Hongzhou",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "Yumei",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Wen ; Linlin",
                    "suffix": ""
                },
                {
                    "first": "Wei",
                    "middle": [],
                    "last": "Bao",
                    "suffix": ""
                },
                {
                    "first": "Hong",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                },
                {
                    "first": "Chong",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "Jiayi",
                    "middle": [],
                    "last": "Xiao",
                    "suffix": ""
                },
                {
                    "first": "Jing",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Qi",
                    "middle": [],
                    "last": "Xue",
                    "suffix": ""
                },
                {
                    "first": "Jiangning",
                    "middle": [],
                    "last": "Lv",
                    "suffix": ""
                },
                {
                    "first": "Pin",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Yanfeng",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "Feifei",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "Yajin",
                    "middle": [],
                    "last": "Qi",
                    "suffix": ""
                },
                {
                    "first": "Fengdi",
                    "middle": [],
                    "last": "Qu",
                    "suffix": ""
                },
                {
                    "first": "Zhiguang",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Haisheng",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                },
                {
                    "first": "Shuran",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "Mingya",
                    "middle": [],
                    "last": "Gong",
                    "suffix": ""
                },
                {
                    "first": "Guanpeng",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Shunyi",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Zhiqi",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Wenjie",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                },
                {
                    "first": "Yunlin",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Linna",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                },
                {
                    "first": "Xing",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Qiang",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Wei ; Rhinesmith",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Fu",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Coronavirus Disease 2019 (COVID-19) Daily Data Summary, NYC Health",
            "volume": "39",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.30.2004736542"
                ]
            }
        },
        "BIBREF158": {
            "ref_id": "b158",
            "title": "Hepatitis A, B, and C",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Christenson",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Manaloor",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Jj",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Pediatrics in Review",
            "volume": "37",
            "issn": "10",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF159": {
            "ref_id": "b159",
            "title": "The pandemic pipeline",
            "authors": [
                {
                    "first": "John",
                    "middle": [],
                    "last": "Hodgson",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Nature Biotechnology",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF160": {
            "ref_id": "b160",
            "title": "for the China Medical Treatment Expert Group for Covid",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Ni",
                    "suffix": ""
                },
                {
                    "first": "Yu",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Ou",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Shan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Lei",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Hui",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "K.-Y",
                    "middle": [],
                    "last": "Zeng",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Yuen",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                },
                {
                    "first": "Jin-Lin",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Peng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "Ya-Hua",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "Jian-Ming",
                    "middle": [],
                    "last": "Peng",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Qiu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Luo",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ye",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Zhong",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF161": {
            "ref_id": "b161",
            "title": "Clinical Characteristics of Coronavirus Disease 2019 in China",
            "authors": [],
            "year": null,
            "venue": "The New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF163": {
            "ref_id": "b163",
            "title": "Spread of SARS-CoV-2 in the Icelandic Population",
            "authors": [
                {
                    "first": ";",
                    "middle": [],
                    "last": "Duchin",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Df Gudbjartsson",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Helgason",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Jonsson",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Magnusson",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Melsted",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Norddahl",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Saemundsdottir",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Sigurdsson",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Sulem",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Agustsdottir",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Eiriksdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Fridriksdottir",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Gardarsdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Georgsson",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Gretarsdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Kr Gudmundsson",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Gunnarsdottir",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Gylfason",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Holm",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Bo Jensson",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Jonasdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Jonsson",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Josefsdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Kristjansson",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Magnusdottir",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Le Roux",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Sigmundsdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Sveinbjornsson",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Sveinsdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Sveinsdottir",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Thorarensen",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Thorbjornsson",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "L\u00f6ve",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Masson",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Jonsdottir",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "M\u00f6ller",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Gudnason",
                    "suffix": ""
                },
                {
                    "first": "U",
                    "middle": [],
                    "last": "Kristinsson",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Thorsteinsdottir",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Stefansson",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF167": {
            "ref_id": "b167",
            "title": "Novel Coronavirus in the United States",
            "authors": [],
            "year": null,
            "venue": "New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF169": {
            "ref_id": "b169",
            "title": "MD Covid-19 in Critically Ill Patients in the Seattle Region",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Greninger",
                    "suffix": ""
                },
                {
                    "first": "Sudhakar",
                    "middle": [],
                    "last": "Pipavath",
                    "suffix": ""
                },
                {
                    "first": "Mark",
                    "middle": [
                        "M"
                    ],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Wurfel",
                    "suffix": ""
                },
                {
                    "first": "Ph",
                    "middle": [
                        "D"
                    ],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "Laura",
                    "middle": [],
                    "last": "Evans",
                    "suffix": ""
                },
                {
                    "first": "Patricia",
                    "middle": [
                        "A"
                    ],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Kritek",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "Eoin"
                    ],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "West",
                    "suffix": ""
                },
                {
                    "first": "Mph",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "Andrew",
                    "middle": [],
                    "last": "Luks",
                    "suffix": ""
                },
                {
                    "first": "Anthony",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Gerbino",
                    "suffix": ""
                },
                {
                    "first": "Chris",
                    "middle": [
                        "R"
                    ],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Dale",
                    "suffix": ""
                },
                {
                    "first": "Jason",
                    "middle": [
                        "D"
                    ],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Goldman",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                },
                {
                    "first": "O&apos;",
                    "middle": [],
                    "last": "Shane",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Mahony",
                    "suffix": ""
                },
                {
                    "first": "Carmen",
                    "middle": [],
                    "last": "Mikacenic",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Case Series New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF170": {
            "ref_id": "b170",
            "title": "Clinical Characteristics of Coronavirus Disease 2019 in China",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Ni",
                    "suffix": ""
                },
                {
                    "first": "Yu",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Ou",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Shan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Lei",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Hui",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "K.-Y",
                    "middle": [],
                    "last": "Zeng",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Yuen",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                },
                {
                    "first": "Jin-Lin",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Peng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "Ya-Hua",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "Jian-Ming",
                    "middle": [],
                    "last": "Peng",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Qiu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Luo",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ye",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Zhong",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "New England Journal of Medicine",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF171": {
            "ref_id": "b171",
            "title": "Effectiveness of Measles Vaccination and Immune Globulin Post-Exposure Prophylaxis in an Outbreak Setting",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "J"
                    ],
                    "last": "Arciuolo",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Jablonski",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Rr",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Zucker",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Rosen",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Jb",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Clinical Infectious Diseases",
            "volume": "65",
            "issn": "11",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF172": {
            "ref_id": "b172",
            "title": "Safety and varicella outcomes after varicella zoster immune globulin administration in pregnancy",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "K"
                    ],
                    "last": "Swamy",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Dotters-Katz",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Sk",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "American Journal of Obstetrics and Gynecology",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF173": {
            "ref_id": "b173",
            "title": "Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: varicella outcomes and safety results from a large, open-label, expanded-access program",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Levin",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Duchon",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "K"
                    ],
                    "last": "Swamy",
                    "suffix": ""
                },
                {
                    "first": "Aa ;",
                    "middle": [],
                    "last": "Gershon",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [
                        "K"
                    ],
                    "last": "Bharti",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Thakur",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Rao",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "MMWR. Recommendation of the Immunization Practices Advisory Committee (ACIP) Postexposure Prophylaxis of Hepatitis B",
            "volume": "14",
            "issn": "",
            "pages": "217749--55",
            "other_ids": {}
        },
        "BIBREF174": {
            "ref_id": "b174",
            "title": "Characteristics of Ocular Findings of Patients With Coronavirus Disease",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Duan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Luo",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "JAMA Ophthalmol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF175": {
            "ref_id": "b175",
            "title": "Transfusion-associated circulatory overload (TACO): Time to shed light on the pathophysiology",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "W"
                    ],
                    "last": "Semple",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Rebetz",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Kapur",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "ISBT Sci Ser",
            "volume": "14",
            "issn": "1",
            "pages": "136--139",
            "other_ids": {}
        },
        "BIBREF176": {
            "ref_id": "b176",
            "title": "HLA class II antibodies in transfusion-related acute lung injury",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "M"
                    ],
                    "last": "Kopko",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Popovsky",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "R"
                    ],
                    "last": "Mackenzie",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Transfusion",
            "volume": "41",
            "issn": "",
            "pages": "1244--1252",
            "other_ids": {}
        },
        "BIBREF177": {
            "ref_id": "b177",
            "title": "Transfusion and the lung: circulatory overload and acute lung injury",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Popovsky",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Vox Sang",
            "volume": "87",
            "issn": "s2",
            "pages": "62--65",
            "other_ids": {}
        },
        "BIBREF178": {
            "ref_id": "b178",
            "title": "An analysis of blood management in patients having a total hip or knee arthroplasty",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "E"
                    ],
                    "last": "Bierbaum",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Callaghan",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "O"
                    ],
                    "last": "Galante",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "E"
                    ],
                    "last": "Rubash",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "E"
                    ],
                    "last": "Tooms",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "B"
                    ],
                    "last": "Welch",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "J Bone Joint Surg Am",
            "volume": "81",
            "issn": "1",
            "pages": "2--10",
            "other_ids": {}
        },
        "BIBREF179": {
            "ref_id": "b179",
            "title": "Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Rana",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "R"
                    ],
                    "last": "Fernandez-Perez",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "Khan",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Transfusion",
            "volume": "46",
            "issn": "9",
            "pages": "1478--1483",
            "other_ids": {}
        },
        "BIBREF180": {
            "ref_id": "b180",
            "title": "How we view and approach transfusion-associated circulatory overload: pathogenesis, diagnosis, management, mitigation, and prevention",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Andrzejewski",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Casey",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Popovsky",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Transfusion",
            "volume": "53",
            "issn": "",
            "pages": "3037--3084",
            "other_ids": {}
        },
        "BIBREF181": {
            "ref_id": "b181",
            "title": "A retrospective review of patient factors, transfusion practices, and outcomes in patients with transfusion-associated circulatory overload",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Lieberman",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Maskens",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Cserti-Gazdewich",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Transfusion Med Rev",
            "volume": "27",
            "issn": "",
            "pages": "206--218",
            "other_ids": {}
        },
        "BIBREF182": {
            "ref_id": "b182",
            "title": "COVID-19 and the cardiovascular system",
            "authors": [
                {
                    "first": "Y",
                    "middle": [
                        "Y"
                    ],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "T"
                    ],
                    "last": "Ma",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "Y"
                    ],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Xiang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature Rev Cardiology",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1038/s41569-020-0360-5"
                ]
            }
        },
        "BIBREF183": {
            "ref_id": "b183",
            "title": "Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Qin",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Shen",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Cai",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Transfusion-associated circulatory overload (TACO) Definition",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1001/jamacardio.2020.095067"
                ]
            }
        },
        "BIBREF184": {
            "ref_id": "b184",
            "title": "Transfusion-related acute lung injury: incidence and risk factors",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Toy",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Gajic",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Bacchetti",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Blood",
            "volume": "119",
            "issn": "",
            "pages": "1757--67",
            "other_ids": {}
        },
        "BIBREF185": {
            "ref_id": "b185",
            "title": "HLA class II antibodies in transfusion-related acute lung injury",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "M"
                    ],
                    "last": "Kopko",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Popovsky",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "R"
                    ],
                    "last": "Mackenzie",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Transfusion",
            "volume": "41",
            "issn": "",
            "pages": "1244--1252",
            "other_ids": {}
        },
        "BIBREF186": {
            "ref_id": "b186",
            "title": "Mechanism of transfusion related acute lung injury induced by HLA class II antibodies",
            "authors": [
                {
                    "first": "U",
                    "middle": [
                        "J"
                    ],
                    "last": "Sachs",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Wasel",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Bayat",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Blood",
            "volume": "117",
            "issn": "",
            "pages": "669--77",
            "other_ids": {}
        },
        "BIBREF187": {
            "ref_id": "b187",
            "title": "Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Reil",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Keller-Stanislawski",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Gunay",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Vox Sang",
            "volume": "95",
            "issn": "",
            "pages": "313--320",
            "other_ids": {}
        },
        "BIBREF188": {
            "ref_id": "b188",
            "title": "Acute lung injury after ruptured abdominal aortic aneurysm repair: the effect of excluding donations from females from the production of fresh frozen plasma",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "E"
                    ],
                    "last": "Wright",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "P"
                    ],
                    "last": "Snowden",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "C"
                    ],
                    "last": "Athey",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Crit Care Med",
            "volume": "36",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF189": {
            "ref_id": "b189",
            "title": "Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components",
            "authors": [
                {
                    "first": "O",
                    "middle": [],
                    "last": "Gajic",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Yilmaz",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Iscimen",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Crit Care Med",
            "volume": "35",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF190": {
            "ref_id": "b190",
            "title": "A consensus redefinition of transfusion-related acute lung injury",
            "authors": [
                {
                    "first": "Apj",
                    "middle": [],
                    "last": "Vlaar",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Toy",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Fung",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "R"
                    ],
                    "last": "Looney",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "P"
                    ],
                    "last": "Juffermans",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Bux",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Bolton-Maggs",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "L"
                    ],
                    "last": "Peters",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "C"
                    ],
                    "last": "Silliman",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Kor",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Kleinman",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Transfusion",
            "volume": "59",
            "issn": "7",
            "pages": "2465--2476",
            "other_ids": {}
        },
        "BIBREF191": {
            "ref_id": "b191",
            "title": "Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "R"
                    ],
                    "last": "Harvey",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "V"
                    ],
                    "last": "Basavaraju",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "W"
                    ],
                    "last": "Chung",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Kuehnert",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Transfusion",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF192": {
            "ref_id": "b192",
            "title": "Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Hirayama",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Br J Haematol",
            "volume": "160",
            "issn": "",
            "pages": "434--478",
            "other_ids": {}
        },
        "BIBREF193": {
            "ref_id": "b193",
            "title": "Hemovigilance Module Surveillance Protocol v2.1.3. Atlanta: Centers for Disease Control and Prevention",
            "authors": [
                {
                    "first": "Cdc",
                    "middle": [],
                    "last": "Nhsn Biovigilance",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Component",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF194": {
            "ref_id": "b194",
            "title": "and the World Allergy Organization. World Allergy Organization anaphylaxis guidelines: summary",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "E"
                    ],
                    "last": "Simons",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "R"
                    ],
                    "last": "Ardusso",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "B"
                    ],
                    "last": "Bilo",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "J Allergy Clin Immunol",
            "volume": "127",
            "issn": "",
            "pages": "1--22",
            "other_ids": {}
        },
        "BIBREF195": {
            "ref_id": "b195",
            "title": "and the BCSH Blood Transfusion Task Force. Guideline on the investigation and management of acute transfusion reactions. Prepared by the BCSH Blood Transfusion Task Force",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Tinegate",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Birchall",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Gray",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Br J Haematol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF196": {
            "ref_id": "b196",
            "title": "Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "Y"
                    ],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Curry",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "R"
                    ],
                    "last": "Pesola",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Ann Emerg Med",
            "volume": "36",
            "issn": "",
            "pages": "462--68",
            "other_ids": {}
        },
        "BIBREF197": {
            "ref_id": "b197",
            "title": "Histamine antagonists in the treatment of acute allergic reactions",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "W"
                    ],
                    "last": "Runge",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Martinez",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "M"
                    ],
                    "last": "Caravati",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "G"
                    ],
                    "last": "Williamson",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "C"
                    ],
                    "last": "Hartsell",
                    "suffix": ""
                }
            ],
            "year": 1992,
            "venue": "Ann Emerg Med",
            "volume": "21",
            "issn": "",
            "pages": "237--427",
            "other_ids": {}
        },
        "BIBREF198": {
            "ref_id": "b198",
            "title": "Technical Manual, 18th edn",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Fung",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Grossman",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "D"
                    ],
                    "last": "Hillyer",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Westhoff",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF199": {
            "ref_id": "b199",
            "title": "Transfusion reactions in pediatric compared with adult patients: a look at rate, reaction type, and associated products",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Pandey",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "N"
                    ],
                    "last": "Vyas",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "U"
                    ],
                    "last": "Wieding",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Vehmeyer",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Dittman",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Hiddemann",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "K\u00f6hler",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Lanzer",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "D"
                    ],
                    "last": "Oakley",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Woods",
                    "suffix": ""
                },
                {
                    "first": "Arnold",
                    "middle": [
                        "S"
                    ],
                    "last": "Young",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "P"
                    ],
                    "last": "Transfusion",
                    "suffix": ""
                }
            ],
            "year": 1994,
            "venue": "65S 79S",
            "volume": "52",
            "issn": "",
            "pages": "563--70",
            "other_ids": {}
        },
        "BIBREF200": {
            "ref_id": "b200",
            "title": "Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions",
            "authors": [
                {
                    "first": "Kevy",
                    "middle": [],
                    "last": "Sv",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Schmidt Pj",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "H"
                    ],
                    "last": "Mcginniss",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Workman Wg ; Muylle",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Joos",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Wouters",
                    "suffix": ""
                },
                {
                    "first": "De",
                    "middle": [],
                    "last": "Bock",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Peetermans",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "E"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 1962,
            "venue": "Febrile, nonhemolytic transfusion reactions and the limited role of leukoagglutinins in their etiology",
            "volume": "2",
            "issn": "",
            "pages": "",
            "other_ids": {
                "PMID": [
                    "1445546"
                ]
            }
        },
        "BIBREF201": {
            "ref_id": "b201",
            "title": "Transfusion premedications: a growing practice not based on evidence",
            "authors": [
                {
                    "first": "H",
                    "middle": [
                        "J"
                    ],
                    "last": "Nielsen",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Reimert",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "N"
                    ],
                    "last": "Pedersen",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Dybkjoer",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Br\u00fcnner",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Alsbj\u00f8rn",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "S"
                    ],
                    "last": "Skov",
                    "suffix": ""
                }
            ],
            "year": 1997,
            "venue": "Br J Anaesth",
            "volume": "78",
            "issn": "6",
            "pages": "548--52",
            "other_ids": {
                "PMID": [
                    "9175970"
                ]
            }
        },
        "BIBREF202": {
            "ref_id": "b202",
            "title": "Transfusion-associated circulatory overload after plasma transfusion",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Narick",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Triulzi",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "H"
                    ],
                    "last": "Yazer",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "The Johns Hopkins Hospital",
            "volume": "52",
            "issn": "",
            "pages": "",
            "other_ids": {
                "PMID": [
                    "17524101"
                ]
            }
        },
        "BIBREF203": {
            "ref_id": "b203",
            "title": "The risk of transmitting cytomegalovirus infection by fresh frozen plasma",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Bowden",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Sayers",
                    "suffix": ""
                }
            ],
            "year": 1990,
            "venue": "Transfusion",
            "volume": "30",
            "issn": "",
            "pages": "762--765",
            "other_ids": {}
        },
        "BIBREF204": {
            "ref_id": "b204",
            "title": "Effect of leucocyte reduction on the potential alloimmunogenicity of leucocytes in fresh-frozen plasma products",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Hiruma",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Okuyama",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Vox Sang",
            "volume": "80",
            "issn": "",
            "pages": "51--57",
            "other_ids": {}
        },
        "BIBREF205": {
            "ref_id": "b205",
            "title": "Non-infectious serious hazards in plasma transfusion",
            "authors": [
                {
                    "first": "U",
                    "middle": [
                        "J"
                    ],
                    "last": "Sachs",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Transfus Apher Sci",
            "volume": "43",
            "issn": "",
            "pages": "381--387",
            "other_ids": {}
        },
        "BIBREF206": {
            "ref_id": "b206",
            "title": "Administrative and Technical Regulations",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "M"
                    ],
                    "last": "Williamson",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "P"
                    ],
                    "last": "Allain",
                    "suffix": ""
                }
            ],
            "year": 1995,
            "venue": "Vox Sang",
            "volume": "69",
            "issn": "",
            "pages": "159--165",
            "other_ids": {}
        },
        "BIBREF207": {
            "ref_id": "b207",
            "title": "Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zou",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "A"
                    ],
                    "last": "Dorsey",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "P"
                    ],
                    "last": "Notari",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Foster",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "E"
                    ],
                    "last": "Krysztof",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Musavi",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "Y"
                    ],
                    "last": "Dodd",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "L"
                    ],
                    "last": "Stramer",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Transfusion",
            "volume": "50",
            "issn": "",
            "pages": "1495--504",
            "other_ids": {}
        },
        "BIBREF208": {
            "ref_id": "b208",
            "title": "Current incidence and residual risk of hepatitis B infection among blood donors in the United States",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zou",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "L"
                    ],
                    "last": "Stramer",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "P"
                    ],
                    "last": "Notari",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "C"
                    ],
                    "last": "Kuhns",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Krysztof",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Musavi",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "T"
                    ],
                    "last": "Fang",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "Y"
                    ],
                    "last": "Dodd",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Transfusion",
            "volume": "49",
            "issn": "",
            "pages": "1609--1629",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF1": {
            "text": "participante y proceso de identificaci\u00f3n de potenciales sujetos. Sujetos entre 65presenten hace menos de 48 hs alguno de los siguientes s\u00edntomas: (a) temperatura 37,5\u00b0C o equivalente febril (definido por sensaci\u00f3n de fr\u00edo o escalofr\u00edos o sudoraci\u00f3n inexplicada), combinado con (b) tos seca y/o disnea y/o anosmia/disgeusia y/o odinofagia y/o fatiga y/o anorexia y/o mialgias y/o rinorrea.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "NYHA (NEW YORK HEART ASSOCIATION) VALORACI\u00d3N FUNCIONAL DE INSUFICIENCIA CARD\u00cdACA.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Pavan K. Bhatraju, M.D., Bijan J. Ghassemieh, M.D., Michelle Nichols, M.D., Richard Kim, M.D., Keith R. Jerome, M.D., Arun K. Nalla, Ph.D., Alexander L. Greninger, M.D., Sudhakar Pipavath, M.D., Mark M. Wurfel, M.D., Ph.D., Laura Evans, M.D., Patricia A. Kritek, M.D., T. Eoin West, M.D., M.P.H., Andrew Luks, M.D., Anthony Gerbino, M.D., Chris R. Dale, M.D.,Jason D. Goldman, M.D., acenic, M.D. COVID-19 in Critically Ill Patients in the Seattle Region Case Series New England Journal of Medicine. DOI: 10.1056/NEJMoa2004500 51. W. Guan, Z. Ni, Yu Hu, W. Liang, C. Ou, J. He, L. Liu, H. Shan, C. Lei, D.S.C. Hui, B. Du, L. Li, G. Zeng, K.-Y. Yuen, R. Chen, C. Tang, T. Wang, P. Chen, J. Xiang, S. Li, Jin-lin Wang, Z. Liang, Y. Peng, L. Wei, Y. Liu, Ya-hua Hu, P. Peng, Jian-ming Wang, J. Liu, Z. Chen, G. Li, Z. Zheng, S. Qiu, J. Luo, C. Ye, S. Zhu, and N. Zhong. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. DOI: 10.1056/NEJMoa2002032 52. Arciuolo, R. J., Jablonski, R. R., Zucker, J. R., & Rosen, J. B. (2017). Effectiveness of Measles Vaccination and Immune Globulin Post-Exposure Prophylaxis in an Outbreak Setting New York City, 2013. Clinical Infectious Diseases, 65(11), 1843 1847. doi:10.1093/cid/cix639 53. Swamy, G. K., & Dotters-Katz, S. K. (2019). Safety and varicella outcomes after varicella zoster immune globulin administration in pregnancy. American Journal of Obstetrics and Gynecology. doi:10.1016/j.ajog.2019.07.003 54. Levin MJ, Duchon JM, Swamy GK, Gershon AA. Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: varicella Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT)",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "LA EFICACIA DE LA ADMINISTRACI\u00d3N DE PLASMA DE CONVALECIENTE DE COVID-19 EN LA DISMINUCI\u00d3N DE LA PROGRESI\u00d3N A ENFERMEDAD SEVERA EN ADULTOS MAYORES CON S\u00cdNTOMAS LEVES POR SARS-COV2",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "(mascara de reservorio de O2) y/o utilizaci\u00f3n de soporte respiratorio no invasivo (soporte de VNI incluyendo CPAP) y/o admisi\u00f3n a UTI y/o requerimiento de ventilaci\u00f3n mec\u00e1nica invasiva por SARS-CoV2 en pacientes entre 65-Disminuir la enfermedad cr\u00edtica definida como (a) presencia de falla 200 mm Hg.) y/o (b) shock (definido por necesidades de soporte con drogas vasoactivas para mantener P.A.M. igual o mayor a 65 mm. Hg), y/o (c) s\u00edndrome de disfunci\u00f3n multiorg\u00e1nica (SDMO): injuria renal aguda (definida por aumento de creatinina por dos o m\u00e1s veces con respecto al basal o aumento de creatinina 0.3 mg/dl), elevaci\u00f3n de Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT)",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": "hace menos de 48 horas: (A)Temperatura axilar 37,5\u00b0C o equivalente febril (definido por sensaci\u00f3n de fr\u00edo y/o escalofr\u00edos y/o sudoraci\u00f3n inexplicada), combinado con (a) tos seca y/o (b) dificultad respiratoria y/o (c) odinofagia y/o (d) anosmia/disgeusia y/o (e) alguno de los siguientes s\u00edntomas: fatiga, anorexia, mialgias o rinorrea.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "Sujetos entre 65presenten hace menos de 48 hs alguno de los siguientes s\u00edntomas: (a) temperatura 37,5\u00b0C o equivalente febril (definido por sensaci\u00f3n de fr\u00edo o escalofr\u00edos o sudoraci\u00f3n inexplicada), combinado con (b) tos seca y/o disnea y/o anosmia/disgeusia y/o odinofagia y/o fatiga y/o anorexia y/o mialgias y/o rinorrea.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF8": {
            "text": "Cheryl D. Fryar, M.S.P.H., Yechiam Ostchega, Ph.D., R.N., Craig M. Hales, M.D., M.P.H., Guangyu Zhang, Ph.D., and Deanna Kruszon-Moran, M.S. Hypertension Prevalence and Control Among Adults: United States, 2015 2016. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. Center for Disease Control and Prevention.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF9": {
            "text": ". U.S. Department of Health and Human Services, Center for Disease Control and Prevention. National Diabetes Statistics Report, Estimates of Diabetes and Its Burden in the United States 38. Craig M. Hales, M.D., Margaret D. Carroll, M.S.P.H., Cheryl D. Fryar, M.S.P.H., and Cynthia L. Ogden, Ph.D. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017 2018. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. Center for Disease Control and Prevention. 39. Lara J. Akinbami, M.D.; and Xiang Liu, M.Sc. Chronic Obstructive Pulmonary Disease Among Adults Aged 18 and Over in the United States, 1998 2009. Center for Disease Control and Prevention. 51. W. Guan, Z. Ni, Yu Hu, W. Liang, C. Ou, J. He, L. Liu, H. Shan, C. Lei, D.S.C. Hui, B. Du, L. Li, G. Zeng, K.-Y. Yuen, R. Chen, C. Tang, T. Wang, P. Chen, J. Xiang, S. Li, Jin-lin Wang, Z. Liang, Y. Peng, L. Wei, Y. Liu, Ya-hua Hu, P. Peng, Jian-ming Wang, J. Liu, Z. Chen, G. Li, Z. Zheng, S. Qiu, J. Luo, C. Ye, S. Zhu, and N. Zhong. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. DOI: 10.1056/NEJMoa2002032 52. Arciuolo, R. J., Jablonski, R. R., Zucker, J. R., & Rosen, J. B. (2017). Effectiveness of Measles Vaccination and Immune Globulin Post-Exposure Prophylaxis in an Outbreak Setting New York City, 2013. Clinical Infectious Diseases, 65(11), 1843 1847. doi:10.1093/cid/cix639 53. Swamy, G. K., & Dotters-Katz, S. K. (2019). Safety and varicella outcomes after varicella zoster immune globulin administration in pregnancy. American Journal of Obstetrics and Gynecology. doi:10.1016/j.ajog.2019.07.003 54. Levin MJ, Duchon JM, Swamy GK, Gershon AA. Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: varicella outcomes and safety results from a large, open-label, expanded-access program. PLoS One 2019;14: e0217749 55. MMWR. Recommendation of the Immunization Practices Advisory Committee (ACIP) Postexposure Prophylaxis of Hepatitis B. https://www.cdc.gov/mmwr/preview/mmwrhtml/00022736.htm Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT)",
            "latex": null,
            "type": "figure"
        },
        "FIGREF10": {
            "text": "Co-Investigators: Dra. Romina Libster (INFANT / CONICET), Dr. Gonzalo P\u00e9rez Marc (HMC), Dr. Diego Wappner (SMG), Dr. Jorge Lantos ( Los Arcos), Dr. Ricardo Valentini (CEMIC), Dr. Federico Etchenique (Ecco), Dr. Mariano Girasolli (OSECAC), Dr. Gabriel Leberzstein (OSECAC) , Dr. Miguel Gonz\u00e1lez (Finochietto), Dr. Andrea Gamarnik (Leloir / CONICET), Dr. Jorge Geffner (UBA / CONICET ), Bioq. Silvina Coviello (INFANT), Dr. Mauricio Caballero (INFANT / CONICET) , Dr. Dami\u00e1n Alvarez Paggi (INFANT / CONICET), Dr. Sebasti\u00e1n Esperante (INFANT / CONICET) , Dr. Federico Dimase (HMC), Dr. Susana Pastor Arg\u00fcello (HMC) , Dr. Juan Sebasti\u00e1n Riera (Ministry of Health of the Province of Buenos Aires), Dr. Enio Garc\u00eda (Ministry of Health of the Province of Buenos Aires), Dr. Juan Canela (Ministry of Health of the Province of Buenos Aires), Dr. Mario Rovere (Ministry of Health of the Province of Buenos Aires) , Dr. Fernando Althabe (WHO), Dr. Eduardo Bergel (IECS).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF11": {
            "text": "T , Du R , Fan G , Liu Y , Liu Z , Xiang J , Wang Y , Song B , Gu X , Guan L , Wei Y , Li H , Wu , Xu J , Tu S , Zhang Y , Chen H , Cao B . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. , Alia Alkalbani , Ghaya Albadi , Hassib Narchi , and Graham Hall . Is forced oscillation technique the next respiratory function test of choice in childhood asthma. World J Methodol . 2017 Dec 26; 7 (4): 129 138. doi: 10.5662 / wjm.v7.i4.129 23. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14States, March 1 30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 458 464. DOI: http://dx.doi.org/10.15585/mmwr.mm6915e3 24. Feng, Y. et al. COVID-19 with Different Severity: A Multi-center Study of Clinical Features. Am. J. Respir. Crit. Care Med. 0 , null. https://doi.org/10.1164/rccm.202002-0445OC 25. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. Published online April 06, 2020. doi: 10.1001 / jama.2020.5394 26. Integrated Surveillance Bulletin. National Directorate of Epidemiology and Analysis of the Health Situation. N \u00b0 424 -EW 39 -September 2018 27. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19), 16-24 February 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/who-china-jointmission-on-COVID-19-final-report.pdf . Accessed March 09, 2020. 28. Updates on COVID-19 in Republic of Korea. April 15, 2020, Division of Risk assessment and International cooperation, Korean Center for Disease Control and Prevention https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030 &act=view&list_no=366892&tag=&nPage= 129. Wu, JT, Leung, K., Bushman, M., Kishore, N., Niehus, R., de Salazar, PM Leung, GM (2020). Estimating clinical severity of COVID-19 from the GK, & Dotters-Katz, SK (2019). Safety and varicella outcomes after varicella zoster immune globulin administration in pregnancy. American Journal of Obstetrics and Gynecology. doi: 10.1016 / j.ajog.2019.07.003 54. Levin MJ, Duchon JM, Swamy GK, Gershon AA. Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: varicella outcomes and safety results from a large, open-label, expanded-access program. PLoS One 2019; 14: e0217749 55. MMWR. Recommendation of the Immunization Practices Advisory Committee (ACIP) Postexposure Prophylaxis of Hepatitis B. https://www.cdc.gov/mmwr/preview/mmwrhtml/00022736.htm 56. Bharti, OK, Thakur, B., & Rao, R. (2019). Wound-only injection of rabies immunoglobulin (RIG) saves lives and costs less than a dollar per patient by Vaccine. doi: 10.1016 / j.vaccine.2019.07.087 57. Wu P, Duan F, Luo C, et al. Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. Published online March 31, 2020. doi: 10.1001 / jamaophthalmol.2020.1291 58. Semple JW, Rebetz J, Kapur R. Transfusion-associated circulatory overload (TACO): Time to shed light on the pathophysiology. ISBT Sci Ser. 2018; ISBT Sci Ser. 2019; 14 (1): 136-139 59. Kopko PM, Popovsky MA, MacKenzie MR, et al. HLA class II antibodies in transfusion-related acute lung injury. Transfusion 2001; 41: 1244-8. 60. Popovsky MA. Transfusion and the lung: circulatory overload and acute lung injury. Vox Sang 2004; 87 (s2 Suppl 2): 62-65 61. Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am. 1999; 81 (1): 2-10. 62. Rana R, Fernandez-Perez ER, Khan SA, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion. 2006; 46 (9): 1478-1483. patient factors, transfusion practices, and outcomes in patients with transfusion-associated circulatory overload. Transfusion Med Rev 2013; 27: 206-12. 65. Zheng YY, Ma YT, Zhang JY, Xiang X. COVID-19 and the cardiovascular system. Nature Rev Cardiology 2020. https://doi.org/10.M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020. https://doi.org/10.1001/jamacardio.2020.0950 67. Transfusion-associated circulatory overload (TACO) Definition (2018) IHN / ISBT haemovigilance working party / AABB 68. Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood 2012; 119: 1757-67 69. Kopko PM, Popovsky MA, MacKenzie MR, et al. HLA class II antibodies in transfusion-related acute lung injury. Transfusion 2001; 41: 1244-8. 70. Sachs UJ, Wasel W, Bayat B, et al. Mechanism of transfusion related acute lung injury induced by HLA class II antibodies. Blood 2011; 117: 669-77. 71. Reil A, Keller-Stanislawski B, Gunay S, et al. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang 2008; 95: 313-7. 72. Wright SE, Snowden CP, Athey SC, et al. Acute lung injury after ruptured abdominal aortic aneurysm repair: the effect of excluding donations from females from the production of fresh frozen plasma. Crit Care Med 2008; 36: 1796. 73. Gajic O, Yilmaz M, Iscimen R, et al. Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components. Crit Care Med 2007; 35: 1645. 74. Vlaar APJ, Toy P, Fung M, Looney MR, Juffermans NP, Bux J, Bolton-Maggs P, Peters AL, Silliman CC, Kor DJ, Kleinman S. A consensus redefinition of transfusion-related acute lung injury. Transfusion. 2019 Jul; 59 (7): 2465nonhemolytic transfusion reactions and the limited role of leukoagglutinins in their etiology. KEVY SV, SCHMIDT PJ, McGINNISS MH, WORKMAN WG Transfusion. 1962; 2: 7. PMID 1445546 88. Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions. Muylle L, Joos M, Wouters E, De Bock R, Peetermans ME. Transfusion. 1993; 33 (3): 195.89. Nielsen HJ, Reimert C, Pedersen AN, Dybkjoer E, Br\u00fcnner N, Alsbj\u00f8rn B, Skov PS. Leukocyte Derived bioactive substances in fresh frozen plasma. Br J Anaesth. 1997; 78: 548 52. [PubMed: 9175970] 90. Transfusion premedications: a growing practice not based on evidence. Tobian AA, King KE, Ness PM, Transfusion. 2007; 47 (6): 1089. Department of Pathology, Transfusion Medicine Division, The Johns Hopkins Hospital, Baltimore, Maryland 21287, USA. atobian1@jhmi.edu PMID17524101 91. Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. Transfusion. 2012; 52: 160 5. [PubMed: 21762464] 92. Bowden R, Sayers M. The risk of transmitting cytomegalovirus infection by fresh frozen plasma. Transfusion. 1990; 30: 762-3. [PubMed: 2171162] 93. Hiruma K, Okuyama Y. Effect of leucocyte reduction on the potential alloimmunogenicity of leucocytes in fresh-frozen plasma products. Vox Sang. 2001; 80: 51 6. [PubMed: 11339069] 94. Sachs UJ. Non-infectious serious hazards in plasma transfusion. Transfus Apher Sci. 2010; 43: 381 6. [PubMed: 20934385] 95. Williamson LM, Allain JP. Virally inactivated fresh frozen plasma. Vox Sang, 69: 159-165, 1995.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF12": {
            "text": "Assessment Criteria (up to 15 days or, thereafter, up to a maximum of 2 5 days after the administration of treatment if continued hospitalization)",
            "latex": null,
            "type": "figure"
        },
        "FIGREF13": {
            "text": "Test article and transfusion medicine 11.1. Voluntary donation of convalescent plasma All procedures will be done in accordance with the STRATEGIC PLAN TO REGULATE THE USE OF PLASMA BY COVID-19 RECOVERED PATIENTS FOR THERAPEUTIC PURPOSES. (IF-2020-26315442-APN-SCS # MS)https://www.boletinoficial.gob.ar/detalleAviso/primera/227976/20200418 Convalescent plasma will be obtained by inviting patients who experienced COVID-19 and have recovered satisfactorily in the Autonomous City and Province of Buenos Aires to participate as a voluntary donor, following the donation criteria established by the authorities. If the patient wishes to donate, they will voluntarily and altruistically sign the plasma donation consent (ANNEX).Donors will be identified by the ministerial and institutional authorities (if it is a private body), contacted, and invited to donate in one of the five Blood Banks participating in this study: a) Institute of Hemotherapy of the Province of La Plata b) Central Military Hospital c) Hemocentro Buenos Aires Foundation d) Sarmiento Hematology Foundation e) CEMIC",
            "latex": null,
            "type": "figure"
        },
        "FIGREF14": {
            "text": "-Yes (At least one of the six events was registered in the 15/25 days) -No (None of the six events in",
            "latex": null,
            "type": "figure"
        },
        "FIGREF15": {
            "text": "Figure 1: Consort 13",
            "latex": null,
            "type": "figure"
        },
        "FIGREF16": {
            "text": "Kaplan-Meier survival curve of severe respiratory disease due to SARS-CoV2 by treatment group ITT Analysis 17",
            "latex": null,
            "type": "figure"
        },
        "FIGREF17": {
            "text": "Kaplan-Meier survival curve of severe respiratory disease due SARS-CoV2 in 65-74 years old by treatment group ITT Analysis Kaplan-Meier survival curve of severe respiratory disease due SARSyears old by treatment group ITT Analysis 18",
            "latex": null,
            "type": "figure"
        },
        "FIGREF18": {
            "text": "Kaplan-Meier survival curve. Time to support with maximum oxygen therapy and/ or non-invasive respiratory support and/or admission to UCI and/or invasive mechanical ventilation assistance requirement by treatment group-ITT analysis Kaplan-Meier survival curve. Time to critical systemic Illness by treatment group-ITT analysis Kaplan-Meier survival curve. Time to mortality due to COVID-19 by treatment group-ITT analysis Kaplan-Meier survival curve. Time to Support with maximum oxygen therapy and/ or non-invasive respiratory support and/or admission to UCI and/or invasive mechanical ventilation assistance requirement and/or critical systemic Illness and/or mortality ITT analysis19",
            "latex": null,
            "type": "figure"
        },
        "FIGREF19": {
            "text": "Kaplan-Meier survival curve of severe respiratory disease due SARS-CoV2 in 65-74 years old by treatment group ITTm analysis Kaplan-Meier survival curve of severe respiratory disease due SARSyears old by treatment group ITTm analysis 22",
            "latex": null,
            "type": "figure"
        },
        "FIGREF20": {
            "text": "-Yes (At least one of the six events was registered in the 15/25 days) -No (None of the six events in",
            "latex": null,
            "type": "figure"
        },
        "FIGREF21": {
            "text": "Subjects that received the intervention but lost eligibility before being transfused (presence of primary outcome before transfusion)",
            "latex": null,
            "type": "figure"
        },
        "FIGREF22": {
            "text": "Kaplan-Meier survival curve of severe respiratory disease due to SARS-CoV2 by treatment group ITT Analysis",
            "latex": null,
            "type": "figure"
        },
        "FIGREF23": {
            "text": "Kaplan-Meier survival curve of severe respiratory disease due SARS-CoV2 in 65-74 years old by treatment group ITT Analysis Kaplan-Meier survival curve of severe respiratory disease due SARS-CoV2 in 75 years old by treatment group ITT Analysis",
            "latex": null,
            "type": "figure"
        },
        "FIGREF24": {
            "text": "Kaplan-Meier survival curve. Time to critical systemic Illness by treatment group-ITT analysis Kaplan-Meier survival curve. Time to mortality due to COVID-19 by treatment group-ITT analysis Kaplan-Meier survival curve. Time to Support with maximum oxygen therapy and/ or non-invasive respiratory support and/or admission to UCI and/or invasive mechanical ventilation assistance requirement and/or critical systemic Illness and/or mortality ITT analysis",
            "latex": null,
            "type": "figure"
        },
        "FIGREF25": {
            "text": "Kaplan-Meier survival curve of severe respiratory disease due to SARS-CoV2 by treatment group ITTm Analysis",
            "latex": null,
            "type": "figure"
        },
        "FIGREF26": {
            "text": "Kaplan-Meier survival curve of severe respiratory disease due SARS-CoV2 in 65-74 years old by treatment group ITTm analysis Kaplan-Meier survival curve of severe respiratory disease due SARS-CoV2 in 75 years old by treatment group ITTm analysis",
            "latex": null,
            "type": "figure"
        },
        "FIGREF27": {
            "text": "Kaplan-Meier survival curve. Time to critical systemic Illness by treatment group ITTm Analysis",
            "latex": null,
            "type": "figure"
        },
        "TABREF1": {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT)",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Diagn\u00f3stico previo de S\u00cdNDROMES LINFOPROLIFERATIVOS CR\u00d3NICOS.",
            "latex": null,
            "type": "table"
        },
        "TABREF3": {
            "text": "Cronograma de procedimientos del estudio.",
            "latex": null,
            "type": "table"
        },
        "TABREF4": {
            "text": "Bajo la estrategia de an\u00e1lisis primario, usaremos la distribuci\u00f3n de l\u00edmite de producto de Kaplan-Meier para comparar los grupos de tratamiento durante el tiempo necesario para alcanzar el resultado primario. Tambi\u00e9n se informar\u00e1 una estimaci\u00f3n del riesgo relativo y el intervalo de confianza del 95%.11. Art\u00edculo de prueba y medicina transfusional 11.1. Donaci\u00f3n voluntaria de plasma de convaleciente Todos los procedimientos se har\u00e1n acorde al PLAN ESTRAT\u00c9GICO PARA REGULAR EL USO DE PLASMA DE PACIENTES RECUPERADOS DE COVID-19 CON FINES TERAP\u00c9UTICOS. (IF-2020-26315442-APN-SCS#MS) https://www.boletinoficial.gob.ar/detalleAviso/primera/227976/20200418El plasma de convaleciente se obtendr\u00e1 invitando a participar como donante voluntario a pacientes que hayan padecido la enfermedad COVID-19 y se hayan recuperado satisfactoriamente en la Ciudad Aut\u00f3noma y Provincia de Buenos Aires siguiendo los criterios de donaci\u00f3n establecidos por las autoridades. Si el paciente desea donar, de forma voluntaria y altruista firmara el consentimiento de donaci\u00f3n de plasma (ANEXO).",
            "latex": null,
            "type": "table"
        },
        "TABREF7": {
            "text": "Mortalidad por covid-19.Combinaci\u00f3n de los criterios secundarios de valoraci\u00f3n de eficacia #1-19).",
            "latex": null,
            "type": "table"
        },
        "TABREF9": {
            "text": "Infecci\u00f3n conocida por HIV, HBV o HCV. 12. Administraci\u00f3n cr\u00f3nica (definida como m\u00e1s de 14 d\u00edas corridos) de",
            "latex": null,
            "type": "table"
        },
        "TABREF10": {
            "text": "Cronograma de procedimientos del estudio.",
            "latex": null,
            "type": "table"
        },
        "TABREF11": {
            "text": "Toma de muestra de sangre luego de completada la infusi\u00f3n \u00danica muestra a las 24 hs (+/-4 hs) Este procedimiento no ser\u00e1 requerido si se encuentra un resultado disponible por un m\u00e9todo valido al momento de pesquisar el paciente Se considerar\u00e1 que el paciente completa su participaci\u00f3n al llegar el d\u00eda 15 (si el paciente ya est\u00e1 dado de alta), al alta hospitalaria entre el d\u00eda 15 y el d\u00eda 25 o al cumplirse el d\u00eda 25 de continuar hospitalizado.",
            "latex": null,
            "type": "table"
        },
        "TABREF12": {
            "text": "Investigador Principal del Programa: Dr. Fernando P. Polack (INFANT)",
            "latex": null,
            "type": "table"
        },
        "TABREF13": {
            "text": "Art\u00edculo de prueba y medicina transfusional 11.1. Donaci\u00f3n voluntaria de plasma de convaleciente Todos los procedimientos se har\u00e1n acorde al PLAN ESTRAT\u00c9GICO PARA REGULAR EL USO DE PLASMA DE PACIENTES RECUPERADOS DE COVID-19 CON FINES TERAP\u00c9UTICOS. (IF-2020-26315442-APN-SCS#MS) https://www.boletinoficial.gob.ar/detalleAviso/primera/227976/20200418El plasma de convaleciente se obtendr\u00e1 invitando a participar como donante voluntario a pacientes que hayan padecido la enfermedad covid-19 y se hayan recuperado satisfactoriamente en la Ciudad Aut\u00f3noma y Provincia de Buenos Aires siguiendo los criterios de donaci\u00f3n establecidos por las autoridades. Si el paciente desea donar, de forma voluntaria y altruista firmara el consentimiento de donaci\u00f3n de plasma (ANEXO).Los donantes ser\u00e1n identificados por las autoridades ministeriales e institucionales si se trata de un organismo privado, contactados, e invitados a donar en uno de los cinco Bancos de Sangre participantes de este estudio:Para poder donar plasma, el paciente debe cumplir con las condiciones determinadas a la fecha (https://www.boletinoficial.gob.ar/detalleAviso/primera/227976/20200418) o seguir la actualizaci\u00f3n de ellas que realice el Ministerio.",
            "latex": null,
            "type": "table"
        },
        "TABREF15": {
            "text": "(CONSENSO HIPERTENSION PORTAL BAVENO IV)",
            "latex": null,
            "type": "table"
        },
        "TABREF16": {
            "text": "Feng, Y. et al. COVID-19 with Different Severity: A Multi-center Study of Clinical Features. Am. J. Respir. Crit. Care Med. 0, null. https://doi.org/10.1164/rccm.202002-0445OC",
            "latex": null,
            "type": "table"
        },
        "TABREF17": {
            "text": "71. ReilA, Keller-Stanislawski B, Gunay S, et al. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang 2008;95:313-7. 72. Wright SE, Snowden CP, Athey SC, et al. Acute lung injury after ruptured abdominal aortic aneurysm repair: the effect of excluding donations from females from the production of fresh frozen plasma. Crit Care Med 2008; 36:1796. 73. Gajic O, Yilmaz M, Iscimen R, et al. Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components. 77. CDC. NHSN Biovigilance Component, Hemovigilance Module Surveillance Protocol v2.1.3. Atlanta: Centers for Disease Control and Prevention, 2014. 78. Simons FE, Ardusso LR, Bilo MB, et al, and the World Allergy Organization. 81. 16 Runge JW, Martinez JC, Caravati EM, Williamson SG, Hartsell SC. Histamine antagonists in the treatment of acute allergic reactions. Principal Investigator of the Program: Dr. Fernando P. Polack (INFANT) Title : Evaluation of the efficacy of COVID-19 convalescent plasma administration in reducing the progression to severe disease in older adults with mild symptoms due to SARS-CoV2 (ENGLISH VERSION FROM SPANISH). EVALUATION OF THE EFFICACY OF COVID-19 CONVALESCENT PLASMA ADMINISTRATION IN REDUCING THE PROGRESSION TO SEVERE DISEASE IN OLDER ADULTS WITH MILD SYMPTOMS DUE TO SARS-COV2 Dr. Carlos Bocalandro Hospital Principal Investigator: Dr. An\u00edbal Rondan Principal Investigator Simply Evita Hospital: Dra. Valeria Fern\u00e1ndez Vi\u00f1a Evita Pueblo Hospital Principal Investigator: Dra. Maria Clarisa Barolin San Juan de Dios Hospital Principal Investigator: Dra. Ivonne Ritou Principal Investigator of the Program: Dr. Fernando P. Polack (INFANT)",
            "latex": null,
            "type": "table"
        },
        "TABREF18": {
            "text": "Treatment Assignments",
            "latex": null,
            "type": "table"
        },
        "TABREF19": {
            "text": "Present at the time of inclusion SEVERE RESPIRATORY DISEASE defined ambient air <93%. 2. HEART FAILURE in functional class III and IV (according to the functional classification of the New York Heart Association). 3. Known diagnosis of CHRONIC KIDNEY INSUFFICIENCY in filtration stages KNOWN HYPERSENSITIVITY to the administration of immunoglobulins, plasma, monoclonal antibodies and / or vaccines. 10. Active cancer, defined as receiving or having received or receiving chemotherapy, radiotherapy, or new designer or monoclonal drug treatments in the last six months. 11. Known HIV, HBV, or HCV infection. 12. Chronic administration (defined as more than 14 calendar days) of",
            "latex": null,
            "type": "table"
        },
        "TABREF21": {
            "text": "Schedule of study procedures.",
            "latex": null,
            "type": "table"
        },
        "TABREF22": {
            "text": "",
            "latex": null,
            "type": "table"
        },
        "TABREF24": {
            "text": "Weining Xiong , Dexiang Yang , Rong Chen ; Fangying Lu ; Yunfei Lu , et al. COVID-19 with Different Severity: A Multi-center Study of Clinical Feature. doi.org/10.1164/rccm.202002-0445OC",
            "latex": null,
            "type": "table"
        },
        "TABREF25": {
            "text": "Treatment Assignments",
            "latex": null,
            "type": "table"
        },
        "TABREF27": {
            "text": "Schedule of study procedures.",
            "latex": null,
            "type": "table"
        },
        "TABREF28": {
            "text": "",
            "latex": null,
            "type": "table"
        },
        "TABREF29": {
            "text": "HEART FAILURE NYHA SCALE (NEW YORK HEART ASSOCIATION) FUNCTIONAL ASSESSMENT OF HEART FAILURE.Class IIIMarked limitation of physical activity. No symptoms at rest. Less than ordinary physical activity causes fatigue, palpitations or dyspnea. Class IV Inability to carry out any physical activity; symptoms of heart failure are present even at rest and increase with any physical activity.CIRRHOSIS (PORTAL BAVENO IV HYPERTENSION CONSENSUS)",
            "latex": null,
            "type": "table"
        },
        "TABREF30": {
            "text": "SAMPLE SIZE AND DETENTION RULES ACCORDING THE PROTOCOL (Pag 5)",
            "latex": null,
            "type": "table"
        },
        "TABREF31": {
            "text": "",
            "latex": null,
            "type": "table"
        },
        "TABREF32": {
            "text": "Primary outcomes definition. O2 sat<93% at room air from 12 hours from the start of the infusion until 15 days since the administration of the treatment (12h 15 d).-Yes (At least one day had some of the two events) -No (None of the two events in the 15 days) hours from the start of the infusion until 15 days since the administration of the treatment (12h 15 d).-Yes (At least one day had some of the two events) -No (None of the two events in the 15 days) 12 hours from the start of the infusion until 15 days since the administration of the treatment (12h 15 d). (Form 5, Variable 2 y 5) (3) Oxygen saturation <93% at room air Presence O2 sat<93% at room air from 12 hours from the start of the infusion until 15 days since the administration of the treatment (12h 15 d). -Yes (At least one day had some of the two events) -No (None of the two events in the 15 days)",
            "latex": null,
            "type": "table"
        },
        "TABREF33": {
            "text": "Secondary outcomes definition.Oxygen support and/or non-invasive respiratory support and/or admission to ICU and/or invasive mechanical ventilation assistance from 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital.Need of non-invasive respiratory support from 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital.-Yes (the event was registered in the 15/25 days) -No (The event was not registered in the 15/25 days) Non-invasive respiratory support (Form 7, variable 16) 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital. (Form 5, Variable 2 y 5) (7) UCI admission Admission to the intensive care unit (ICU) from 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital. -Yes (the event was registered in the 15/25 days) -No (The event was not registered in the 15/25 days) UCI admission (Form 7, variable 15) 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital. (Form 5, Variable 2 y 5) infusion until 15/25 days if the patient remains in hospital. -Yes (At least one of the three events was registered in the 15/25 days) -No (None of the three events in the 15/25 days) (10) Acute respiratory failure Presence of acute respiratory failure: from 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital. -Yes (the event was registered in the 15/25 days) -No (The event was not registered in the 15/25 days) 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital. (Form 5, Variable 2 y 5). (11) Shock Need of support with vasoactive drugs to maintain the mean arterial pressure 65 mm Hg from 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital. -Yes (the event was registered in the 15/25 days) -No (The event was not registered in the 15/25 days) Shock (Form 7, variable 20). 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital. (Form 5, Variable 2 y 5).",
            "latex": null,
            "type": "table"
        },
        "TABREF34": {
            "text": "Secondary outcomes definition (cont.) Presence of some of the following events from 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital. -Acute renal injury: increase in two or more times from baseline or creatinine increase of 0.3 mg/dl. -Increase of hepatic enzymes (transaminase) in three or more times the normal range. -Acute cardiomyopathy: increase of troponin above normal range and/ or new electrocardiographic or echocardiographic abnormalities due to myocardial damage. -Yes (At least one of the three events was registered in the 15/25 days) -No (None of the three events in the 15/25 days) Acute renal injury (Form 7, variable 19.a) Mortality due to covid-19 from 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital. -Yes (the event was registered in the 15/25 days) -No (The event was not registered in the 15/25 days) Patient death (Form 7, variable 21). 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital (Form 5, Variable 2 y 5).",
            "latex": null,
            "type": "table"
        },
        "TABREF35": {
            "text": "Adverse events definition Presence of cardiac volume overload associated with the transfusion during the infusion and between 12 hours after. -Yes (the event was registered) -No (The event was not registered) (20) Hematoma at site Presence of hematoma at site during the infusion and between 12 hours after. -Yes (the event was registered) -No (The event was not registered) (21) Nervous injury Presence of nervous injury at site during the infusion and between 12 hours after. -Yes (the event was registered) -No (The event was not registered) Presence of tetany (hyperventilation) during the infusion and between 12 hours after. -Yes (the event was registered) -No (The event was not registered) Eligible for COVID diagnosis confirmed by RT-PCR (Form 1, item. 25) SARS-COv2 diagnosis confirmed by RT-PCR (Form 1, item. 29) Signed Informed consent for participation (Form 1, item. 31)Cases that achieved 15 days since investigational product infusion",
            "latex": null,
            "type": "table"
        },
        "TABREF36": {
            "text": "Socio-demographic characteristics, vital signs and primary and secondary comorbidities Systolic blood pressure* Diastolic blood pressure* Respiratory rate* Oxygen saturation at room air* Hours from initiation of symptoms* Respiratory rate Oxygen saturation < 93% Primary Comorbidities Hypertension under treatment Diabetes under treatment Obesity COPD under treatment Cardiovascular disease** Chronic renal failure Secondary comorbidities Asthma or other respiratory disease Non-cirrhotic liver disease Cancer (not active) Neurologic disease History of smoking Receives medications regularly Received medications in last 15 days * Media and Standard deviation ** Define as Known diagnosis of coronary disease, stroke history, congenital heart failure (EF < 40%).September 11 th -Version 1.0",
            "latex": null,
            "type": "table"
        },
        "TABREF37": {
            "text": "Primary Endpoint. Proportion of cases ITT analysis",
            "latex": null,
            "type": "table"
        },
        "TABREF38": {
            "text": "Primary Endpoint. Proportion of cases ITTm analysis Respiratory Rate minuto Oxygen satiration at room air <93%",
            "latex": null,
            "type": "table"
        },
        "TABREF39": {
            "text": "Secondary outcomes: Case proportions ITT Oxygen support and/ or noninvasive respiratory support and/or admission to UCI and/or invasive mechanical",
            "latex": null,
            "type": "table"
        },
        "TABREF40": {
            "text": "EFFECTIVENESS ASSESSMENT CRITERIA 4 SAMPLE SIZE AND DETENTION RULES ACCORDING THE PROTOCOL. 7",
            "latex": null,
            "type": "table"
        },
        "TABREF41": {
            "text": "Characteristics of ITT population 15",
            "latex": null,
            "type": "table"
        },
        "TABREF42": {
            "text": "Characteristics of ITTm population 16",
            "latex": null,
            "type": "table"
        },
        "TABREF43": {
            "text": "Primary Endpoint. Proportion of cases -ITT 17",
            "latex": null,
            "type": "table"
        },
        "TABREF44": {
            "text": "Primary Endpoint: Time to event -ITT 17",
            "latex": null,
            "type": "table"
        },
        "TABREF45": {
            "text": "Primary outcome: Proportion of primary endpoint cases by age group -ITT 17",
            "latex": null,
            "type": "table"
        },
        "TABREF46": {
            "text": "Primary outcome. Time to event by group age -ITT 17",
            "latex": null,
            "type": "table"
        },
        "TABREF47": {
            "text": "Secondary outcomes: Case proportions ITT 18",
            "latex": null,
            "type": "table"
        },
        "TABREF48": {
            "text": "Secondary outcomes: Time to event ITT analysis 19",
            "latex": null,
            "type": "table"
        },
        "TABREF49": {
            "text": "Requested adverse events ITT analysis 20",
            "latex": null,
            "type": "table"
        },
        "TABREF50": {
            "text": "Primary Endpoint. Proportion of cases -ITTm 21",
            "latex": null,
            "type": "table"
        },
        "TABREF51": {
            "text": "Primary Endpoint: Time to event -ITTm 21 Figure 9: Kaplan-Meier survival curve of severe respiratory disease due to SARS-CoV2 by treatment group ITTm Analysis 21",
            "latex": null,
            "type": "table"
        },
        "TABREF52": {
            "text": "Primary outcome: Proportion of primary endpoint cases by age group -ITTm 21",
            "latex": null,
            "type": "table"
        },
        "TABREF53": {
            "text": "Primary outcome. Time to event by age group -ITTm 21",
            "latex": null,
            "type": "table"
        },
        "TABREF54": {
            "text": "Secondary Outcomes: Case proportions ITTm analysis 22",
            "latex": null,
            "type": "table"
        },
        "TABREF55": {
            "text": "Secondary outcomes: Time to event ITTm analysis 23 Figure 12: Kaplan-Meier survival curve. Time to support with maximum oxygen therapy and/ or non-invasive respiratory support and/or admission to UCI and/or invasive mechanical ventilation assistance requirement by treatment group ITTm analysis 23 Figure 13: Kaplan-Meier survival curve. Time to critical systemic Illness by treatment group ITTm Analysis 23 Figura 14: Kaplan-Meier survival curve. Time to mortality due to COVID-19 by treatment group-ITT analysis ITTm Analysis 24 Figura 15: Kaplan-Meier survival curve. Time to Support with maximum oxygen therapy and/ or non-invasive respiratory support and/or admission to UCI and/or invasive mechanical ventilation assistance requirement and/or critical systemic Illness and/or mortality ITTm analysis 24",
            "latex": null,
            "type": "table"
        },
        "TABREF56": {
            "text": "Requested adverse events ITTm analysis 24",
            "latex": null,
            "type": "table"
        },
        "TABREF57": {
            "text": "Secondary outcomes definition (cont.) Presence of some of the following events from 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital. -Acute renal injury: increase in two or more times from baseline or creatinine increase of 0.3 mg/dl. -Increase of hepatic enzymes (transaminase) in three or more times the normal range. -Acute cardiomyopathy: increase of troponin above normal range and/ or new electrocardiographic or echocardiographic abnormalities due to myocardial damage. -Yes (At least one of the three events was registered in the 15/25 days) -No (None of the three events in the 15/25 days) Acute renal injury (Form 7, variable 19.a) Mortality due to covid-19 rom 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital. -Yes (the event was registered in the 15/25 days) -No (The event was not registered in the 15/25 days) Patient death (Form 7, variable 21). 12 hours from the start of the infusion until 15/25 days if the patient remains in hospital (Form 5, Variable 2 y 5).",
            "latex": null,
            "type": "table"
        },
        "TABREF58": {
            "text": "Adverse events definition Presence of cardiac volume overload associated with the transfusion during the infusion and between 12 hours after. -Yes (the event was registered) -No (The event was not registered) (20) Hematoma at site Presence of hematoma at site during the infusion and between 12 hours after. -Yes (the event was registered) -No (The event was not registered) (21) Nervous injury Presence of nervous injury at site during the infusion and between 12 hours after. -Yes (the event was registered) -No (The event was not registered)",
            "latex": null,
            "type": "table"
        },
        "TABREF59": {
            "text": "Primary Endpoint. Proportion of cases -ITT",
            "latex": null,
            "type": "table"
        },
        "TABREF60": {
            "text": "Primary Endpoint: Time to event -ITT",
            "latex": null,
            "type": "table"
        },
        "TABREF61": {
            "text": "Primary outcome: Proportion of primary endpoint cases by age group -ITT",
            "latex": null,
            "type": "table"
        },
        "TABREF62": {
            "text": "Primary outcome. Time to event by group age -ITT",
            "latex": null,
            "type": "table"
        },
        "TABREF63": {
            "text": "Secondary outcomes: Case proportions ITT Support with maximum oxygen therapy and/ or non-invasive respiratory support and/or admission to UCI and/or invasive mechanical ventilation assistance requirement 100% oxygen support -Non-invasive respiratory support",
            "latex": null,
            "type": "table"
        },
        "TABREF64": {
            "text": "Secondary outcomes: Time to event ITT analysis Support with maximum oxygen therapy and/ or non-invasive respiratory support and/or admission to UCI and/or invasive mechanical",
            "latex": null,
            "type": "table"
        },
        "TABREF65": {
            "text": "Requested adverse events ITT analysis",
            "latex": null,
            "type": "table"
        },
        "TABREF66": {
            "text": "Primary Endpoint. Proportion of cases -ITTm",
            "latex": null,
            "type": "table"
        },
        "TABREF67": {
            "text": "Primary Endpoint: Time to event -ITTm",
            "latex": null,
            "type": "table"
        },
        "TABREF68": {
            "text": "Primary outcome: Proportion of primary endpoint cases by age group -ITTm",
            "latex": null,
            "type": "table"
        },
        "TABREF69": {
            "text": "Primary outcome. Time to event by age group -ITTm",
            "latex": null,
            "type": "table"
        },
        "TABREF70": {
            "text": "Secondary Outcomes: Case proportions ITTm analysis",
            "latex": null,
            "type": "table"
        },
        "TABREF71": {
            "text": "Secondary outcomes: Time to event ITTm analysis Support with maximum oxygen therapy and/ or non-invasive respiratory support and/or admission to UCI and/or invasive mechanical",
            "latex": null,
            "type": "table"
        },
        "TABREF72": {
            "text": "Figura 14: Kaplan-Meier survival curve. Time to mortality due to COVID-19 by treatment group-ITT analysis ITTm Analysis Figura 15: Kaplan-Meier survival curve. Time to Support with maximum oxygen therapy and/ or non-invasive respiratory support and/or admission to UCI and/or invasive mechanical ventilation assistance requirement and/or critical systemic Illness and/or mortality ITTm analysis",
            "latex": null,
            "type": "table"
        },
        "TABREF73": {
            "text": "Requested adverse events ITTm analysis Original analysis plan in Spanish developed for the interim analysis and submitted to the Data Safety Monitoring Board.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "3.0 23-jun-20 Eligibility criteria were updated to include elderly subjects with cognitive impairment as represent a vulnerable population for COVID-19 disease severity. 4.0 22-jul-20 Secondary endpoint definition update: a) Inclusion of a combined analysis of the three secondary endpoints and, b) Inclusion of an additional secondary endpoint for duration of the oxygen supplementation in patients with oxygen saturation <93% at room air. 5.0 27-jul-20 Inclusion of geriatric institutions transformed by the health system into lowcomplexity units were as study centers. 6.0 02-nov-20 As recommended by the DSMB the analysis plan was updated to include a stratified analysis by age ( Need of respiratory support with maximum oxygen therapy (oxygen reservoir mask) and/or the use of non-invasive respiratory support (NIV support including CPAP) and/or admission to the intensive care unit (ICU) and/or invasive mechanical ventilation assistance due to SARS-CoV2. Critical systemic illness defined as: (a) presence of acute respiratory failure ( and/ or (b) shock and/or (c) multiorganic shock syndrome, acute renal injury, increase of hepatic enzymes and acute cardiomyopathy due of SARS-Cov2. Mortality due to SARS-Cov2. Combination of secondary criteria of effectiveness evaluation, #1 (Need of Mortality due to SARS-Cov2). Duration of oxygen support requirement in patients with COVID-19 due to O2 sat<93% at room air. Comparison of IgG antibodies titer.",
            "cite_spans": [
                {
                    "start": 683,
                    "end": 684,
                    "text": "(",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "annex"
        },
        {
            "text": "The socio-demographic characteristics, vital signs and comorbidities of primary and secondary interest of the participants will be described. For both primary and secondary outcomes the proportion by treatment group and the relative risk with its 95% confidence interval will be reported. A logistic regression model will be used in case it is necessary to adjust for covariates. Time to event will be evaluated using Kaplan-Meier survival analysis comparing the groups with Log-Rank test. When necessary Cox regression model will be used to make adjustments. The analysis of the primary outcome will be done stratifying by age groups.The analysis will be made over two populations: 1) Intention-to-treat (ITT). All the randomized patients with follow-up until 15 days from transfusion beginning date (or since randomization if they had not received treatment) will be included. 2) Modified intention-to-treat (mITT). All the randomized patients with follow-up until 15 days from transfusion beginning date will be included, with the exception of patients with the following conditions: a. Has not received the treatment b. Has lost eligibility criteria between randomization and treatment administration, regardless if they had received the treatment. (I.e., those patients who, in advance or at the time of starting treatment, had already developed severe disease, primary outcome of the study).In addition, serious and non-serious adverse events according to treatment group will be reported November 6th 2020 Version 2.0 7 Main conclusions will be based on the mITT population analysis.",
            "cite_spans": [
                {
                    "start": 967,
                    "end": 969,
                    "text": "15",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "STATISTICAL ANALYSIS"
        },
        {
            "text": "Given the relative complexity of implementing this intervention, the minimally clinically important difference was set at a 40% relative reduction for an expected outcome rate of 50% in the control group reduced to 30% in the intervention group.A total sample size of 210 subjects (105 per trial arm) was estimated to have 80% power at a significance level (alpha) of 0.05 using a two-sided z-test with continuity correction.November 6th 2020 Version 2.0 8 VARIABLES DEFINITION Presence of per minute or O2 sat<93% at room air from 12 hours from the start of the infusion until 15 days since the administration of the treatment (12h 15 d).-Yes (At least one day had some of the two events) -No (None of the two events in the 15 days)Variables definition in (2) and (3) (2) Respiratory rate (RR) per minutePresence of respiratory rate per minute from 12 hours from the start of the infusion until 15 days since the administration of the treatment (12h 15 d).- ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "SAMPLE SIZE AND DETENTION RULES ACCORDING THE PROTOCOL."
        }
    ]
}